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Abstract
One of the most important controversies in the field of cancer epigenetics is the question
of whether aberrant CpG island methylation of tumour suppressor genes can cause
cancer or whether such abnormalities of DNA methylation are secondary to the
malignant process. We address this question by prospectively causing abnormal
methylation events in vivo. We have produced transgenic mice which over-express the
de novo methyltransferase Dnmt3b under the widely expressed CAG promoter.
Tg(Dnmt3b)+ mice devlop normally and are fertile, but die at 4-5 months, developing
dilated cardiomyopathy. CpG island methylation is globally increased, and abnormal
methylation of specific genes, including the tumour suppressor genes Cdknla, Cdkna2a
and Hid is detectable. However, there is no spontaneous cancer incidence. Crossing
the mice with the intestinal tumour prone Apc+/min mice does not lead to a significant
increase in tumour number, methylation of the Ape promoter occurs with equal
frequency in microdissected tumours from Apc+Imm mice regardless of Tg(Dnmt3b)+
genotype and is not detectable in normal mucosa. However the proportion of tumours
showing dysplasia is increased. The results show that increases of methylation can be
well tolerated, suggesting that although methylation can be increased, active silencing by
methylation is more unusual. In particular, the active silencing of tumour suppressor
genes by de novo methylation is unlikely to be a primary event in the formation of
tumours, although it may play a role in modulating tumour progression.
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1. Introduction
Methylation of DNA is an important feature of the biology of higher eukaryotic
organisms, appearing essential for normal mammalian development. Abnormalities of
methylation are some of the most common abnormalities seen in cancer, and are widely
viewed as having a causative role in the development of cancer. In this thesis, the role
of DNA methylation in normal biology and cancer is reviewed, and the development of
a transgenic mouse model for abnormal increases in methylation is described.
1.1 Essential biology of DNA methylation and CpG islands
Covalent modification of DNA by post-synthetic addition of a methyl group occurs in
the full spectrum of living organisms. Its oldest function in evolutionary terms is as part
of the restriction enzyme defence system against phage viruses in prokaryotic
organisms, which show methylation of both adenine and cytosine bases. In eukaryotic
organisms, methylation appears to be confined to the 5'- position of the cytosine ring. In
evolution as a whole, DNA methylation is clearly not absolutely essential for life or the
development of multicellular organisms, since the amount of methylation present in the
genome varies widely among eukaryotic organisms. Yeasts and Caenorrhabditis
elegans (C.Elegans) do not have detectable methylation and do not have detectable
DNA methyltransferase genes in their genomes, and DNA methylation is detectable but
rare in Drosophila Melanogaster (D.Melanogaster), whereas methylation is common in
plants and vertebrates (For review see Bird 2002).
Methylation in mice is almost entirely (but not completely) restricted to cytosine
residues immediately 5' to guanosine in genomic DNA- the CpG dinucleotide
(Ramsahoye, et al 2000). In organisms which have substantial DNA methylation, the
CpG dinucleotide is under represented in the genome. The ratio CpG to GpC as
measured by nearest neighbour analysis is 0.23, indicating that the frequency of CpG in
the mammalian genome is approximately 4 times less than would be expected by
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chance given the frequencies of C and G in the genome (Swartz, et al 1962). It is
thought that the depletion of the CpG dinucleotide is likely to have occurred during
evolution by conversion of methylated cytosines to thymidine. Unmethylated cytosines
are converted to uracil by hydrolytic deamination which occurs spontaneously even at
neutral pH (Lindahl and Nyberg 1974). This can be recognised by DNA repair
mechanisms as incorrect and removed by base excision repair. However,
methylcytosine is deaminated to form thymidine, creating a C to T mutation which is
then heritable if not corrected (Ehrlich, et al 1986). The methyl binding protein Mbd4
acts as a DNA repair enzyme repairing C-T mismatches and may offer protection against
such errors (Millar, et al 2002).
However, there are regions of the genome in which the expected frequency of CpG is
preserved, which are referred to as CpG islands. CpG islands and their relationship to
DNA methylation were initially identified by comparing discordant restriction digestion
patterns between the restriction enzyme Hpall (CCGG) which is inhibited by CpG
methylation and its isoschizomer Mspl which is methylation insensitive. Mspl digests
genomic DNA into low molecular weight fragements, whereas most of the DNA
digested with Hpall remains high molecular weight, indicating that the majority of CpG
dinucleotides in Hpall sites are methylated (Singer, et al 1979). The unmethylated
minority of the genome which was sensitive to Hpall digestion was found to be C+G
and CpG rich. Based on sequence data from this analysis, sequence criteria for defining
a CpG island were developed: G+C content greater than 0.5 and observed:expected CpG
dinucleotide ratio of >0.6, both occurring within a window of 200bp or greater
(Gardiner-Garden and Frommer 1987). These criteria are the most widely used for
defining a CpG island, although alternative criteria, derived from modern genomic
sequencing data have been proposed (increasing the required G+C content to >0.55 and
the window size threshold to greater than 500bp), which decreases the identification of
regions of repetitive sequence (Takai and Jones 2002).
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CpG islands, then, are regions of the DNA which are enriched for the CpG dinucleotide
and appear to be protected from DNA methylation, in contrast to the bulk of DNA which
is CpG depleted and methylated. Classification of CpG islands according to the original
definition shows that the promoter region lies within a CpG island in 50% of known
genes, including all housekeeping genes, and that most CpG islands, excluding those
within repetitive sequence, are associated with genes (Lindsay and Bird 1987). The
chromatin structure of CpG islands is also different to bulk DNA with increased
acetylation of histones H3 and H4, decreased levels of HI and nucleosome-ffee regions
(Tazi and Bird 1990). The majority of CpG island genes are unmethylated even if the
gene is not expressed in adult life.
In normal physiology, there are three established exceptions to the principle that CpG
island DNA is unmethylated: the phenomena of gene imprinting, X chromosome
inactivation and silencing of transposable elements. These phenomena are associated
with silencing of the methylated gene. X chromosome inactivation and imprinting share
the phenomenon of monoallelic gene expression. X inactivation involves the random
silencing of transcription from one female chromosome, whereas imprinting involves
silencing of one allele according to parental origin. In these cases, methylation is
associated with silencing of the gene on the inactive allele. Since both alleles are
exposed to the same conditions and transactivating factors in the nucleus, this suggests
that DNA methylation is part of a system to allow regulation of transcription that is
independent of regulation by transcription factors. DNA methylation patterns can be
copied on to the daughter strand during cell division, and therefore allow heritable
control of gene expression at the methylated allele. Imprinting and X inactivation
provide model systems for investigating the mechanisms of establishing epigenetic
silencing and the mechanisms by which silencing is effected. These mechanisms are
discussed in the following section.
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1.2 Establishment of methylation patterns
1.2.1 The eukaryotic DNA methyltransferase system
There are three known families of DNA methyltransferases in eukaryotes of which two
have an established role in producing DNA methylation. All three families share a
conseved C-terminal catalytic domain which shows considerable homology to bacterial
methyltransferases, but differ substantially in their N-terminal regions (For review see
Chen and Li 2004).
The first to be discovered was Dnmtl, which was identified by protein purification from
murine cells and peptide sequencing (Bestor, et al 1988). Murine Dnmtl has a somatic
cell specific isoform of 1620 amino acids and an oocyte specific isoform initiated within
exon 4 of 1616 amino acids, both of which are catalytically active. The Dnmtl N-
terminal region includes nuclear localisation, replication focus targeting, methyl-
binding, PCNA binding and bromo-adjacent homology domains (Figure 1.1). Dnmtl is
constitutively expressed in proliferating cells and is ubiquitous in somatic tissues during
development. Dnmtl is a nuclear protein and changes its nuclear distribution during cell
cycle, associating with replication foci during S phase (Leonhardt, et al 1992). Dnmtl
has a 5- to 50 fold increased activity against hemi-methylated substrates compared to
unmethylated substrates in vitro (Pradhan, et al 1999, Ruchirawat, et al 1987, Yoder, et
al 1997), and fails to induce de novo methylation in ES cells (Chen, et al 2003a) or
D.Melanogaster (Lyko, et al 1999). Deletion of Dnmtl in embryonic stem cells leads to
progressive demethylation of the genome (Li, et al 1992) but does not affect de novo
methylation of integrated MMLV provirus DNA (Lei, et al 1996). Dnmtl is essential
for development, with homozygous null mutant mice failing to survive past mid-
gestation and developing genomic demethylation (Li, et al 1992). Mice with a
hypomorphic Dnmtl allele which express Dnmtl at approximately 10% normal level are
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viable but runted and show reduced levels of global methylation, though not as severe as
in the null mice (Gaudet, et al 2003). These results suggest that Dnmtl is primarily
concerned with the maintenance of DNA methylation patterns by copying the
methylation signal following cell division, and has little if any involvement in the
establishment of new DNA methylation patterns.
The second family of established importance is the Dnmt3 family which are the major
enzymes concerned with de novo methyltransferase activity. The residual ability of
Dnmtl null ES cells to methylate proviral DNA had suggested the presence of an
independent methyltransferase mediating de novo methyltransferase activity. The
Dnmt3 family was subsequently discovered by identification of EST clones from a
human database showing homology to bacterial DNA methyltransferases (Okano, et al
1998a, Xie, et al 1999). There are two members of the family with active catalytic
domains. The murine Dnmt3a gene encodes at least 2 proteins, Dnmt3a of 908 amino
acids and Dnmt3a2 of 689 amino acids, by initiation from alternative promoters.
Dnmt3a is localised to heterochromatin wheras Dnmt3a2 is diffusely distributed in the
nucleus. The Dnmt3b gene encodes at least 4 isoforms in the mouse: Dnmt3bl,
Dnmt3b2, Dnmt3b3 and Dnmt3b6. Dnmt3bl and Dnmt3b2 are active enzymes,
whereas the other isoforms lack motifs in the catalytic domain and are inactive (Chen
and Li 2004). In addition to these enzymes, the Dnmt3 family also includes the
Dnmt3L protein which lacks an active catalytic domain but which still appears to play a
role in determining imprinting by interaction with other methyltransferases (Aapola, et
al 2001, Bourc'his, et al 2001, Hata, et al 2002).
The Dnmt3a and 3b proteins are closely related with the N terminal region including 2
conserved regions: a cysteine rich region with a zinc fmger and plant homeodomain- like
sequence, which interacts with the histone deacetylase Hdacl and a putative
transcriptional repressor RP58, and a PWWP domain, which is of unknown function but
may be involved in DNA binding and is essential for localisation to heterochromatin.
Dnmt3a2 and Dnmt3bl are highly expressed in ES cells, germ cells and early embryos,
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but are almost undetectable in mature somatic tissues, whereas Dnmt3a and Dnmt3b3
are expressed at low levels in most somatic tissues (Chen, et al 2002). Dnmt3a and
Dnmt3b have equal affinity in vitro for unmethylated and hemi-methylated DNA and
were shown to be essential for de novo methylation by targeted deletion of the catalytic
domain of either or both enzymes in embryonic stem cells (Okano, et al 1998a).
Methylation of retroviral DNA following infection with MMLV was found to be absent
in cells with both enzymes deleted, showing that the two enzymes together probably
represent the entire set of de novo methyltransferases, and there is redundancy between
the two enzymes in the function of methylation of retroviral insertions.
Both Dnmt3a and Dnmt3b are essential for normal development. Dnmt3b~ ~ embryos
do not survive to term and have multiple defects including neural tube defects,
ventricular septal defects, liver hypoplasia and growth impairment, although
development appears normal until day E9.5 (Okano, et al 1998a, Ueda, et al 2006).
Dnmt3a" embryos survive to term but are runted and die by 4 weeks of age (Okano, et
al 1998a). Double mutant Dnmt3b~ ~ Dnmt3a '~ embryos, produced by intercrossing
compound heterozygote mice have a much more severe phenotype, lacking somites and
dying before El 1.5. Double mutant embryos have impaired levels of methylation of
endogenous retroviral DNA, which remains constant between blastocysts and E9.5
embryos. In contrast, Dnmtl null mice show loss of methylation between the blastocyst
stage and E9.5, suggesting that de novo methylation is absent but maintenance
methylation is intact. The results suggest that Dnmt3b and Dnmt3a have distinct
functions during development but have overlapping functions in early embryogenesis.
Further evidence for the importance of DNMT3B in humans comes from the rare
inherited ICF syndrome which has been been shown to be caused by deletions involving
the DNMT3B locus at 20ql 1 (OMIM reference #242860
http://www.ncbi.nlm.nih.gov/entrez/query.fcgiVdb^OMIM). The syndrome consists of
variable immunodeficiency, centromeric instability involving chromosomes 1, 9 and 16
and facial dysmorphism. ICF patients show demethylation of DNA, with changes in
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gene expression, decondensation of pericentromeric heterochromatin and impaired
methylation of retroviral sequences.
The set of known mammalian DNA methyltransferases is completed by Dnmt2 which
has a less well defined function. The Dnmt2 gene encodes a protein of 415 amino acids
in the mouse or 391 amino acids in the human (Van den Wyngaert, et al 1998, Yoder
and Bestor 1998). In addition, Dnmt2 like proteins are present in Saccharomyces pombe
(Wilkinson, et al 1995) and D.Melanogaster (Tweedie, et al 1999). Despite the
presence of all regions of the catalytic domain, cloned Dnmt2 proteins do not have
detectable catalytic activity in vitro. While there is some evidence that Dnmt2 proteins
may have activity in vivo in D.Melanogaster, and may be involved with non-CpG
methylation, no function has been detected in mammalian systems. Deletion of Dnmt2
has no effect on methylation patterns or ability to methylate DNA de novo in mouse ES
cells, and has no detectable effect in homozygous knockout mice or on embryonic
development in D.Melanogaster (Okano, et al 1998b). Interestingly a recent paper has
shown that Dnmt2 has RNA methyltransferase activity, methylating a specific cytosine
residue in the aspartate tRNA (Goll, et al 2006). The authors speculate that this might
indicate evolution of the eukaroyotic DNA methyltransferases from prototypic RNA
methyltransferases rather than prokaryotic DNA methyltransferases. However, the data
do not support functional importance for Dnmt2, although the fact that it has remained
highly conserved through evolution suggests that a vital role may still await discovery.
1.2.2 Factors determining methylation patterns
Although the presence of the appropriate DNA methyltransferases is clearly a necessary
condition for the establishment of DNA methylation patterns, the pattern of enzyme
activity is clearly an insufficient explanation for the determination of which regions in
the genome are methylated, and in particular why CpG islands are normally
unmethylated but are methylatable in certain circumstances.
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There is evidence that targeting of de novo methyltransferases to specific regions can
involve DNA sequence factors, protein-protein interactions, and RNA dependent
mechanisms, and it is probable that different combinations of these factors are important
in different contexts.
DNA sequence motifs involved in controlling methylation have been discovered for
several imprinting genes including the Igf2r gene and the H19 gene. The Igf2r gene is a
maternally expressed gene, in which a region in intron 2 becomes methylated on the
maternal chromososme. A 113 bp segment within this region appears to control
methylation, with mutation at the 5'end of this segment leading to bi-allelic methylation,
and mutation at the 3' end preventing methylation on both alleles (Birger, et al 1999).
In the paternally methylated H19 gene, point mutations in CTCF binding sites in the
differentially methylated regions of the maternal chromosome allows methylation of the
maternal chromosome to occur (Schoenherr, et al 2003), whereas deletion of a 1.6kb
region of the parental differentially methylated region leads to mice being unable to
maintain methylation and silencing of the promoter region (Thorvaldsen, et al 1998).
These examples suggest that both repression and promotion ofmethylation by sequence
motifs can be important for imprint establishment.
There has been considerable interest in the role of protein-protein interactions with other
transcription repression systems in the recruitment of DNA methyltransferases and
establishment of methylation. The largest body of evidence concerns interactions with
histone proteins and their covalent modifications. As noted above, there is partial
localisation of the de novo methyltransferases to pericentric heterochromatin, which is
also characterised by methylation of lysine 9 of histone H3 (H3K9). The Suv39h
histone methyltransferase co-immunoprecipitates with Dnmt3b, and knockout of Suv39h
in embryonic stem cells leads to loss of H3K9 methylation, and loss of CpG methylation
at pericentric heterochromatin (Lehnertz, et al 2003), suggesting that in at least some
cases H3K9 methylation is required for DNA methylation. Other protein interactions
that have been proposed to induce DNA methylation by recruitment of de novo
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methyltransferases include polycomb group proteins (Mager, et al 2003, Vire, et al
2006), and recruitment by site-specific transcription factors- which has been
demonstrated in a pathological context for the Myc oncogene (Brenner, et al 2005) and
the PML-RARA fusion protein (Di Croce, et al 2002). However the significance of site-
specific recruitment by transcription factors remains to be demonstrated in normal
physiology.
Finally, an emerging area of interest is the role of RNA-dependent mechanisms in
directing DNA methylation. In plants, transcriptional as well as translational silencing is
induced by RNAi, and this is often associated with de novo methylation of the
corresponding promoter. While this occurs much less commonly in mammalian cells,
there are reports of de novo methylation occurring in mammalian cell lines following
RNAi directed at the promoter region (Castanotto, et al 2005, Morris, et al 2004a)
accompanied with transcriptional silencing. In one of these reports (Morris et al 2004a),
there was robust evidence of transcriptional silencing of a reporter transgene by RNAi,
which was reversed with 5'-azacytidine treatment. However the extent of methylation
induced by RNAi in this study is not clear, since the only direct evidence for
methylation was a PCR assay at a single restriction site. These studies have the
weakness that they are performed in transformed cell lines in which epigenetic
regulation may not reflect normal physiology. However, there is a case report of DNA
methylation at the alpha globin locus occurring in an alpha-thalassaemia patient with a
deletion which results in a truncated, widely expressed gene (LUC7L),which is
transcribed from the antisense strand, becoming juxtaposed to a structurally normal «-
globin gene and leads to the presence of antisense alpha globin transcripts (Tufarelli, et
al 2003). The effects on DNA methylation of disruption of the RNAi machinery by
deletion of the Dicer gene are conflicting (Kanellopoulou, et al 2005, Murchison, et al
2005) but raise the possibility of the involvement of endogenous miRNA or siRNA in
the normal control of methylation at some loci. However, the fact that there are very
few reports describing RNAi-induced DNA methylation in mammalian cells, even
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though it is an attractive and obvious phenomenon to seek, would tend to suggest that it
is of genuinely rare occurrence.
1.3 Mechanisms of transcriptional regulation
We have seen in the paragraph above that there is considerable interaction with other
systems of transcriptional silencing in the establishment of methylation at specific loci.
In this section, the complementary interactions are reviewed- the mechanism by which
DNA methylation marks may promote transcriptional silencing. The simplest
mechanism is that the methyl group may prevent access of transcription factors to their
binding sites. The clearest example that this is the case is in the role of CTCF binding in
the silencing of the imprinted Igf2/H19 locus. Expression of the Igf2 gene is dependent
on a downstream enhancer element. Binding of the enhancer blocking CTCF protein at
the imprinting control region between the Igf2 gene and its enhancer thus prevents
expression of the gene. The imprinting control region is methylated on the paternal
allele, corresponding to its paternal- restricted expression pattern; CTCF binding can be
shown to be abolished both by methylation in vitro, and by mutation of the binding sites
in vivo (Bell and Felsenfeld 2000).
A second mechanism of transcriptional regulation by methylated DNA involves the
interaction with methyl binding proteins. A family of methyl binding proteins (Fig 1.1)
sharing a common methyl-CpG binding domain has been identified, which comprises
the proteins Mbdl, Mbd2, Mbd3, Mbd4 (Hendrich and Bird 1998) and MeCP2 (Lewis,
et al 1992). In addition there are further methyl-DNA binding proteins including Kaiso
proteins, which do not posess a classical methyl binding domain but recognise
methylated DNA through C-terminal zinc finger domains (Prokhortchouk, et al 2001)
(for review see Hendrich and Tweedie 2003). The first described entity with methyl
binding activity (Meehan, et al 1989) is now known to be a protein complex (MeCPl),
which includes the Mbd2 protein (Ng, et al 1999) and the nuclear remodelling complex
(NuRD) which consists of multiple proteins with transcriptional repressive activities
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(Zhang, et al 1999), including the histone deactylases Hdacl and 2. Mammalian Mbd3
does not have methyl DNA binding activity (Hendrich and Bird 1998) but also interacts
with the NuRD complex separately to Mbd2. MeCP2 was the first distinct methyl
binding protein to be isolated (Lewis, et al 1992, Meehan, et al 1992), has strong affinity
for methyl DNA and also recruits histone deacetylases. Mbdl also has transcription
repression activity which is partially mediated by histone deactetylase recruitment, and
has the ability to inhibit transcription from both methylated and unmethylated sequence
(Cross, et al 1997, Fujita, et al 2000, Fujita, et al 1999). Finally Mbd4 appears to have a
quite distinct function being more concerned with DNA repair in order to prevent C->T
transitions caused by deamination of methylcytosine, as predicted by its increased
affinity for mCpG:TpG mismatches and confirmed by the increased frequency of C->T
transitions in Mbd4"/_ knockout mice (Millar, et al 2002, Wong, et al 2002).
Despite the ability ofmethyl binding proteins to silence transcription upon binding to
methylated DNA, the alterations in transcription and phenotypic changes of knockout
mice for most individual methyl binding proteins are in fact fairly subtle, in contrast to
the effects of deletion of the DNA methyltransferase enzymes. The exceptions are
MeCP2 which shows neurological features similar to those seen in Rett syndrome (Guy,
et al 2001), and Mbd3 (Hendrich and Bird 1998), which is even more surprising as it
does not have methyl binding activity. The obvious explanation for this contrast is that
there is redundancy in the methylation-reading machinery, with one of the remaining
methyl binding proteins being able to compensate for the loss of one of the others. The
evolutionary evidence that duplication of methyl binding protein genes appears to have
occurred at the invertebrate-vertebrate transition, which corresponds to the increase of
methylation in the genome, is perhaps supportive of this hypothesis.
An alternative, more radical possibility that is difficult to discount completely is that
many of the regulatory functions of the DNA methyltransferases are mediated through
mechanisms other than DNA methylation, and it is in fact the DNA methylation itself
that is redundant. Since Dnmt3 proteins are able to interact directly with histone
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deacetylases, and Dnmtl also has multiple protein interactions, their role in
transcriptional regulation may be primarily effected through this route. In addition,
there is evidence in a number of models that gene silencing and histone modifications
(in particular histone 3 lysine 9 methylation) precede, and are necessary for development
of DNA methylation (Mutskov and Felsenfeld 2004). It has also been shown that
silencing of X-inactivated genes (Sado, et al 2004), and establishment of imprinted gene
expression (Lewis, et al 2004), can occur without de novo DNA methylation, suggesting
that methylation is not necessary for epigenetic silencing. However, the accepted model
is that histone modifications, chromatin structure and DNA methylation form an
interrelated system mediating epigenetic silencing. In this model, recruitment of methyl
binding proteins by methylated DNA and recruitment of DNA methyltransferases by
histone modifications form a positive feedback loop to maintain the stability of
transcriptional silencing. Since the heritability of DNA methylation is a well defined
mechanism, it may be that the most important role of DNA methylation is to promote
heritability of transcriptional silencing during cell replication, although experimental
evidence that organisms that have DNA methylation have greater stability of epigenetic
regulation during replication is lacking.
1.4 DNA methylation and genome stability
Although the majority of work on DNA methylation has focussed on its role in
transcriptional silencing, it may have an equally important role in genome stability. As
noted above, the DNA methylation system may have evolved as part of the bacterial
defence system against viruses, and it retains this importance in eukaryotes. The
methylation of integrated retroviral sequences (Harbers, et al 1981) and the reactivation
of retroviruses on treatment with demethylating agents (Jahner, et al 1982) has long
been established. In addition to this role, there is evidence that deficiencies in both de
novo and maintenance DNA methylation lead to increased chromosomal instability. As
noted above, in the ICF syndrome, partial loss of function of Dnmt3b leads to
pericentromeric demethylation, and centromeric instability; these results have also been
19
shown in a mouse model (Ueda, et al 2006). Deletion of the maintenance enzyme
Dnmtl in embryonic stem cells (Chen, et al 1998) led to interstitial deletions; the
importance of this effect was confirmed in vivo by the finding of increased chromosome
alterations in lymphomas from Dnmtl hypomorphic mice compared to that found in
retroviral tumours (Gaudet, et al 2003). The balance between the effects of
demethylation on genome stability and the effects ofhypermethylation on gene silencing
is a particularly important question in tumour biology and will be discussed at several
points below.
1.5 DNA methylation in developmental biology
The establishment of methylation patterns is a dynamic process during development,
with waves of genome-wide demethylation and remethylation occurring. Following
fertilisation, the genome becomes demethylated, although imprinted genes are spared
demethylation, retaining their parent-specific methylation pattern. Methylation patterns
are subsequently re-established between the morula and blastocyst stages of
development. There is a second wave of demethylation which occurs in primordial
germ cells during which methylation patterns are reprogrammed in a sex specific
manner to establish parental-specific imprinted marks in gametes to pass on the
appropriate imprints to the next generation. Further de novo methylation rarely occurs
in development subsequent to gastrulation.
Given the expansion of genomic DNA methylation frequency in higher organisms, it is
tempting to suggest that DNA methylation has a role in maintaining tissue-specific gene
expression patterns, enabling stability of tissue specification for the development of
complex organs. While methylation patterns have long been shown to vary between
tissues, a correlation between methylation and expression has been harder to establish.
For tissue specific genes without a CpG island promoter, there are several examples
where methylation of specific sites appears to regulate transcription, of which the (3
globin locus is probably the best studied example (Busslinger, et al 1983, Yisraeli, et al
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1988). In contrast, the majority of CpG island genes are not regulated by methylation-
the CpG island is unmethylated regardless of the transcriptional state. The strongest
evidence that tissue specific expression can in some cases be regulated by methylation of
CpG island genes comes from the maspin (SERPINB5) gene which shows a strong
inverse correlation between expression and promoter methylation status in primary cell
lines from various tissues (Futscher, et al 2002). Other strong candidates include the
MAGE genes which are methylated in somatic tissues but unmethylated and expressed
in the testis (De Smet, et al 1999). More recently, RLGS experiments from primary
mouse tissues have identified as many as 150 CpG island regions which show tissue
specific methylation (including CpG islands in intronic or exonic regions as well as
promoter CpG islands) and correlation with tissue specific expression for a number of
these genes (Song, et al 2005). While these experiments indeed suggest that there are
tissue specific methylation patterns which correlate with tissue specific gene expression,
it remains to be proven still what role these methylation marks play in tissue
specification- whether they are necessary for tissue specification, promote stability of
tissue specification or are simply footprints of gene silencing effected by other means.
1.6 Pathology of DNA methylation- role in cancer
It has long been recognised that the normal patterns of genomic DNA methylation
described above are altered in cancer. The prototypical alteration seen is demethylation
of the bulk DNA, but this is accompanied by aberrant CpG island methylation (for
review see Herman and Baylin 2003). Both abnormalities have the potential to
contribute to the pathogenesis of cancer, and it is a major area for research determining
the mechanisms by which these abnormalities arise, and the exact role they play in the
biology of cancer.
Hypomethylation may be involved with the pathogenesis in cancer by a number of
mechanisms. Firstly, the demethylation of regions normally silenced by methylation
may lead to reactivation of imprinted genes, X inactivated genes or retroviral elements.
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Secondly, demethylation may lead to increased chromosome instability particularly in
the pericentromeric regions. Lines of evidence that this mechanism indeed plays a role
in cancer include the increase of chromosomal abnormalites and development of
aggressive lymphomas in Dnmtl hypomorphic mice (Gaudet, et al 2003).
Abnormal methylation of CpG islands has the potential to influence tumour
development by the inactivation of tumour suppressor genes. This may provide an
alternative mechanism of inactivation in addition to mutation or genomic deletion,
which are well established mechanisms of carcinogenesis. Silencing by methylation
could act as an early event in cancer, providing a second hit inactivating the normal
allele after the opposite allele has been inactivated by somatic or inherited mutation. In
addition, methylation could possibly inactivate both alleles at a tumour suppressor locus
or several loci, which may be sufficient to cause cancer. Alternatively (or additionally),
methylation increased as a secondary consequence of malignant transformation could
promote the progression of already established tumours, leading to inactivation of
further genes which could increase tumour growth or metastasis. Finally, it could act to
stabilise epigenetic inactivation of tumour suppressor genes which have been
epigenetically inactivated by other mechanisms such as histone modification.
That aberrant methylation of tumour suppressor genes can be identified in cancer, both
in cells from primary tumours and cell lines, is not in doubt, and there are an ever
increasing number of reports from many different tumour types describing the
methylation of genes involved with such diverse functions as cell cycle regulation, cell-
cell adhesion, drug resistance, genome stability. It appears that certain genes seem to be
particularly prone to abnormal methylation in tumours, and it has also been suggested
that specific patterns of methylation may be characteristic of the origin of the tumour
(Esteller 2002 for review). A number of these genes have been shown to become
expressed upon treatment with demethylating agents such as 5'-azacytidine. This has
been taken as proof that these genes have been pathologically silenced by methylation
and that pharmacological demethylation is restoring them to their normal state of
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expression, with the implication that methylation is contributing to the behaviour of the
tumour. However other observations show that these arguments are simplistic. Firstly,
genomic experiments aimed to discover new hypermethylated genes in cancer in an
unbiased manner show that there are in addition many aberrantly methylated genes for
which it is difficult to predict a role in cancer pathogenesis (Dai, et al 2001, Rush, et al
2001, Rush, et al 2004). Since it is difficult to suggest that methylation of these genes
would give a selective advantage to the cell such that a clone with methylation of these
genes would become dominant, this observation favours the hypothesis that much of the
aberrant CpG island methylation seen in cells is a bystander effect with no direct role in
tumour behaviour. Secondly, 5'-azacytidine treatment clearly has substantial effects on
gene expression independent of its demethylating action, with activation of silent but
unmethylated genes demonstrable, since experiments using microarray analysis for
genes upregulated by 5'-azacytidine as a method of identifying methylated genes have
shown a variable rate of success in identification of genuinely methylated genes (Liang,
et al 2002, Schmelz, et al 2005, Yamashita, et al 2006). This suggests that reactivation
by 5'azacytidine is insufficient evidence to demonstrate that a gene would normally be
active, and thus it is possible that methylated tumour suppressor genes may have been
silent anyway with their methylation making no contribution to tumour behaviour.
More sophisticated arguments that DNA methylation does have an important role in
cancer come from two lines of evidence. The first is the finding of an increased
frequency ofmethylation at tumour suppressor gene loci in sporadic cases of tumours
compared to hereditary cases in which a genomic abnormality of one allele is inherited.
One of the oldest models is retinoblastoma, a retinal tumour caused by biallelic
inactivation of the Rb gene, which occurs both sporadically and in a familial form in
which a genomic abnormality of the Rb locus is inherited on one allele (OMIM
reference +180200, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM). The
frequency of hypermethylation in unilateral, sporadic tumors was 9.3% (13/140),
whereas the frequency was 1.0% in bilateral hereditary tumors (1/ 101) (Ohtani-Fujita,
et al 1997), suggesting that there may be a background rate of inactivation by
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methylation at this locus contributing to tumorigenesis independently. A second model
is methylation of the mismatch repair gene MLH1 in colonic tumours. This model is
particularly instructive since the presence of the downstream consequence of MLH1
inactivation, microsatellite instability, offers evidence that methylation has caused
functionally significant inactivation (Herman, et al 1998). In one study, methylation of
the MLH1 locus was found in 7/10 sporadically occurring colon tumours with
microsatellite instability compared to 0/10 in tumours from hereditary non-polyposis
coli patients with inherited mutations of the MLH1 gene (Wheeler, et al 2000),
suggesting that DNA methylation is likely to be an early event in tumour formation.
Finally, in colon cancer patients with inherited germline mutations ofMLH1 and breast
cancer patients with inherited mutations of BRCA1, there is a greatly increased incidence
of methylation in patients with retention ofboth alleles in the tumour compared to those
with loss of heterozygosity at the mutated locus (Esteller, et al 2001).
The second line of evidence comes from experimental animal models. The animal
system which has been most widely studied in this context is the Apc+"mn mouse. The
Apc+,mm mouse is one of the oldest established models of inherited tumour
predisposition, and carries a mutation produced by chemical mutagenesis in the Ape
gene which causes reduced expression. The phenotype is dominantly inherited, and
mice develop multiple bowel tumours which appear to progress from microadenomas to
adenomas to adenocarcinomas (Moser, et al 1990). The mouse Ape gene is the
homologue of the human A PC gene, which is mutated in the human inherited cancer
syndrome of familial adenomatous polyposis coli (Su, et al 1992). The earliest evidence
for an involvement of DNA methylation in the pathogenesis ofApe mm mice came from
demonstrating reduced tumour frequency with 5'-azacytidine treatment (Laird, et al
1995). More convincing is the demonstration of reduced frequency of tumours in mice
carrying the min mutation on a background of various combinations ofDnmtl
hypomorphic alleles (Cormier and Dove 2000, Eads, et al 2002). The number of polyps
was reduced in proportion to the severity of Dnmtl depletion, with complete suppression
of polyps in the most severely depleted animals. More recently, these results have been
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elaborated in Apc+ mm mice with compound heterozygosity for DnmtI-null and Dnmtl
hypomorphic alleles (Yamada, et al 2005). This system showed an increased number of
microadenomas as defined by abnormal nuclear beta-catenin staining but a decreased
number of polyps, with increase in loss of heterozygosity in microadenomas from the
Dnmtl deficient mice. The results are interpreted as indicating an increased rate of
tumour initiation as a result of chromosomal instability, but a reduction in survival to
form established adenomas because of a requirement for maintenance methylation for
tumour survival. In addition the role of maintenance methylation is clearly not simple,
since as well as reduced intestinal tumour formation, there were increases in other types
of cancer such as T cell lymphoma (Gaudet, et al 2003) or liver tumors (Yamada, et al
2005).
The role of de novo methyltransferases in Apc+ mm mice has also been investigated by
establishing Apc+,mm mice with conditional deletion of Dnmt3b in the intestine (Lin, et
al 2006). In contrast to the results in Dnmtl depleted mice, deletion ofDnmt3b was
found to reduce the number of colonic adenmomas but not the formation of
microadenomas. Importantly, Dnmt3b was found not to be essential for tumour
formation since Dnmt3b negative tumours (both micro and macroadenomas) were
found, although the proportion of macroadenomas which were Dnmt3b negative was
reduced. These studies did not demonstrate the silencing by methylation of tumour
suppressor genes, and thus strictly speaking demonstrate the necessity for
methyltransferase enzymes rather than for DNA methylation itself. However,
circumstantial evidence that DNA methylation itself may be important for tumour
establishment in Apc+mm mice is provided by the reduced incidence of tumours in
Apc+ mm mice crossed with Mbd2 deficient mice (Sansom, et al 2003). Independent of
the Ape model system, decreases in intestinal tumour formation have also been seen on
an Mlhl deficient background (Trinh, et al 2002).
Looking at other tumour model systems, Dnmtl deficiency has also been shown to
reduce lung tumour formation in a tobacco-carcinogen induced lung tumour model
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(Belinsky, et al 2003). The most direct demonstration that methylation can act in a
causative manner to silence tumour suppressor genes is the study of tumours in Hicl
heterozygous mice. The Hicl transcription factor is a putative human tumour suppressor
gene. Mice heterozygous for a Hicl mutation develop both solid tumours and
lymphomas with high frequency from around 70 weeks of age (Chen, et al 2003b).
Importantly, allele specific methylation specific PCR demonstrates methylation of the
wild type allele but not the mutated allele in tumours from these mice, which
corresponds to loss of Hicl expression.
A major question is of the origin of abnormal methylation patterns in tumours. From an
aetiological viewpoint, increased methylation of CpG islands have been described in
association with aging (Issa, et al 1994, Waki, et al 2003), chronic inflammation (Hsieh,
et al 1998, Issa, et al 2001) and chemical insults (Lee, et al 1995, Mass and Wang
1997). However, it remains unproven whether this corresponds to silencing of the gene,
since the regions methylated in these models are mostly exonic or far upstream regions
of the promoter, with the region immediately covering the transcription start site
remaining unmethylated. Regarding the molecular mechanism of abnormal methylation
induction, it has been suggested that dense, silencing-inducing methylation of core
promoter regions may spread from sporadic methylation events or distant regions of
methylation, perhaps caused by factors such as those described above (Stirzaker, et al
2004). Diminished transcription, including that caused by siRNA has also been shown
to favour methylation (see above), and H3K9 methylation has been shown to precede
DNA methylation in the remethylation of cancer cells following 5'-azacytidine
treatment (Bachman, et al 2003). Finally DNA methyltransferases must be involved in
development of abnormal methylation. Since little de novo methylation occurs after
gastrulation and the de novo methyltransferases are downregulated, development of
abnormal methylation events must be preceded by an increase in de novo methylation
capacity. Accordingly, levels of DNA methyltransferases have been found to be
upregulated in primary tumours (see Clark and Melki 2002 for review). As would be
expected, the presence of both maintenance and de novo methyltransferase activity
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seems necessary for maintaining cancer cell demethylation patterns (Leu, et al 2003,
Rhee, et al 2002). More controversially it has been suggested that Dnmtl may exhibit
de novo methytransferase activity especially in the pathological context (J air, et al
2006). The ability of DNA methyltransferases to cause abnormal methylation events
was shown by the increased number of CpG islands methylated by over-expressing
DNMT1 in human cancer cell lines (Feltus, et al 2003, Vertino, et al 1993), although
levels of DNMT1 over-expression in this study far exceeded those seen in normal or
pathological contexts. In addition the detection of abnormal CpG island methylation
does not necessarily direct de novo methylation by Dnmtl; aberrant methylation events
could still occur through improved maintenance of methylation established by proven de
novo methyltransferases.
An important point about the above studies is that they are all conducted in cell lines,
which are immortalised and in that sense may be argued to be already neoplastic. While
they provide considerable insights into possible mechanisms, they tell us little about the
actual course of events in vivo, and in particular they tell us nothing about the effects of
disturbing DNA methylation mechanisms in normal cells, which is of critical importance
if it is to be argued that methylation disturbance is an early, causative event in cancer.
Current controversy surrounds the question of whether certain tumours are more prone
to abnormal methylation than others- the so called CpG island hypermethylator
phenotype (CIMP). The existence of a discrete hypermethylator phenotype would be
highly persuasive evidence that methylation in tumours has a distinct, independent cause
which could be targeted, especially if a relationship to tumour prognosis or evolution
can be shown to correlate with such a phenotype. As is often the case with this type of
concept, there is no clear definition of what constitutes a hypermethylator phenotype.
The largest study which claims the existence of the CIMP phenotype, an analysis of 864
colorectal tumours from patients with colonic cancer (Samowitz, et al 2005), examined a
small panel of 5 genes for methylation. Undoubtedly there were tumours with different
numbers of genes methylated, and multivariate analysis showed a relationship between
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methylation of several genes (2/5) with age, stage and differentiation state. However,
studies have given conflicting results on whether there is a bimodal distribution of
methylated genes, which is surely an essential consequence if there is a distinct CIMP
phenotype reflecting the presence or absence of a specific mechanism promoting
methylation. A recent paper (Weisenbergcr, et al 2006) uses cluster analysis on a large
set of cancer methylated genes in primary tumour samples from colorectal cancer
patients. Following selection of genes which are aberrantly methylated in colorectal
cancer, unsupervised clustering using these genes in an independent sample did appear
to identify a subset of tumours with high numbers of methylated genes. Interestingly,
the presence of mutation in the BRAF kinase appeared to be a necessary condition for
membership of this group. However the cluster analysis also identified a set of genes
which are commonly methylated in cancer but did not have a high frequency of
methylation in the "hypermethylator" group. What this would seem to indicate is that
specific methylation patterns can be consequent upon specific genomic abnormalites,
and methylation patterns could therefore be characteristic of other abnormalities in the
cell. While this paper does convincingly demonstrate a hypermethylator phenotype, in
the sense of a distinct group of tumours which has extensive aberrant methylation, it
remains to be seen whether there there is a truly independent hypermethylator concept.
The identification of this will need to await the results of studies looking at unbiased
selections of CpG islands and studies in other tumour types.
The attraction of DNA methylation in cancer as a subject for study is that methylation
changes are potentially reversible with demethylating agents such as 5'-azacytidine and
decitabine. If methylation induced silencing of genes essential for tumour behaviour can
be reversed, this could be a powerful therapeutic strategy. Unfortunately, the results of
clinical studies with demethylating agents do not really support a simple activity of
widespread reactivation of tumour essential genes, as is often proposed by more
enthusiastic advocates (Figure 1.2). The methylation inhibitor 5'-azacytidine has been
available since the 1960s, and was initially used in clinical studies as a standard
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cytotoxic nucleoside analogue. Despite its ability to prevent tumour development in
animal models, it has had a disappointing record in human tumours. The most
widespread experience clinically has been in the treatment of myelodysplasia, a set of
clonal haematological stem cell disorders which are characterised by peripheral blood
cytopenias and a variably aggressive risk of transformation to acute leukaemia. While
5'-azacytidine clearly does have activity in some patients with myelodysplasia,
improving peripheral cell counts and improving survival, the results in real terms are
disappointing, with an improvement in median survival of 7 months in the largest
published study (Silverman, et al 2002b). It is unclear how much of this effect is due to
methylation and how much due to the cytotoxic effect, though it might be predicted that
demethylation effects would predominate at the low doses used, and also the clinical
effects are probably stronger than in studies of treatment with low dose cytarabine,
another cytosine analogue without demethylating ability. 5'-Azacytidine is a less than
satisfactory drug for long-term administration due to its mutagenic effects and the need
for administration by injection. In contrast there are no clinical reports of activity in
solid tumours, even though much of the evidence for methylation in cancer comes from
solid tumours, and it seems unlikely that a previously ineffective drug will become
effective because of the discovery of an additional mode of action. A deeper
understanding of the cause and effects of methylation in cancer could help to restrict
clinical study to those patients and tumours in which demethylating agents are more
likely to succeed.
Secondly, even if methylation changes do not always have a causative role in cancer
they could still have a role in diagnosis and monitoring. The fundamental difficulty with
the use of molecular techniques in cancer is the diversity of abnormalities found in
tumours. The search for individual mutations in a tumour from a given patient is too
labour intensive for clinical use, and so there is a need for abnormalities that are
common across tumours of a given type between a significant number of patients. Such
abnormalities are available for a small subset of tumours, for example the common
chromosomal translocations in leukaemia, but are rare overall. The study of commonly
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methylated genes as a molecular diagnostic technique has the attraction that a given
methylated gene shows the same abnormality in tumours from different patients (or
different types of tumour for that matter), enabling a higher throughput of testing. The
use of methylation abnormalities for diagnosis and monitoring would have more validity
if it can be shown that these abnormalities are essential to the behaviour of the tumour,
although this can only be fully validated empirically in the clinical situation.
1.7 Aims of the project
To summarise the discussion above, there are a number of open questions regarding the
development of CpG island methylation and its role in transcriptional regulation, in
particular with reference to cancer. While abnormal CpG methylation is clearly a
phenomenon associated with cancer, it remains unproven whether it can act as a primary
cause of cancer. More generally, it also remains unproven whether DNA methylation
can act as an initial mechanism to inactivate gene expression, or whether prior gene
silencing and/ or histone modification is a necessary condition preceding methylation.
Secondly, it is uncertain whether abnormal methylation events occur stochastically,
essentially representing errors in determining correct methylation patterns, or whether
they are targeted to specific loci. Finally, given the downregulation of de novo
methyltransferases in adult life, it is uncertain whether the lack of the occurrence of
further de novo methylation events post-gastrulation is mainly a consequence of
insufficient de novo enzyme activity, allowing dysregulation of de novo
methyltransferases to cause abnormal DNA methylation patterns, or whether there is a
more coordinated direction of DNA methylation patterns.
In this project, an attempt is made to address some of these questions by prospectively
creating abnormal patterns of DNA methylation in vivo. As noted earlier, it is necessary
to work in vivo rather than in transformed cell lines to prove the role of abnormal
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methylation events in the earliest stages of tumour formation, since cell lines have
already in some respect undergone neoplastic transformation and also have increased
levels of de novo methyl transferases. On the basis that over-expression of a de novo
methyltransferase is a necessary condition for producing abnormal methylation events,
the approach chosen is this is the development of transgenic mice which over-express
Dnmt3b. Dnmt3b is particularly implicated in the development of aberrant methylation
in cancer since it is more consistently increased in tumours than Dnmt3a or
Dnmtl (Robertson, et al 1999). Dnmt3b has also been shown to be necessary for
maintaining aberrant methylation patterns in tumour cell lines (Rhee, et al 2002), and
for soft agar colony formation in mouse embryonic fibroblasts and human bronchial
epithelial cells transformed with ras and SV40 large T antigen (Soejima, et al 2003).
The primary question that can be answered by this system is whether increases in de
novo methyltransferase activity are sufficient to cause abnormal methylation events,
either at CpG islands at specific loci or globally. If abnormal methylation events are
indeed a consequence of DNA methyltransferase over-expression, it can be asked
whether this has any consequences for normal development, and whether there is any
spontaneous incidence of tumours. If it could be shown that there are differences in
gene expression associated with methylation, or spontaneous tumour formation with
silencing of tumour suppressor genes, this would be very strong evidence that DNA
methylation can be a direct cause of gene silencing or tumour formation. If there is no
spontaneous tumour formation, could Dnmt3b over-expression still play a role in tumour
behaviour by influencing gene silencing later on in the natural history of tumour
development? This question is addressed by studying the effects of Dnmt3b in a
carcinogenesis model and also in the context of inherited cancer prone mutations, to
study effects of DNA methylation in a system where the molecular mechanism of
tumour formation is well defined.
Subsidiary questions that may be answered by over-expressing Dnmt3b in vivo include
whether changes in methylation in the context of active de novo methyltransferase
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activity occur in a stochastic or pre-determined pattern, and to determine the
relationship between DNA methylation and transcription- specifically, whether DNA
methylation events precede transcriptional silencing and whether prior silencing is a
necessary or sufficient condition to allow methylation in the context of active de novo
methyltransferase activity.
In the following chapters the production of Dnmt3b over-expressing mice and analysis
of their phenotype are described. The consequences of Dnmt3b over-expression on
DNA methylation patterns in vivo are then demonstrated. Finally, the effects of
increased Dnmt3b are investigated with respect to two specific phenomena which have
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Figure 1.1 The mammalian DNA methyltransferases and methyl-binding proteins. Figure 1 .lal is reproduced
fromTurek-Plewa and Jagodzinski (2005) PBD- PCNA binding domain NLS- nuclear localisation signal. PHD-
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Figure 1.2 An optimistic view of demethylating agents in cancer. Reproduced from MGI
Pharma booklet "Innovation in the treatment ofhaemato logicat malignancies"
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2. Production and characterisation of Dnmt3b over-expressing mice
Mice over expressing Dnmt3 were produced by electroporating embryonic stem cells
with a Dnmt3b expression construct consisting of full length Dnmt3bl cDNA driven by
the ubiquitously expressed CAG promoter (shown in Figure 7.2). The construct has
previously shown to be active, rescuing the global methylation levels in Dnmt3b_/~
Dnmt3a~ embryonic stem cells (Jackson, et al 2004). A total of 10 chimaeric mice were
successfully produced by injection into C57BL6 blastocysts of transformed ES cells
derived from a single ES cell clone. The male chimaeras were backcrossed and
maintained on a C57BL6 background to form a transgenic strain Tg(Dnmt3b), and were
genotyped by western blot.
2.1 Tg(Dnmt3b)+ mice are developmentally normal
Tg(Dnmt3b)+ mice develop to term and are born in the expected 50% transgenic - non
transgenic ratio, with equal numbers of male and female mice born. They develop to
term normally and appear to have no morphological abnormalities from birth to early
adult life. Both males and females are fertile giving rise to viable young, although litter
sizes are slightly below that expected for C57BL6 mice with a median litter size of 4.5
(mean 4.8+/-SD 2.3, n=57 litters) compared to expected size of 7 (Festing 1999). The
effect may be on male fertility since litters derived from female transgenic mice are
possibly larger with a median size of 7 (mean 5.9 SD 2.0 n=7 litters), although the
difference is not statistically significant (95% confidence interval for difference in litter
size between male and female transgenic parents=2.9 to -0.74).
Tg(Dnmt3b)+ mice are significantly smaller at all ages after weaning than Tg(Dnmt3b)-
mice from the same strain although growth rates appear comparable (Figure 2.1, Table
2.1). The 95% confidence interval for ratio of weights is 0.74-0.92 for females and
0.66-0.75 for males, as estimated by linear regression of weights of Tg(Dnmt3b)+
against Tg(Dnmt3b)- mice (Figure 2.2). The outlying points on the regression graphs
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represent a fall in weight of transgenic animals in the last 1-2 weeks of life as they
become unwell.
2.2 Tg(Dnmt3b)+ mice over-express Dnmt3b in a wide range of tissues
Western blot analysis confirms that Dnmt3b is strongly expressed in the transgenic
animals in a range of tissues in which it is weakly expressed if at all in adult wild type
mice. Expression is seen in tissues including skin, heart, lung, kidney, gut and brain
(Figure 2.3). The data are consistent with the tissue expression in other transgenic
mouse models where expression is driven by the CAG promoter (Isoda, et al 2002,
Okabe, et al 1997, Wiekowski, et al 2001). Dnmt3b is not detectable by Western blot in
these tissues in wild type mice. While published data does suggest that Dnmt3b is
transcribed at low levels in adult tissues (Xie, et al 1999) and in tissue stem cells
(Hamra, et al 2004, Morris, et al 2004b), it can be concluded from this data that
Tg(Dnmt3b)+ mice show expression of Dnmt3b protein which is many times higher in
the above tissues than in wild type mice.
2.3 Tg(Dnmt3b)+ mice have reduced survival
A reproducible phenotype has emerged in Tg(Dnmt3b)+ mice. Tg(Dnmt3b)+ mice
become unwell and die at a median age of 120 days (95% confidence interval 116-125
days). As can be seen from the survival curve in Figure 2.4, almost all deaths occur in a
small range of ages, with very few animals surviving past 150 days. There is no
significant sex difference in mortality (Figure 2.5). Figure 2.6 compares Kaplan-Meier
estimates of survival between generations for all mice up to the F7 generation (including
animals that were sacrificed early in the analysis as censored obsevations), and suggests
there is a significant difference in survival between animals of different generations.
There is no significant difference if F1 animals are excluded from the analysis, and there
are no significant pairwise differences in survival between animals of generations other
than F1 by post-hoc analysis of variance. This suggests that survival is particularly
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reduced in the F1 generation but remains stable in subsequent generations. Possible
explanations for this difference are that Dnmt3b over-expression is more toxic on a 129
strain background, and thus mice live longer with further outcrossing on to a C57BL6
background, or that transgene expression is stronger in the first generation of mice,
possibly as a result of variegated transgene silencing in later generations (see Section
4.3).
2.4 Tg(Dnmt3b)+ mice have a reproducible phenotype which includes
cardiomyopathy
There are three phenotypic abnormalites that appear to be characteristic of Tg(Dnmt3b)+
animals. All abnormalities are present in heterozygous dosage; there has been no
attempt so far to create mice with homozygous expression of Tg(Dnmt3b). The most
striking abnormality is the development of cardiomyopathy, which is probably the most
likely cause of premature death in the animals. Post-mortem analysis shows that hearts
from Tg(Dnmt3b)+ animals are enlarged and have significantly increased mass (mean
0.3g +/- SD 0.07g vs 0.15+/- 0.03g for age matched non-transgenic control hearts from
the same (Fl) generation). Gross morphological analysis shows dilatation of both
ventricular chambers and thinning of the ventricular walls (Figure 2.7). Atrial thrombus
is often present at post mortem though this may be a post-mortem artefact. The liver
commonly, though not invariably, shows congestion in keeping with the effects of heart
failure. Histological analysis shows myofibre drop out and pallor, vacuolation and
myocyte nuclear hypertrophy with prominent nucleoli (Figure 2.8a), and prominent
interstitial fibrosis (Figure 2.8b). To determine whether the cardiac enlargement was due
to hyperplasia or hypertrophy, BrdU immunostaining following in vivo labelling, and
PCNA immunostaining were performed. These show that the myocardium remains non¬
proliferative (Figure 2.9). The histological findings are best described as those of a
dilated cardiomyopathy, and appearances favour this being an inherited cardiomyopathy
as there are no other features suggesting a haemodynamic cause such as hypertension.
Further characterisation of the heart phenotype is discussed in chapter 4.
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A second histological abnormality at post mortem is in the kidneys (Figure 2.10).
Tg(Dnmt3b)+ mice develop abnormalities in the juxtamedullary glomeruli with
podocyte proliferation, and the presence of dilatation of the renal tubules with protein
casts. Proteinuria is confirmed on testing ofurine from Tg(Dnmt3b)+ mice. The
changes have some similarities to renal abnormalities seen in the aging mouse kidney,
but are present at a much younger age than expected and are not present in littermate
wild type animals.
A final abnormality is behavioural. As noted above, Tg(Dnmt3b)+ females bred with
wild type males produce morphologically normal offspring. However offspring are
invariably killed and eaten by the mothers within 24 hours ofbirth. The finding is
clearly a maternal effect, since offspring survive normally when fostered at birth to CD 1
strain mothers. In addition, there is no increase in infanticide in offspring derived from
male Tg(Dnmt3b)+ males and wild type C57BL6 females. Anecdotally, Tg(Dnmt3b)+
females also seem to have impaired nest-building activity with pregnant females
building shallow nests similar to virgin females or male mice, although this finding has
not been confirmed in a blinded manner.
2.5 Phenotypic changes are confirmed in a second line
Two possible confounding explanations are possible for the abnormal phenotypes seen
in the initial Tg(Dnmt3b)+ mouse line. The first possibility is that phenotypic changes
are due to disruption of a gene by transgene integration, although the presence of the
phenotype in heterozygous dosage would argue against this. A second, though more
remote, possibility is that phenotypic changes may be influenced by the expression of
the zeocin resistance gene (zeo) included in the construct as a selection marker.
Although transgenic animals produced with zeo expression constructs reported in the
literature do not show any of the phenotypic changes described here, it could be argued
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that the effects of zeo expression in the context of active Dnmt3b expression are
unknown.
In order to address these issues a second mouse strain was produced by electroporation
of ES cells and blastocyst injection. A modified construct was produced withfrt
sequences inserted flanking the zeo gene to enable removal of the resistance marker
using Flp recombinase either in vitro following selection or by crossing with Flp
expressing mice. In order to answer the more pressing question of transgene integration
more rapidly, blastocysts were injected with cells containing the non-recombined
construct with a view to crossing with Flp expressing mice if the phenotype was
confirmed.
A total of 6 male chimaeras, derived from a single ES cell clone survived to weaning age
for establishment of a second line. One chimaera died at 4 months, and the remaining 5
chimaeras remain healthy at approximately 1 year of age. Chimaeras were backcrossed
on to a C57BL6 background, as for the original line.
Successful transmission of the transgene to the F1 generation was detectable by PCR.
There is a much higher rate of transgene silencing in the new line with only 3/9 F1
animals positive by PCR showing skin expression by western blot although transgene
was detected by PCR in 5/9. However, all 3 animals with strong expression died early
(93, 111, 88 days). In addition 2 animals which were found sufficiently soon after death
for post-mortem analysis had enlarged hearts (heart weight/body weight ratios 9.3x10"
■5
and 14.2x10" ), and had cardiomyopathic changes on histological evaluation. The
confirmation of the phenotype, in particular the finding of early death only in animals
with strong transgene expression leads us to conclude that the cardiomyopathy is indeed
caused by over-expression of Dnmt3b. It has not been possible to exclude the possibility
of a contribution due to the zeo gene as transgene expression has not been maintained
past the first generation to enable crossing with Flp recombinase animals.
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2.6 Discussion
In this chapter the successful production of mice which show strong over-expression of
Dnmt3b is described. This is the simplest and least incontrovertible finding but in many
ways it is also the most profound. The fact that strong over expression of a de novo
methyltransferase does not lead to widespread developmental abnormalities suggests
that epigenetic silencing is tightly regulated in early development and is not perturbed
simply by over expression of a de novo methyltransferase. Dnmt3b clearly has an
important role in early development since Dnmt3b '~ mice die between 13.5 and 16.5
days post-conception (Okano, et al 1998a). Since methylation patterns are determined
early in normal development when Dnmt3b is strongly expressed, and little de novo
methylation occurs after gastrulation when Dnmt3b expression is much weaker, it could
have been hypothesised that continued strong expression of Dnmt3b would lead to
abnormal methylation and gene silencing. While later chapters will demonstrate that
this has indeed occurred to some extent, the essentially normal development of the mice
suggests that the most important genes in development are protected from silencing by
de novo methylation by other mechanisms. It also argues that de novo methyltransferase
activity in early development is sufficient, in the sense that there is sufficient activity to
create methylation patterns necessary for development, and so further increases in
activity do not produce further gene silencing of genes essential for development.
Again, this points to a coordinated regulation of epigenetic silencing and methylation
determination early in development. The fact that animals are fertile suggests that de
novo methylation in primordial germ cells may also be similarly sufficient.
However, the presence of reproducible phenotypic changes suggests that there are
exceptions to this, and that over expression of a de novo methyltransferase is indeed able
to perturb cellular biology in some cases. The fact that phenotypic changes occur
reproducibly in all animals which show strong transgene expression rather than the
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development of abnormalities at random suggests that this vulnerability is also pre¬
determined in some sense and that certain genes may be "primed for methylation" and
remain unmethylated only because of the absence of de novo methyltransferase activity
in adult life. It is equally possible as well that the perturbation of cell biology caused by
Dnmt3b over-expression may be primarily mediated by functions of Dnmt3b other than
DNA methylation such as direct recruitment of histone deacetylases. Evidence that
abnormalities of DNA methylation indeed occur in Tg(Dnmt3b)+ mice are discussed in
the following chapter.
Along similar lines, it is an important question as to why the most prominent phenotypic
changes are confined to particular organs. The most trivial explanation is that this is
related to the level of transgene expression. While Figure 2.3 is not intended to be
quantitative, it is clear that there is very strong expression in the heart. This is consistent
with published data from transgenic mice which express spermine under the control of
the CAG promoter, in which the highest spermine levels were achieved in heart and
muscle (Ikeguchi, et al 2004). However it is clear that the presence of a phenotype is
not solely related to the expression level of Dnmt3b, since the lung and skin have strong
transgene expression but are phenotypically normal whereas the kidney has weak
transgene expression but appears phenotypically abnormal. In the spermine over-
expression model above, and in northern blots from a separate model where the tet-
activator was overexpressed under control of the CAG promoter (Wiekowski, et al
2001) the relative expression of the transgene between these tissues was similar. Again,
in the following chapter, the question of whether phenotypic changes are associated with
methylation changes and whether these changes are causative or associative is explored
further.
Moving on to the specific phenotypic alterations, the remainder of this project is
concentrated on the cardiomyopathy phenotype since this is the most striking and easily
defined abnormality. Detailed characterisation of the cardiac phenotype and the possible
role of transcriptional regulation and epigenetic alterations in its pathogenesis are
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described in the following 2 chapters. However it is worth commenting on other aspects
of the Tg(Dnmt3b)+ phenotype at this point as these suggest possible areas for further
study.
The observation that Tg(Dnmt3b)+ mice are slightly smaller than wild type animals is
noteworthy. It is unlikely that this finding is due to strain differences since wild type
animals in the analysis are littermates of the Tg(Dnmt3b)+ animals and will have a
similar genetic composition. A second possibility is that the smaller size represents
chronic low grade ill health. While this is impossible to discount completely, there does
not appear to be any clinically obvious difference in health between transgenic and wild
type mice in early life. Furthermore, the reasonably linear correlation of weights of wild
type with transgenic animals suggests that both sets of animals have similar rates of
growth in early adult life, arguing against chronic ill health. A more speculative
possibility is that over-expression of Dnmt3b may have altered imprinting behaviour,
with post-meiotic germ cells positive for Tg(Dnmt3b) developing additional methylation
and silencing of paternal-chromosome inherited genes (given that the mouse line is
routinely propagated through the male germline). Since as a gross oversimplification
paternal-expressed genes tend to favour growth whereas maternal-expressed genes tend
to inhibit growth, this could be a mechanism for the observed size discrepancy. A
simple way to investigate this possibility would be to compare weights of animals where
the transgene is passed through the female germline, however given the difficulties with
infanticide it would be non-trivial to produce sufficient offspring to compare
statistically, especially since differences in weight are fairly subtle.
The finding of infanticide by Tg(Dnmt3b)+ mothers is particularly intriguing for a
number of reasons, but difficult to investigate formally. Infanticide in mice is fairly
common in response to distress and so the simplest possibility is that infanticide may
occur because of maternal illness, perhaps as a result of early effects of the
cardiomyopathy. However, since the infanticide seems to be universal in Tg(Dnmt3b)+
mothers and occurs in young animals which do not appear unwell, the possibility that
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more direct effects of Dnmt3b over-expression are causing this could be considered.
There are a number of phenomena where epigenetic changes have been shown to alter
maternal behaviour. Mbd2 deficient mice appear to show impaired maternal instincts
(Hendrich, et al 2001), although this manifests as reduced offspring weights prior to
weaning rather than infanticide. In addition the paternally inherited imprinted gene
Peg3 has also been shown to regulate maternal behaviour (Li, et al 1999), with mothers
inheriting a mutant paternal allele showing decreased nest building and infant retrieval.
More fancifully, an interesting hypothesis is that the mothers may have abnormalities in
olfaction. An intact olfactory system is necessary for maternal behaviour; mothers with
surgical destruction of the olfactory bulb also demonstrate infanticide invariably
(Gandelman, et al 1971). Since nuclear transfer experiments have demonstrated that
olfactory receptor selection in a given olfactory cell is epigenetically determined (Eggan,
et al 2004), it would be attractive to speculate that the olfactory repertoire may have
been altered by over-expressing Dnmt3b. Finally the existence of neurological
syndromes in association with mutations in DNMT3B (ICF syndrome) and the methyl
binding protein MeCP2 (Rett syndrome) together with the presence of CNS
abnormalities in Dnmt3b~' and Dnmt3a~' mice emphasise the importance of methylation
changes in CNS development. Such methylation changes may also be susceptible to
environmental manipulation post-natally with neuroendocrine and possibly also
behavioural effects (Weaver, et al 2004). Since Dnmt3b is over-expressed in the brain
of Tg(Dnmt3b)+ mice, it would thus appear feasible that methylation changes may
indeed have caused behavioural changes which may include abnormal maternal
behaviour. Identification of the nature of these abnormalities could be extremely
instructive but it will be challenging to find objective measures of behaviour and also to
identify the significance of molecular changes in what is a relatively unexplored area for
research.
The renal phenotype remains under-characterised. Given the histological similarities to
age related renal changes, it is an interesting question of whether the effect of Dnmt3b
expression in the kidney has been to produce premature aging. Further work could
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certainly be done to seek the presence of other age related changes such as glomerular
basement membrane thickening and immunoglobulin deposition- electron microscopy
would probably give the largest amount of information not dependent on mechanistic
speculation. It would also be useful to investigate changes in renal function in vivo by
measurement of electrolytes, glomerular filtration rate and protein excretion and their
changes with age in wild type and transgenic mice. Given the interest in age-related
methylation changes and its biological significance, it would be an important result if it
could be shown that increases in methyltransferases can cause premature aging. The
difficulty of course is of defining in a rigorous way what constitutes a cellular or
molecular definition of aging.
While there are still many unanswered questions regarding the phenotypic changes in
Tg(Dnmt3b)+ mice, for the purposes of this project the generic effects on DNA
methylation, and a few specific areas of the phenotype are studied in detail. In the next
chapter the changes in DNA methylation found in Tg (Dnmt3b)+ mice are demonstrated.
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Figure 2.1 Weight of Tg(Dnmt3b) mice by age. Weight of Tg(Dmnt3b)+ mice compared with




Mean Weight by age: Females
Tg(Dnmt3b)- Tg(Dnmt3b)+
RatioAge(d) Mean Wt(g) n= Mean Wt(g) n=
30-39 17.5 2 14.7 4 0.84
40-49 18.4 2 19.8 1 1.08
50-59 20.8 4 17.4 4 0.84
60-69 22.3 4 19.4 5 0.87
70-79 23.3 9 21.5 7 0.92
80-89 27.0 5 25.3 3 0.94
90-99 23.6 18 22.5 13 0.95
100-109 26.8 14 25.6 6 0.95
110-119 25.2 12 23.0 10 0.91
120-129 28.0 9 26.3 2 0.94
130-139 25.2 14 21.7 9 0.86
140-149 28.9 6 21.0 2 0.72
B)
Mean Weight by age: Males
Tg(Dnmt3b)- Tg(Dnmt3b)+
RatioAge(d) Mean Wt(g) n= Mean Wt(g) n=
30-39 20.2 5 20.1 8 0.99
40-49 None 0 24.1 1
50-59 24.9 6 24.3 11 0.98
60-69 27.3 6 26.5 12 0.97
70-79 30.2 7 25.6 1 0.85
80-89 33.0 3 29.9 8 0.90
90-99 30.3 15 28.2 11 0.93
100-109 32.9 6 30.4 10 0.92
110-119 32.5 9 27.2 1 0.84
Tables 2.1A and 2.1B Weight of Tg(Dnmt3b) mice by age and genotype. Comparison of
weight at different ages between Tg(Dnmt3b)+ and Tg(Dnmt3b)-. Data are grouped by age, and
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Figure 2.2 Regression of weight v age. Results ofweighted linear regression of mean weights
of Tg(Dnmt3b)+ mice against mean weights of sibling Tg(Dnmt3b)- mice with data points at
each age group as in Table 2.1. Data are weighted in the regression analysis according to the
number ofobservations contributing to the mean at each data point. The dotted line shows 95%
confidence limits for the regression line. The light shaded solid line gives 95% confidence
limits for the mean predicted weight of transgenic animals at a given age given the weight of the
non-transgenic animals at the same age.
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Figure 2.3 Tissue distribution of Dnmt3b expression. Western blots, using polyclonal anti
Dnmt3b antiserum and poyclonal anti-histone H3 as loading control. Tg=Tg(Dnmt3b)+ mice(3
month old). WT=wild type mice. Br-Brain Sk-skin (ear) Ht- heart(ventricle) Ki-Kidney Lu-
Lung Gu-Gut ( distal small intestine). +ve= positive control from Tg(Dumt3b)+ ear clip. The
top panel compares expression with ES cell protein extracts in order to demonstrate antibody
specificity. WT= wild type ES cell. -/- = Dnmt3b-/- ES cell. R= Dnmt3b-/- ES cell rescued









Figure 2.4 Survival of Tg(Dnmt3b)+ mice. The proportion ofTg(Dnmt3b)+ mice surviving to
a given age. The analysis includes all transgenic mice up to and including the f7 generation
(n=68). Mice which were sacrificed early are excluded from the analysis. 95% confidence















Figure 2.5 Survival of Tg(Dnmt3b)+ mice by sex. Survival curves and 95% confidence limits
for the quartiles of the survival function, comparing male and female Tg(Dnmt3b)+ mice. Mice
which were sacrificed early are excluded. The significance value for the survival curves based
on the null hypothesis that they are equivalent is calculated using the log-rank test. Data





f1 —— f2 f3 f4 f5 f6 f7
Generation n observed n censored median survival (d) 95% conf. interval
f1 40 18 118 108-121
f2 7 1 115 114-158
f3 21 12 131 118-139
f4 7 3 147 140-not reached
f5 14 9 140 139-not reached
f6 21 9 140 127-157
f7 19 10 144 126-229
Figure 2.6 Survival of Tg(Dnmt3b)+ mice by generation. Kaplan-Meier estimate of survival
and median survival for Tg(Dnmt3b)+ mice from successive generations. All animals are
included in the analysis with mice sacrificed early included as censored observations.
Significance value by log-rank test for the survival curves, based on the null hypothesis that all
curves are equivalent is shown for the whole data set. Significance value for the data set
excluding the fl generation is also shown, suggesting that shortened survival of the fl mice is




Figure 2.7 Gross anatomy of hearts from Tg(Dnmt3b) mice. Heart from a 4 month old
F2 Tg(Dnmt3b)+ mouse compared to a wild type control. The transverse section in B) shows
dilatation of both left (LV) and right (RV) ventricles. Scale shows 1mm major graduations.
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A) H+E stained sections from heart
Transgenic Wild type
B) Sirius red stained sections from heart
Wild type
50pm
Figure 2.8 Histology of hearts from Tg(Dnmt3b)+ mice. A) H+E stained sections from 4
monthold F10 mice, showing myo fibre dropout with central pallor (P), cytoplasmic
vacuolation(V) and prominent nucleoli (N) in the transgenic animals.
B) Sirius red stained section from the same animals showing extensive fibrosis in the transgenic
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Figure 2.9 Proliferation in Tg(Dnmt3b)+ hearts. A) shows gut tissue as positive control,
showing nuclear BrdU staining. B) myocardium from 4 month old F11 Tg(Dnmt3b)+ mouse
following 6 hour in vivo BrdU labelling, showing absent staining. C) shows staining ofan
adenoma from an Apc+/min mouse as a positive control, demonstrating strong nuclear staining
especially in the most cellular parts of the tumour. D) shows absence ofPCNA staining in 4
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C) Transgenic renal tubules C) Wild type renal tubules
Figure 2.10 Kidney histology from Tg(Dnmt3b)+ mice. A and B) H+E stained section s
showing a glomerulus (G) from the juxtamedullary region with abnormal podocyte proliferation
in the transgenic sample A). C) and D) H+E stained section showing dilated renal tubules with
protein casts (C) in the transgenic sample C). Samples are from 4 month old F10 mice.
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3. Effects of Dnmt3b over-expression on methylation
3.1 Introduction
In the previous chapter, the production of transgenic mice which over-express Dnmt3b
was described, and it was confirmed that the mice show increased Dnmt3b protein
expression in a wide range of tissues, and show reproducible phenotypic changes in the
heart, kidney and in maternal behaviour. In this chapter, the changes in DNA
methylation consequent on this over-expression and the possible links between the
methylation changes and phenotypic changes are described. Finally, what these changes
tell us about the role of de novo methyltransferases in the determination of methylation
patterns is discussed.
3.2 Global levels of methylation are increased in Tg(Dnmt3b)+ mice
Global changes in methylation in Tg(Dnmt3b)+ mice were measured by Nearest
Neighbour analysis. Genomic DNA from heart and lung was extracted from 8 week old
F13 Tg(Dnmt3b)+ mice and their wild type littermates. In order to examine changes in
CpG methylation specifically in CpG island DNA, genomic DNA was digested with
Msel, and the 2-4 kb fraction which is enriched for CpG islands was extracted for
analysis.
In the heart there was a significant increase in methylation between Tg(Dnmt3b)+ and
Tg(Dnmt3b)- animals (Figure 3.1) in this fraction of the genome. Mean CpG
methylation in Tg(Dnmt3b)- hearts was 36.7% (SD 0.49%, n=3) compared to 46.0% (SD
3.2% n=3) giving a 95% confidence interval for increase in methylation of +1.7% to
+16.9%. Replicate testing on one sample from each group shows the technique to have
good precision with replicates within 2% of each other. In the lung, there was an
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increase in methylation of a similar order of magnitude (7% increase between 1 pair of
animals).
3.3 Aberrant, dense methylation of CpG islands occur in Tg(Dnmt3b)+ mice
It is not clear from the global methylation analysis whether the increase in methylation is
the result of a diffuse increase in CpG methylation, or whether it has resulted in the
dense methylation of CpG islands at specific loci. Methylation sensitive restriction
fingerprinting (MSRF) was used as a screening technique to identify CpG islands which
are aberrantly methylated in transgenic animal. In MSRF, genomic DNA is first
digested with Msel to enrich for CpG islands and then with the methylation sensitive
enzyme BstUI. The double-digested DNA is subjected to PCR with short, non-specific
primers, and the patterns of PCR products can then be compared between transgenic and
wild type animals.
Sample results from the MSRF experiment in are shown in Figure 3.2. Differences in
restriction fingerprinting patterns were present in the heart, strongly suggesting that
there are genes which are abnormally methylated in the hearts from transgenic animals,
whereas there are also potentially methylatable sites which are resistant to methylation
despite over-expression of the methyltransferase (see Figure 3.2 legend). In contrast to
the results in heart, there were no differentially methylated bands identified in MSRF
from lung or gut (Figure 3.3), despite the finding of increased global CpG island
methylation in the lung.
DNA eluted from bands in the gel which suggest abnormal methylation was re
amplified, cloned and sequenced. Clones were identified by BLAST search against the
NCBI mouse genome database. A summary of genes thus identified and expression of
the corresponding gene using data from microarray expression profiling in the heart (see
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chapter 4) is given in Figure 3.4. Of the small number of genes identified, those
showing differential methylation appear to have, at most, low level expression in both
normal and transgenic animals.
In order to confirm the results from the MSRF experiment, the CpG islands which were
aberrantly methylated according to the MSRF experiment were bisulphite sequenced.
The CpG islands identified for the Wnt3 and Lrfn5 genes extend 5' to the transcriptional
start site and extend in to the first exon and thus probably include the promoter region,
whereas the Viaat CpG island is sited within an exon sequence, and is thus of more
uncertain significance (Figures 3.5-3.7).
We obtained good quality sequence for a total of 17 clones from 3 normal and 13 clones
from 3 transgenic mice (98 days old, F3 generation) for the Viaat CpG island, examining
a total of 32 CpG dinucleotides in the PCR product from bisulphite modified DNA
(Figure 3.9). The region appears to have sporadic methylation in the wild type animal at
individual CpG dinucleotides which differ between clones, with a low level of dense
methylation of the whole region. In the transgenic animals methylation is clearly
increased with what appears to be increases both in the frequency of sporadic
methylation and the proportion of clones showing dense methylation of the whole
region. Since bisulphite conversion was not complete for most of these samples, it is not
possible to exclude that apparent methylation at a particular CpG residue in a particular
clone may be the result of conversion failure, but the difference in pattern is reasonably
robust since the difference in conversion rates is not appreciably different between the
wild type and transgenic clones.
More convincingly, there was a striking increase in methylation in the Wnt3 and Lrfn5
promoter regions. A summary of the methylation state of individual CpG residues in
each clone sequenced is shown in Figures 3.8 and 3.10, showing that in several clones,
the whole region has become densely methylated. There is a good rate of conversion of
non-CpG cytosines to thymidine in both normal and transgenic animals, suggesting that
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failure of deamination is unlikely to have caused the overall difference in methylation,
although it is not possible to exclude the possibility that a given CpG in a given clone
may be apparently methylated as a result of failure of deamination or as a result of PCR
error. Of interest is the finding of CpA methylation in an increased number of clones
from the transgenic animals at one CpA residue in both genes. While this is less
definitive than the finding of increased CpG methylation in these clones, it is in keeping
with the known activity of Dnmt3b in causing non-CpG methylation (Dodge, et al
2002).
3.4 Aberrant methylation of Wnt3 and Lrfn5 occurs in multiple tissues in
Tg(Dnmt3b)+ mice
Quantitative real time PCR following restriction digestion with methylation sensitive
restriction enzymes (M-QPR) was used to compare methylation of Wnt3and Lrfn5 in
several tissues from 3 normal and 3 transgenic mice (4 month old F8 generation).
Methylation levels are expressed as a "methylation index": the ratio between the
absolute quantity of DNA surviving digestion with Hpall and Hhal to the absolute
quantity of starting DNA (as measured by a PCR across a region with no restriction
sites). The results are shown Figures 3.11-3.12. Aberrant methylation is confirmed in
the heart, providing some validation of the assay. The results suggest there is aberrant
methylation of Wnt3 in brain and kidney, though this may be at lower levels than in the
heart (Figure 3.12). The results for Lrfn5 are less consistent as a result of difficulties
with the assay as noted in Section 7.3.4, but there is a consistent difference between the
normal and transgenic group in heart, kidney (Figure 3.12). In addition the Lrfn5
promoter is clearly either unmethylated or methylated at an insignificant level, in liver
and lung of all normal and transgenic animals.
To compare the relationship of expression to methylation levels, expression of Wnt3 and
Lrfn5 were measured by Taqman quantitative real time PCR. Gene expression levels
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normalised relative to actin expression are shown in Table 3.1. There is consistent
expression of both genes in brain and of Wnt3 in gut, but it is at low levels in both
tissues. There is inconsistent data suggesting there may be extremely low level
expression in other tissues- the inconsistency in the data may result if expression is just
at the threshold of sensitivity of the PCR technique. The results are consistent with the
published data regarding the tissue expression of these genes in adult tissues (Morimura,
et al 2006, Roelink, et al 1990).
Importantly, there is no expression of either gene in the tissues from wild type mice in
which abnormal methylation or a histological change is seen in the transgenic mice.
This suggests that methylation of Wnt3 or Lrfn5 is unlikely to have caused silencing of
the gene, but has occurred in a gene that is already silent. In addition, the results show
that the non-expression of a gene is not a sufficient condition to allow abnormal
methylation in the context of active de novo methyltransferases, since there is no
methylation of Wnt3 or Lrfn5 in tissue such as lung in which the gene is silent in the
adult and in which Dnmt3b is strongly expressed.
3.5 Discussion
To summarise the results of this chapter, it has been shown that over-expression of a de
novo DNA methyltransferase in vivo is sufficient to cause dense abnormal methylation
of specific CpG island loci under certain conditions. However, the majority of CpG
dinucleotides in the CpG island- rich fraction of the genome appear to be protected from
methylation. This protection from methylation must include factors other than sequence
or gene expression status, since there is a tissue-specific sensitivity to Wnt3 and Lrfn5
methylation regardless of the presence of strong Dnmt3b expression.
The discovery of abnormal Wnt3 and Lrfn5 methylation provides strong support for the
notion that many of the abnormal methylation events seen in pathological contexts such
as cancer have no causative role in the biology of the disease, since these genes are
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abnormally methylated in the adult animal but were not expressed in the wild type
animal either. A possible alternative hypothesis is that abnormal silencing had occurred
due to methylation earlier in life. However this does not seem likely for the Wnt3 gene
since phenotypic changes seen in the mice to not correspond to the embryonic effects of
Wnt3 disruption. Two phenotypes have been described in association with Wnt3
abnormalities. The first, Wnt3~'~ mice, shows embryonic lethality with failure of
mesoderm formation (Liu, et al 1999). The second, in humans, shows abnormal limb
development (Niemann, et al 2004). While more subtle effects of a tissue specific
interference with Wnt3 expression cannot be ruled out, neither of these phenotypes
appears to show much similarity to the changes in Tg(Dnmt3b)+ mice.
A further observation that has relevance for the role of DNA methylation in cancer is
that abnormal methylation of Wnt3 and Lrfn5 have occurred in the heart, which does not
undergo mitosis in adult life. It has been shown in the previous chapter that there is no
increase in proliferation in the hearts of Tg(Dnmt3b)+ mice. This indicates that
abnormal methylation events are accumulating as a result of the transgene activity rather
than becoming more prominent as a result of cellular proliferation. Thus, methylation
events may accumulate in pathological contexts as a result of dysregulation of the DNA
methyltransferase system in a polyclonal manner, rather than silencing of a tumour
suppressor gene leading to clonal proliferation.
What role does abnormal methylation play in the pathogenesis of the phenotypic
changes in Tg(Dnmt3b)+ mice? It is instructive to note that it is easier to discover
examples of dense CpG island methylation in tissues which are abnormal. The first
possibility is that it is the presence of pathology which provides a suitable millieu for the
development of methylation. In this model, the genome in the normal cell is protected
from methylation. In the Tg(Dnmt3b)+ animals, cellular biology is altered through
mechanisms independent ofmethylation, such as protein-protein interactions involving
the N-terminal domains of Dnmt3b, causing pathological change. As a result of the
disturbed cellular biology, protection of genes from de novo methylation is disturbed,
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allowing the development of methylation. This model has interesting translational
consequences, as it would suggest that cellular damage induced by environmental or
inherited insults could promote the development of abnormal methylation, with
relevance to the finding of abnormal methylation events in cancer and other
circumstances such as aging and inflammation. One difficulty with the extension of this
hypothesis is that methylation changes common in cancer have also been described in
histologically normal tissue surrounding tumours, tending to suggest that methylation
changes occur earlier than cellular transformation. However it is still possible that the
cells with methylation changes have been subject to molecular-level stressors which
have not manifested at the histological level.
A second possibility is that the increase in global methylation indicates that DNA
methylation has had a causative role in inducing the cardiac phenotype, most likely
either by silencing genes which should be active, or preventing the activation of genes in
appropriate contexts. If this could be robustly established, this would probably be the
first direct demonstration that DNA methylation is in itself a sufficient factor to alter
gene expression and alter cellular biology in vivo. The remainder of this this project
concentrates on the heart on the assumption that the tissue with the most abnormal
phenotype may be the most likely to show detectable abnormalities, and further efforts
to prove the role ofmethylation in producing the heart phenotype are described in the
following chapter.
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3.6 Figures and Tables
Wild type Tg(Dnmt3b)+
Figure 3.1 Global methylation in Tg(Dnmt3b) hearts. Sample autoradiographs from Nearest
neighbour analysis comparing methyl CpG to CpG ratio between hearts of transgenic and wild
type mice.
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Figure 3.2. Methyiation sensitive restriction fingerprinting from Tg(Dnmt3b) hearts.
Example of methyiation sensitive restriction fingerprint (MSRF) from heart (A1-A2 primer set),
comparing transgenic (Tg+), wild type (Tg-) and SssI methylase treated DNA (SssI). B=BstUI
digested; M=Msel digested. Band A shows a PCR product corresponding to a region
methylated in the transgenic animal (band present in both lanes 4 (BstUI and Msel digested)
and 5 {Msel digest only)) but not in the wild type animal (band present in Msel digested lanes 2
and 3 but not BstUI digested lanel). Band B shows a potentially methylatable site (Bands
present in both BstUI and Msel-only lanes in SssI methylase treated sample) which remains
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Figure 3.3. MSRF on lung from Tg(Dnmt3b) mice. Auto radio graph from methylation
sensitive fingerprint comparing methylation patterns from lung between transgenic (Tg+) and
wild type (Tg-) animals, showing no difference in BstUI/Msel digest patterns despite increased
globalCpG island methylation. B=BstUIdigested; M=MseIdigested.
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Gene Viaat Wnt3 Hspa5 Dock4 Foxb2 Trim27 Lrfn5
Methylation
Tg(Dnmt 3b)+
+ + " - - - +
Methylation
Tg(Dnmt3b)-
- - - -
Sssl methylase
Methylatable
+ + + + + + +
Expression in
Tg(Dnmt3b)+
2.6 19 727* ? 6 193* No+
Expression in
Tg(Dnmt3b)-
2.3 21 1382* 7 10 151* No+
Figure 3.4 Summary of genes identified by MSRF in heart. Methylation status of genes
cloned from cardiac MSRF fragments as suggested by the presence ofbands in the MSRF gel.
Expression figures represent the arbitrary microarray probe signal strength (see section 4.7) ? -
not represented on chip. * -signal is significantly increased above background (ie. likely that
gene is expressed). Lrfn5 is not represented on array but is not expressed according to our own
data (see section 3.4).
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Sbjct 15175072 ACCCCTGAAGGTCTCTCGTTCTTAGTCTTCACCCTCTCCCACCCCAATTTGGGGGTCCCG
15175131
Query 181 AAGAACCTTCGTTTGCTCACACTTGCATTTCTGTGCTG 218
llllllllllllllllllllllllllllllllllllll
Sbjct 15175132 AAGAACCTTCGTTTGCTCACACTTGCATTTCTGTGCTG 15175169
Figure 3.5 BLAST results fromMSRF: Wnt3
Figures 3.5-3.7 BLAST search results for3 genes identified as abnonnally methylated by MSRF in Tg(Dnmt3b) +
hearts. A) Location of MSRF sequence relative to gene B) Sequence homology between sequence cloned from
MSRF and the mouse genome. Mouse genome data is from NCBI website (see methods)
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I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I III
CCTGGTCCATCATAGCCACAGCGGTGCTGCTGCCCTGCGCCTTCCTGAAGAATCTCAAGG 99384171
CCGTGTCCAAGTTCAGTCTGCTGTGTACGCTGGCCCACTTCGTCATCAACATCCTGGTCA 251
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I
CCGTGTCCAAGTTCAGTCTGCTGTGTACGCTGGCCCACTTCGTCATCAACATCCTGGTCA 99384231
TCGCTTACTGTCTCTCTCGCGCGCGTGATTGGGCCTGGGAGAAGGTGAAGTTCTACATCG 311












I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I
GGGCCGACGAGACCAAGGAAGTCATCACGGATAACCTGCCCGGCTCCATCCGCGCCGTGG 99384531
TCAACCTCTTCCTGGTGGCCAAGGCGCTGCTGTCCTATCCGTTGCCCTTCTTCGCGGCCG 611
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I II I I
TCAACCTCTTCCTGGTGGCCAAGGCGCTGCTGTCCTATCCGTTGCCCTTCTTCGCGGCCG 99384591
ure 3.6 BLAST results fromMSRF: Viaat (legend is with Figure 3.5)
68
A) Location

















I I I I I I I I I I I I I I I I I I I I I I I I II I I I II I I I I II II I I I I I I II I I I II I I I I II I I
Sbjct 19986094 ACTGTTTCTCCCTCCCGGTGCGGTTCTGGGAGTGCTTGTGCAAGTGTGAGTGCGCGCGCG
19986153




Figure 3.7: BLAST results fromMSRF: LrfnS (legend is with figure 3.5)
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H|Cpg methylation A CpA methylation
x poor sequence
Figure 3.8 Wnt3 bisulphite sequencing
Figures 3.8-3.10
Methylation status of genes identified by MSRF as abnormally methylated in heart confirmed
by bisulphite sequencing.
The % conversion figure gives frequency of CpH->TpH conversion as a measure ofbisulphite
conversion efficiency.
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Ci C2 C3 3b, 3b2 3b3
Brain 0 0 0 1.7% 3.1% 0.42%
(+/-) (1.1-2.6%) (1.5-6.2%) (0.31-0.58%)
Gut 0 0 0 0 0 0
(+/-)
Heart 0 0 0 15% 22% 50%
(+/-) (11-19%) (16-31%) (30-81%)
Kidney 0 0 0 4.4% 3.3% 1.2%
(+/-) (3.1-6.3%) (2.6-4.1%) (0.97-1.5%)
Lung 0 0 0 0 0 0
Figure 3.11 Wnt3 methylation by tissue
Figures 3.11 and 3.12 Graphs showing methylation status of Wnt3 and Lrfn5 as measured by
M-QPR in different tissues from Tg(Dnmt3b)+ and wild type mice. The tables show
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Wild Type 1 Wild Type 2 Tg 1 Tg2
Brain
4.5E-03 2.5E-03 1.6E-03 7.9E-04
(4.4-4.5)E-3 (2.2-2.8)E-3 (1.5-1.7)E-3 (6.9-9.2)E-4
Gut
7.2E-05 9.8E-05 2.0E-03 1.0E-05
(6.5-7.9)E-5 (9.7-1,0)E-5 (1.9-2.1)E-3 (0.89-1,2)E-5
Heart ND ND ND ND









Ovary ND ND ND ND
Spleen ND ND ND ND
Thymus ND ND ND ND
B) Lrfn5 expression
Wild Type 1 Wild Type 2 Tgl Tg 2
Brain
1.0E-02 5.6E-03 3.2E-03 1.1E-03





Heart ND ND ND ND
Kidney ND ND ND ND
Liver ND ND ND ND
Lung ND ND ND ND
Ovary ND ND ND ND
Spleen ND ND ND ND
Thymus ND ND ND ND
Table 3.1 Wnt3 andLrfnS expression. Expression levels of A)Wnt3 and B) Lrfn5 relative to
actin expression as measured by quantitative PCR. ND= not detected (limit ofdetection 1 xlO"5
actin level). Error intervals represent transformed standard errors (see methods). Tgl and Tg2
are the Tg(Dnmt3b)+ animals.
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4. Effects of Dnmt3b over-expression in the heart
4.1 Introduction
In this chapter the cardiac pathology of Tg(Dnmt3b)+ mice is explored in more detail.
The development of cardiomyopathy in Tg(Dnmt3b)+ mice is probably the most striking
and unexpected aspect of the phenotype. It is shown in the previous chapters that
cardiomyopathy is not caused by an increase in hyperplastic myocardial growth. It has
also demonstrated the presence of global increases in methylation and abnormal
methylation of specific CpG islands in the hearts of Tg(Dnmt3b)+ mice. Finally it has
been shown that the phenotype can be recapitulated in a second mouse line, thus
excluding an integration event as the cause for the cardiomyopathy. In this chapter,
what is known about the role of epigenetic factors in cardiac development and disease is
discussed, and there is an attempt to establish causative links between Dnmt3b
expression, abnormal methylation and cardiomyopathy.
Cardiomyopathy could be defined as intrinsic disease of the myocardium which leads to
contractile dysfunction, and can be primary (inherited) or secondary to a wide range of
insults. Of these, pressure overload due to valvular disease or hypertension, toxic insults
such as alcohol excess or anthracycline cytotoxic agents, hyperthyroidism,
haemochromatosis, and inflammation due to viral myocarditis or autoimmune disease
are the most important. The natural history of disease is progressive, with initially
compensated disease progressing to the syndrome of heart failure, where the contractile
capability of the heart is no longer sufficient to meet circulatory demands. The
cardiomyopathies are classified morphologically as hypertrophic, dilated or restrictive.
Genetic abnormalities causing dilated cardiomyopathy (DCM), which is the
classification which best describes the pathology of Tg(Dnmt3b)+ mice, have been
identified in a number of inherited cases and provide some background to what is known
about the molecular pathogenesis of this condition. All modes of inheritance including
maternal (mitochondrial) have been described in DCM, although the predominant mode
76
of inheritance is autosomal dominant. The majority of mutations discovered so far
involve cardiac structural and cytoskeletal genes (for review see Fatkin and Graham
2002), and transgenic mouse models have confirmed the importance of a number of
these. Dilated cardiomyopathies also result from mutations in a number of genes
involved in mitochondrial energy metabolism (both nuclear and mitochondrial DNA
encoded genes), usually as part of a multisystem disorder. Cardiomyopathy has also
been caused in transgenic mice with mutations in genes involved with other cellular
processes, including calcium homeostasis, mitochondrial DNA replication fidelity, and
cell signalling.
The most important question to address in our model is whether the phenotypic changes
in Tg(Dnmt3b)+ mice are directly caused by methylation, thus indicating that
methylation is a sufficient condition on its own to perturb cell biology. In this chapter
these questions are addressed by taking three separate approaches.
Firstly, a dose-response relationship between the level of Dnmt3b and the severity of
cardiomyopathy is established, and the chronology of development of the histological
and methylation abnormalities previously discovered in the adult hearts is investigated.
It would support the hypothesis that methylation events are causative if abnormal
methylation can be discovered before the onset of overt cardiac disease.
Secondly, an attempt is made to reverse the phenotype by treatment with demethylating
agents and by breeding with mice deficient for the methyl binding protein Mbd2, in
order to prove the role of DNA methylation in the pathogenesis of the cardiac disease.
Several pharmacological inhibitors of DNA cytosine methyltransferases have been
developed which consist of cytosine molecules modified at the 5- position of the
pyrimidine ring. The most widely used of these are 5-azacytidine (AzC) and 5-aza
2'deoxycytidine/ decitabine (AdC) (Figure 4.1). Both molecules prevent methylation by
becoming incorporated in to DNA and covalently linked to DNA methyltransferase
enzymes. As well as their demethylating actions they also have cytotoxic activities as a
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result of their cytosine analogue actions, inhibiting DNA synthesis and causing
structural instability at their site of incorporation. Decitabine appears to have lower
toxicity, possibly as a result of its predominant incorporation into DNA rather than
RNA, leading to greater specificity of action. Both agents have been widely shown to be
effective demethylating agents both in vivo and in vitro (for review see Goffm and
Eisenhauer 2002). A complementary though indirect experiment which would support
the hypothesis that the phenotype is mediated through DNA methylation would be to
investigate whether the phenotype could be ameliorated by deficiency of downstream
mediators of the methylation signal. As discussed in Section 1.3, the methyl binding
protein Mbd2 is strongly implicated as such a mediator. Mbd2" mice have been
produced by targeted insertion of a P geo cassette into exon 2 of the Mbd2 gene, leading
to a truncated protein with an intact N-terminus but no methyl-binding domain
(Hendrich, et al 2001). Mbd2 deletion leads to deficient silencing of methylated reporter
constructs in cell lines, but does not appear to cause re-expression of imprinted genes or
methylated retroviral elements in vivo. This perhaps suggests that Mdb2 is important for
silencing of de novo methylated elements, but that gene silencing established during
development is maintained by multiple mechanisms, thus leading to redundancy.
Finally we use gene expression profiling to identify genes which are downregulated in
Tg(Dnmt3b)+ hearts and study the methylation status of the most strongly
downregulated genes.
There is a limited but increasing literature on gene expression profiling in various
models of cardiomyopathy and heart failure, which is somewhat contradictory. In the
mouse, the most extensive data set (Blaxall, et al 2003) examines gene expression
profiles from two different transgenic models. Profiles from one structural protein
knockout, Mlpand one calcium binding protein over-expression model (Calsequestrin)
are compared with those from normal mice and with mice which have been rescued
from heart failure. In that study, a total of 73 genes were found to be differently
expressed beween the normal and heart failure models and restored in the rescued
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phenotype. A complementary study examines expression profiles in 4 transgenic
models of cardiac hypertrophy in young mice which have developed hypertrophy but
have not yet developed heart failure (Aronow, et al 2001). In this study, there was no
set of genes which was consistently associated with hypertrophy, with genes differing
from normal instead appearing to reflect the specific models.
In studies from humans with cardiomyopathy and heart failure, many genes have been
found to be dysregulated. Since the subjects for study are necessarily much more
diverse than in mouse studies, and effects may well be confounded by the results of drug
treatment, there is considerable variation between studies as regards dysregulation of
individual genes. However, a number of common patterns do appear to emerge,
including a predominant downregulation of genes involved in calcium homeostasis and
energy metabolism, and an upregulation of sarcomeric, cytoskeletal and extracellular
matrix genes in dilated cardiomyopathy (for review see Sanoudou, et al 2005). The
simplistic message from these studies, as would be expected, is that on the one hand
there do appear to be common changes in transcription which occur in heart failure from
diverse causes, and on the other hand there are changes which are specific to the cause.
It may therefore be possible to differentiate specific changes associated with Dnmt3b
over-expression from non- specific changes as a result of heart failure and preliminary
attempts to do this are described below.
4.2 Cardiomyopathy is absent up to 6 weeks of age
In order to determine the age of onset of cardiac histological changes and methylation
abnormalities, H+E sections from hearts from F10 generation mice sacrificed at 2
weeks, 6 weeks, and 4 months of age were examined by microscopy. The microscopist
was blinded to the age and genotype of the mice. A summary of the animals examined
and cardiac weights is shown in Table 4.1. Histological abnormalities were detected
only in the transgenic mice at 4 months of age.
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In order to investigate whether methylation changes precede histological changes,
genomic DNA extracted from the 2-week and 6-week mice was analysed for
methylation of Wnt3, and the cyclin-dependent kinase inhibitor genes Cdknlb (p21 cipl)
and Cdkn2a (pl9arf) by M-QPR. The cell cycle regulatory genes were chosen on a
candidate gene basis since these have been found to be methylated in cancer, and are
thus potentially prone to aberrant methylation; if these were aberrantly silenced this
could lead to cell proliferation and provide a plausible mechanism for the increase in
heart size. No methylation was detected for any of these genes in either the 2 week or 6
week animals. Standard curves and quantification of DNA by real time PCR showed
100% efficiency of amplification, and detectable PCR product was present in the control
(no restriction sites) reaction, showing that the lack of a PCR product was not due to
failure of the PCR reaction or poor quality of starting DNA.
We conclude that cardiomyopathy occurs late, between 6 weeks and 4 months of age.
The presence of global increases in cardiac CpG methylation at 8 weeks of age (see
Section 3.2), when the mice are also apparently healthy is strong evidence that abnormal
methylation precedes the development of cardiomyopathy and is not simply secondary
to disease. However the late development of methylation at specific loci suggests that at
some loci methylation abnormalities are not present in early life but may be secondary to
either age or disease.
4.3 The presence of cardiomyopathy correlates with the level of Dnmt3b expression
In the later generations (from F11) of Tg(Dnmt3b)+ mice there a decrease in the
proportion of mice showing expression in the skin by western blot has been noted. This
has been particularly marked in a few individual litters ofmice, especially in the F12
generation. The phenomenon appears to be due to silencing of the transgene in skin,
since mice negative by western blot can still be positive by PCR genotyping. Silencing
does not appear to be passed to subsequent generations in any manner which is simply
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predictable, since offspring of mice which are PCR positive for the transgene but have
no expression in the skin can show strong skin expression. Despite the occurrence of
silencing in the skin, early death has still been noted in mice which are transgene
positive by PCR negative by western blot.
A possible explanation for this is that the transgene may still be expressed in other
tissues despite silencing in the skin. In order to determine whether transgene silencing
was occurring in the heart, Dnmt3b expression in the heart at 5 months of age was
analysed in six mice from the F12 generationwhich were PCR positive for transgene but
negative by Western blot in skin (Figure 4.2). The results demonstrate that transgene
silencing can occur in the heart, but that mice showing silencing in the skin can still have
strong expression in heart.
In order to determine whether transgene expression is correlated with phenotypic
changes, H+E and Sirius Red (collagen) stained sections from the hearts were examined
by microscopy. The microscopist was not aware of the cardiac expression results.
Table 4.2 compares the genotype and cardiac Dnmt3b expression with cardiac weights
and the presence or absence of abnormal histology, as judged by the microscopist. In
the small number of mice studied, the strength of transgene expression does appear to
predict the presence or absence of abnormal histology. The correlation is most clearly
seen in the Sirius red stained sections (Figure 4.2) which show a marked increase in
fibrosis only in the animals with strong transgene expression. In addition, heart weight:
body weight ratio is significantly increased in the mice showing transgene expression
(p<0.025 by Mann Whitney U test). There is no significant increase in heart weight to
body ratio for mice which are transgene positive but do not show cardiac expression
(p<0.40 by Mann Whitney U test).
The results show that the cardiomyopathy is caused directly by the action of Dnmt3b
protein as opposed to being an effect of random transgene integration. It is difficult to
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prove that the mice with silent expression in the heart may not have developed
cardiomyopathy at a later age, since it is necessary to sacrifice the mice to investigate
the heart histology and expression level. It is also difficult to prove that silencing of
Dnmt3b in the heart leads to improved survival for similar reasons (and it is also
difficult to prove that early death is caused by cardiac disease). However supportive
evidence that it is transgene expression and not simply inheritance which predicts
survival can be obtained from the second line of mice (Section 2.5) where there is a
much higher frequency of transgene silencing. Out of the 7 from this line so far which
have shown transgene expression in the skin, none have survived past 166 days,
whereas there are currently 14 mice which are positive for transgene transmission by
PCR but not by western blot which remain alive at over 320 days (range 322-389).
The presence of silencing could have implications for the interpretation of other results,
raising the question of whether effects on methylation are really comparable in
experiments performed on mice of different generations. However, the fact that skin
transgene expression inevitably predicts early death, even in later generation mice,
suggests that skin expression is a good predictor of strong expression in other tissues,
especially the heart, although the converse may not always be the case.
4.4 Aberrant CpG island methylation is secondary to cardiomyopathy at some loci
To investigate whether methylation events at specific loci may be secondary to disease,
methylation status of Wnt3, Cdknlb (P21cipl) and Cdkn2a (P19arf) were measured by
M-QPR in the 5 month old animals with variable transgene silencing studied in Section
4.3. Results are shown in Figure 4.3. There is a consistent increase in Cdknlb
methylation, albeit at low level, in the animals showing strong cardiac transgene
expression and cardiomyopathy. However, Wnt3 and Cdknlb methylation is only
detectable in one of the affected animals. Although the number of animals studied is
small, the results confirm that cardiomyopathy can occur before methylation changes at
these loci are detectable. The results suggest that methylation of Wnt3 or Cdknlb are
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not necessary for the development of cardiomyopathy. This also supports the hypothesis
proposed in Section 4.2 that many of the methylation events occurring in the context of
methyltransferase expression may be secondary to or facilitated by the presence of
disease.
4.5 The phenotype of Dnmt3b over-expression is not reversed by 5'aza 2-
deoxycytidine treatment
It would provide strong evidence for the hypothesis that DNA methylation is involved in
the pathogenesis of the heart disease if the phenotype could be prevented or reversed by
treatment with demethylating agents. We therefore attempted to reverse the phenotype
by treating mice with 5'deoxy-2azacytidine (AdC/ decitabine). A total of 9 transgenic
mice from the F5 and F6 generations were administered lmg/kg AdC weekly for 11
weeks by subcutaneous injection starting from 6 weeks of age. The dose of AdC was
chosen as this dose was sufficient to reduce tumour formation and reactivate silenced
genes in Apc+/mm mice (Laird, et al 1995). Wild type littermates were also treated to
control for AdC toxicity.
Treatment with AdC produced no evidence of a difference in survival when compared
against transgenic mice from the F5 and F6 generations (p=0.44 for difference in
survival using Kaplan Meier estimate). The control animals remained healthy with all
non-transgenic animals surviving beyond the longest living transgenic animal. See
Figure 4.4.
Thus, AdC treatment in a dosage shown in previous literature to be sufficient to cause
demethylation is unable to reverse the early mortality in Tg(Dnmt3b)+ mice. While it
has not strictly speaking been proven that the early mortality is caused by
cardiomyopathy, the results are strongly suggestive that a period of demethylating agent
therapy is unable to reverse the cardiomyopathy.
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In order to demonstrate that demethylation in the myocardium is achievable using AdC
treatment, a pilot experiment was carried out to investigate whether an imprinted gene
can be demethylated in the heart by AdC. A separate group of 3 normal and 3
transgenic mice from the F13 generation were administered lmg/kg AdC, and a further
3 transgenic mice were administered a higher dose of 2.5mg/kg. Mice were sacrificed
24 hours following the final injection.
Demethylation at was studied by measurement of methylation at the imprinted Igf2r
locus by M-QPR, and compared to age-matched mice which had not received AdC
treatment (Figure 4.5). As expected, the methylation index underestimates the
proportion of methylated alleles (expected to be 50% in the wild type control animals).
This is because only the most densely methylated alleles which are methylated at all 5
restriction sites within the amplicon are quantified as methylated. There were significant
differences in methylation between the treatment groups (p=0.02 by analysis of
variance). Post-hoc analysis suggests that this is due to a combination of demethylation
being achieved in the AdC treated wild type animals, and hypermethylation in both AdC
treated and untreated transgenic animals. The higher dose of AdC caused more
demethylation in the transgenics, reducing Igf2r to normal levels. We can conclude that
it is likely that AdC treatment failed to reduce mortality as demethylation could not be
achieved in the transgenic animals with the dose administered.
While the higher dose of AdC may have caused more demethylation, this dose appears
too toxic for long term administration. A further three transgenic animals received
ongoing treatment twice weekly with 2.5 mg/kg AdC. Two animals died at 114 and 119
days of age (earlier than would be expected for untreated transgenic animals), and
tissues were too decomposed for analysis; the final animal was sacrificed at 125 days of
age after a total of 12 injections, as it looked unhealthy. Igf2r methylation analysis on
this animal showed evidence of continued demethylation (methylation index. 4.5% ,
transformed standard error 0.5%). There were no histological changes of
cardiomyopathy in this animal, but it is not possible to conclude that AdC treatment
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prevented these changes since the cardiac histology may not yet be detectable at this age.
It would appear more likely that the animals receiving ongoing treatment have died as a
result of AdC toxicity.
4.6 Mbd2 deficiency does not prevent cardiomyopathy in Tg(Dnmt3b)+ mice
Dnmt3b over-expressing mice which are Mbd2 deficient were produced by mating
Tg(Dnmt3b)+ mice (F8 generation) to Mbd2~'~ knockout mice (previously reported in
Hendrich et al 2001) to produce compound heterozygotes. The Tg(Dnmt3b)+, Mbd2+/~
compound heterozygotes were then crossed with Mbd2~!~ mice to produce litters with the
expected Mendelian ration of genotypes Tg(Dnmt3b)+, Mbd2~'~ 25%: Tg(Dnmt3b)~,
Mbd2~'~ 25%: Tg(Dnmt3b)+, Mbd2+i~ 25%: Tg(Dnmt3b)-, Mbd2~'~ 25% .
Survival curves for Tg(Dnmt3b)+, Mbd2'A and Tg(Dnmt3b)+, Mbd2+/~ mice are shown
in Figure 4.6 and are compared with Tg(Dnmt3b)+, Mbd2+/+ mice derived from males
of the same generation used for intercrossing. The Tg(Dnmt3b)+, Mbd2+'~ mice
include both F1 and F2 compound heterozygotes. There is no evidence of any
difference in survival in either Tg(Dnmt3b)+, Mbd2'A or Tg(Dnmt3b)+, Mbd2+/~
genotypes. In addition, hearts from mice at post mortem show histological changes
identical to Tg(Dnmt3b)+, Mbd+/+ mice. Although numbers are small, it can be
concluded that Mbd2 is not necessary for the pathogenesis of the cardiac pathology.
4.7 Downregulation of genes in Tg(Dnmt3b)+ can occur by methylation-
independent mechanisms.
On the basis that phenotypic changes caused by Dnmt3b over-expression are likely to
result from the silencing of gene expression by methylation, gene expression profiles in
hearts from a single 130 day old Tg(Dnmt3b)+ mouse and a wild type littermate control
were measured by microarray, as a screening process in order to find downregulated
genes which may have been aberrantly methylated. The Affymetrix U74v2 array
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contains oligonucleotides representing approximately 12000 genes. Of the transcripts for
which the signal from at least one probe from either animal wass detectable, there were
274 transcripts increased > 2 fold in the transgenic and 204 genes decreased >2 fold
(data not shown).
We investigated the promoter methylation state of the two characterised genes which
showed the greatest downregulation in themicroarray analysis. Bisulphite sequencing of
the promoter region of the Hop and Ces3 genes was performed on DNA extracted from
hearts from normal and transgenic mice. The downregulation of Hop was also
confirmed by western blotting (Figure 4.7b). The Hop gene (6.4 fold reduced in the
Affymetrix data) has a recognised CpG island promoter. There is also a second CpG
island around 20kb 3' to this region, which is immediately 5' to a second region
showing homology to expressed sequence tags corresponding to Hop, which probably
represent an alternative promoter (Figure 4.7a). Both regions were examined by
bisulphite sequencing. There was no evidence of a difference in CpG island
methylation examining the 13 CpG sites present in the product from the most 5' CpG
island (HopPl), or the 17 CpG sites in the 3' island (HopP2) comparing 10 normal to 10
transgenic clones in either CpG island (Fig 4.8). The promoter of the Ces3 gene (17.5-
fold reduced) does not contain a CpG island but does contain a CpG dinucleotide in an
Spl transcription factor binding site which has shown to be important in transcriptional
regulation (Douglas, et al 2001). 5/28 clones showed methylation at this site in the
normal animal compared to 5/16 in the transgenic animal (p=0.16 by Chi-square test).
The lack of change in methylation suggests that these gene expression changes may be




The presence of a cardiac phenotype in the Tg(Dnmt3b)+ mice is perhaps the most
unexpected result but one which could have widespread implications. If it could be
shown that the cardiac pathology is the result of epigenetic silencing caused by Dnmt3b
over-expression, this could open the door to a potentially new area of investigation into
the role of epigenetic regulation and dysregulation in cardiac disease. At the least it may
provide insights in to new mechanisms of cardiomyopathy, which would have relevance
not only for inherited myopathies but also end stage cardiac muscle changes that occur
in heart failure. More interestingly, it is possible that maladaptive epigenetic responses
are involved in the pathogenesis of heart failure and of remodelling of the heart in
response to stresses such as hypertension and following myocardial infarction, which are
major causes of morbidity in the developed world.
Interpretation of the findings of this study is made more difficult because of the limited
understanding of both epigenetic processes in the heart and the transcriptional effects of
heart failure and cardiomyopathy, making it difficult to distinguish between cause and
effect. However some inference can be drawn from the limited number of published
studies in both areas, which are both becoming more prominent areas for research.
While I am unaware of any studies describing functions of DNA methylation in cardiac
development or pathology other than the development of ventricular septal defects in
Dnmt3b~ ' embryos (Ueda, et al 2006), there is an emerging literature of the importance
of histone modifications and histone modifying enzymes in the control of cardiac
hypertrophy.
The earliest suggestion that there may be a link between chromatin structure and cardiac
regulation came from the discovery of increased transcription of fetal gene products,
such as the embryonic beta-myosin heavy chain, with exposure of nuclease
hypersensitive sites (Huang and Liew 1998). Class II histone deacetylases were
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subsequently shown to play a role in this shift in transcription by being exported from
the nucleus in response to phosphorylation by a calcium-calmodulin dependent kinase
(McKinsey, et al 2000).
The classical histone deacetylases (HDAC) cause deacetylation by simple hydrolysis of
the acetyl group and are classified in to two classes: Class I HDACs, which include
proteins Hdacl,2,3 and 8 and have close homology to the yeast transcriptional regulator
RPD3; and class II HDACs, which include Hdac 4,5,6,7,9 and have homology to the
yeast protein HDA3 (for review see de Ruijter, et al 2003). Class I histone deacetylases
are generally ubiquitous whereas class II HDACs tend to have more tissue specific
distributions and in addition to the catalytic regions have other domains that are involved
with protein-protein interactions. In addition there is a third class of HDACs, the
sirtuins or class III HDACs which have homology to the yeast protein SIR2, which are
NAD+ dependent and release acetyl groups as 2'-o-acetyl-ADP-ribose.
The importance of histone deacetylases was confirmed by deleting the Class II histone
deacetylase Hdac9 in transgenic mice. Hdac9~ ~ mice are essentially normal at birth but
gradually develop cardiac hypertrophy by 8 months of age, which is accelerated by
aortic banding pressure overload and increased calcium dependent signalling (Zhang, et
al 2002), suggesting that Hdac9 has an anti-hypertrophic function. Paradoxically in the
light of these findings, treatment with histone deacetylase inhibitors has an inhibitory
effect on cardiac hypertrophy caused by pressure overload (Kong et al 2006) and
pharmacological manipulation (Kee, et al 2006). It has been suggested that this effect
could be explained if class I histone deactetylases have the converse action, promoting
hypertrophy. Indirect evidence that this may be the case comes from study of the
cardiac specific nuclear factor Homeodomain only protein (Hop), which causes cardiac
hypertrophy when over-expressed in transgenic mice by binding to and repressing the
anti hypertrophic transcription factor Serum response factor (Srf). Hop- induced
hypertrophy appears to be dependent on interaction with the class I histone deacetylase
Hdac2, since the phenotype is not produced by a mutant Hop protein with a mutated
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Hdac2 binding site, and is reversed by treatment with the histone deacetylase inhibitor
trichostatin (Kook, et al 2003). Histone acetyltransferases have also been implicated in
cardiac remodelling, with mice with deletion of the p300 acetyltransferase showing
defective remodelling following experimental myocardial infarction (Miyamoto, et al
2006).
The basic message from these studies is that the epigenetic regulation of cardiac
transcription is likely to be a dynamic process in the developed animal, with
transcriptional responses to stimuli being regulated by epigenetic mechanisms as well as
transcription factors. Given the close interactions between DNA methyltransferases and
the histone modification system, it is perhaps not surprising that altering the levels of
DNA methyltransferases may have perturbed the balance of cardiac gene regulation,
either through inducing abnormal methylation or by direct interaction with histone
modifying enzymes. Some features of the current study perhaps favour the latter
possibility, such as the late development of methylation changes and the failure of 5'-
azacytidine treatment or Mbd2 deficiency to reverse the phenotype. Along similar lines,
while it might be thought more than a coincidence that Hop appears to be
downregulated in the Tg(Dnmt3b)+ mice given the close association of Hop with
histone deacetylases, downregulation did not seem to be caused by promoter
methylation. However, it is still quite possible that Dnmt3b over-expression and Hop are
linked in the pathogenesis of the cardiomyopathy, either through methylation
independent silencing ofHop or interference with the function of Hop by altering levels
of histone deacetylases.
One of the major questions arising from Tg(Dnmt3b)+ animals is the question of why
abnormalities occur is specific tissues only, and most severely in the heart. One feature
from the histone deacetylase studies which may be instructive is the timecourse of
events in the Hdac9 knockout animals. While the histological changes in the Hdac9-/-
animals is distinct from the changes in the Tg(Dnmt3b)+ mice, and it might furthermore
be expected that opposite effects would be seen given the recruitment of histone
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deacetylases by Dnmt3b and methyl binding proteins, a similar phenomenon of late
onset disease confined to the heart occurs in both models. One could argue that this may
help to explain why the heart is the most severely affected organ in the Tg(Dnmt3b)+
mice despite widespread expression of the transgene, since Hdac9 is also widely
expressed but depletion only gives a cardiac phenotype. This may indicate a particular
sensitivity to alterations in the balance of epigenetic modifications in the heart.
One can speculate what factors might lead to an increased sensitivity to epigenetic
regulation in the heart. Thinking at the most general level, the two most unusual
characteristics of the heart are the fact that it is non-mitotic, and its heavy metabolic
workload. Since the essential nature of epigenetic modifications is that their control of
transcription is heritable during cell division, this provides a possible mechanism. It is
possible that error-checking processes are important for maintaining the fidelity of
epigenetic replication during mitosis (for example it is known that Dnmtl has higher
specificity for CpG than either of the established de novo methyltransferases), and the
absence of this error checking in the non- mitotic cell may lead to accumulation of errors
in transcriptional regulation. Arguing against this however is the proliferation of
epigenetic abnormalities in cancer where cells are undergoing extensive mitosis.
Could the high metabolic requirements of the heart cause sensitivity to epigenetic
changes? Trivially, the substrates for methylation and acetylation are products of
metabolism. Single carbon groups are not used as energy sources and so interference
with methylation seems unlikely. This is supported by the lack of cardiac effects of
nutritional deficiencies affecting single carbon metabolism such as deficiencies of
vitamin B12, folate or methionine. However, the substrate for histone acetylation is
acetyl-coenzymeA, which is central to energy metabolism. It is an attractive hypothesis
that histone deacetylation could occur under conditions of increased aerobic metabolic
demand or decreased acetyl supply from diet or lipid catabolism, as a result of decreased
acetyl supply to histone acetyltransferases. This could lead to a metabolic
autoregulation of transcription, promoting histone deacetylation and transcriptional
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inactivation under periods of metabolic stress. The hypothesis would be consistent with
the amelioration of pressure induced hypertrophy by histone deacetylases, and would
also be consistent with increased histone deacetylation recruitment in Tg(Dnmt3b) +
mice causing a phenotypic changes in the heart. The hypothesis would be difficult to
prove, not least since there are few molecular biologists with detailed experience of "old
fashioned" methods of manipulating metabolism, but perhaps the simplest
counterexample to seek would be to investigate whether cellular levels of acetyl
coenzyme A fluctuate in response to metabolic demand sufficiently to affect histone
acetylation rates meaningfully.
An alternative, and not mutually exclusive, possibility for the predominant phenotype
being cardiac in nature is that Dnmt3b is involved with maintaining fetal gene
expression patterns, since both Dnmt3b expression and cardiac growth by hyperplasia,
as opposed to hypertrophy, are reduced after birth. The continued expression of Dnmt3b
could result in the failure to terminate fetal expression patterns leading to maladaptive
responses to stimuli similar to those seen in the Hdac9'f' animals.
While the development of cardiomyopathy as a result of Dnmt3b over-expression was
unexpected, it ties in well with the growing interest in the importance of epigenetic
regulation in the heart, and the idea that the heart may be particularly sensitive to
epigenetic changes. Given the widespread interest of epigenetic regulation in
development and in mitotic phenomena such as cancer, it is ironic that the clearest
phenotype seen in Tg(Dnmt3b)+ mice is seen in an organ which is end-differentiated
and has an extremely low cancer incidence. Although it may seem that the over-
expression of Dnmt3b in an organ which it is not normally expressed would at first seem
to have limited relevance to actual physical phenomena, perhaps it raises deeper
questions about the role of epigenetic factors in the end-differentiated cell.
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4.9 Figures and Tables










Figure 4.1 Molecular structures of demethylating drugs. Structure of 5'-azacytidine and 5'-Aza
2'deoxycytidine (decitabine), with structure of cytosine for comparison.
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Age Genotype Body Weight (g) Heart weight (mg) Heart:body ratio (x1E-3) Histology
4 months pos 21.9 170 7.8 abnormal
4 months neg 21.9 165 7.5 normal
4 months neg 24.2 130 5.4 normal
4 months pos 25.0 190 7.6 abnormal
6 weeks neg 23.8 180 7.6 normal
6 weeks pos 21.4 170 7.9 normal
6 weeks pos 22.1 130 5.9 normal
6 weeks neg 19.4 140 7.2 normal
6 weeks pos 18.1 120 6.6 normal
6 weeks neg 18.2 140 7.7 normal
2 weeks pos 9.4 69 7.3 normal
2 weeks pos 10.0 76 7.6 normal
2 weeks pos 9.2 64 7.0 normal
2 weeks neg 9.2 67 7.3 normal
2 weeks neg 9.8 67 6.8 normal
2 weeks neg 10.4 73 7.0 normal
2 weeks neg 8.4 57 6.8 normal
Table 4.1 Presence of cardiomyopathy in Tg(Dnmt3b) mice by age. Relationship between
genotype (by western blot), age and the presence or absence of histological changes
characteristic of cardiomyopathy in F10 Tg(Dnmt3b) mice.
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A)
mouse genotype heart expression histology body wt(g) heart(mg) heart:body
795 - - normal 37.4 171 4.57
796 + - normal 27.7 166 5.99
797 - - normal 26.2 147 5.61
798 - - normal 34.6 205 5.92
799 + - normal 26.9 195 7.25
801 + + abnormal 22.1 167 7.56
802 - - normal 33.2 217 6.54
803 + - normal 25.7 132 5.14
829 + - normal 28.1 214 7.62
837 + + abnormal 20.4 239 11.72
838 + + abnormal 18.25 185 10.14
B)
C)
heart expression n Rank sum Mean rank U
no 8 37.0 4.63 23.0
yes 3 29.0 9.67 1.0
genotype n Rank sum Mean rank U
pos 4 22.0 5.50 4.0
neg 4 14.0 3.50 12.0
p=0.02
p=0.34
Table 4.2 Relationship of heart mass to Dnmt3b expression. A) Comparison ofcardiac
weights and histology according to genotype (as determined byPCR), and cardiac transgene
expression in 5 month old F12 mice. Heart weight: body weight ratios are xlO"3 . B)
Nonparametric statistics for heart:body weight ratio according to cardiac transgene expression
status. C) Nonparametric statistics for heart:body weight ratio according to genotype for animals
which do no^show detectable transgene expression. Significance values are calculated by the 2-
tailed Mann-Whitney U test. The results show an increase in heart mass which is significantly




799 798797 796 795












Figure 4.2 Relationship of cardiac phenotype to Dnmt3b protein expression level. A) PCR
geno typing of mice from F12 litter. M=size marker. B) Western blot of cardiac Dnmt3b
expression from same animals. C) Sirius red stained sections from hearts of above animals
demosnstrating extensive fibrosis only in the animal with strong cardiac trans gene expression.







Figure 4.3 Aberrant methylation levels by Dnmt3b expression level. Methylation status of
Wnt3, Cdknla (p21), Cdkn2a (pl9) in heart, classified according to Tg(Dnmt3b) genotype and
cardiac Dnmt3b expression. neg= Tg(Dnmt3b)-; silent= Tg(Dnmt3b)+ byPCRbut undetectable
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Figure 4.4 Effect of decitabine treatment on survival of Tg(Dnmt3b)+ mice. A) Kaplan-
Meier survival curves and B) estimated median survival, comparing survival of Tg(Dnmt3b)+
mice treated with 1 mg/kg decitabine with untreated Tg(Dnmt3b)+ mice from the same
generations (F5/6). Mice which were sacrificed early are included in the analysis as censored





































Figure 4.5 Effect of decitabine treatment on Igf2r methylation. Graph comparing cardiac
Igf2r methylation as measured by M-QPR following decitabine treatment. Animals were treated
for 2 weeks (5 injections) with the dose shown in the legend. Error bars represent standard error
from 3 separate animals. Significance value is for the existence of difference in means in the
experiment as a whole by one way analysis of variance. The group marked as * is significantly







3b+Mbd2-/- 3b+Mbd2+/- • 3b+Mbd2+/+
B) Genotype n median survival (d) (95% conf. interval)
3b+Mbd2-/- 5 128 107 142
3b+Mbd2+/- 11 113 110 135
3b+Mbd2+/+ 26 127 116 136
Figure 4.6 Effect of Mbd2 deficiency on survival in Tg(Dnmt3b)+ mice. A) Survival curves
and B) median survival data for Tg(Dnmt3b)+ xMbd2'/' mice, classified by Mbd2 genotype. 3b+
indicates Tg(Dnmt3b)+. Significance value quoted in figure 4.6a is based on null hypothesis
that the survival curves are the same.
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Figure 4.7 Hop expression and promoter structure. A) promoter structure ofHop B)
Expression of Hop (8Kda band) by western blot in hearts from Tg(Dnmt3b)+ and wild type
mice.
Fig 4.8 (overleaf) A) Methylation status ofPl promoter in wild type and Tg(Dnmt3b)+ mice
by bisulphite sequencing. B) Methylation status of individual CpG nucleotides in the 3' Hop
promoter (HopP2) by bisulphite sequencing. The number ofclones examined varies at individ¬
ual CpG dinucleotides since clones where sequence was unclear at a given CpG were excluded
from the analysis. Data are fromF3 mice.
100
A) P1 promoter
CpG=distance from start of PCR product
genotype clone # 38 65 69 94 100 191 205 207 214 262 277 353 362 conversion%







09 tm - - 96










SCpG methylation |n |ambiguous sequenceSequence does not correspond to referenceUnreadable sequence
B) P2 promoter Hop_P2(WT)
I □ unmet h■ meth




- I II 1 ■■rT- u.■ I c=
□ unmet h
■ meth
1 2 3 4 5 6 7 9 10 11 12 13 14 15 16 17
CpG
Figure 4.8 Hop promoter methylation in heart. (Legend on preceding page)
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5. Effects of Dnmt3b over-expression on cancer
5.1 Introduction
In this chapter the effects of Dnmt3b over-expression on tumour formation are
examined. Three complementary models are studied: firstly the spontaneous incidence
of tumours in Tg(Dnmt3b)+ mice, secondly the effects of Dnmt3b over-expression on
multi-stage skin carcinogenesis, and finally the effects of Dnmt3b over-expression in
Apc+,mm mice, a hereditary cancer predisposition model in which the mechanism of
tumour formation is well defined. One of the difficulties of investigating tumour
development in Tg(Dnmt3b)+ mice is that their reduced lifespan may not give sufficient
time for tumours to form. We have therefore chosen the two induced cancer models
such that tumours develop with short latency, allowing any effect to be seen within the
lifespan of the Tg(Dnmt3b)+ mice.
Multi stage skin carcinogenesis is a well established model system for studying the
effect of factors which influence susceptibility to cancer. Mice are treated topically
with a carcinogen, 7,12-dimethylbenzanthracene, (DMBA) which causes DNA damage,
in what is referred to as the initiation phase of treatment. This is followed by regular
topical treatment with a mitogen 12-O-tetradecanoylphorbol-13-acetate (TPA) which is
termed the promotion phase of treatment. There are several different treatment
regiments which have different periods of tumour latency. Using an aggressive regimen
of 2 initiation treatments 6 weeks apart and twice weekly promotion treatments, animals
develop tumours at around 10 weeks after starting treatment (Owens, et al 1999). The
mice initially develop benign squamous-cell papillomas, which progress to form
malignant squamous cell carcinomas. A number of molecular abnormalities have been
described in these tumours, especially in the transformation to malignant carcinoma, but
a common feature which occurs in almost all papillomas is the development of
mutations in Ha-ras (Zoumpourlis, et al 2003) for review. In addition, the archetypal
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changes in DNA methylation have been described in papillomas produced by this
regimen, with decreases in global levels of methylation, aberrant methylation of a
number of tumour suppressor genes, and increases in Dnmtl and Dnmt3b (Fraga, et al
2004). The authors of this study imply that levels of DNA methyltransferases may be
correlated with tumour aggressiveness, since the highest levels of methyltransferase
activity are found in the cells with the most malignant behaviour. The system therefore
would appear to meet our requirements for an induced carcinogenesis model of short
tumour latency and a possible role for methylation in modulating tumour behaviour, and
also has the advantage of a simple outcome measure (counting skin tumours).
As an inherited tumour model, the Apcimm mouse has been chosen for study, partly in
view of its short tumour latency, but also since there is substantial evidence for the
importance of DNA methyltransferases in its pathogenesis (see Section 1.6). The Ape
protein binds directly to P catenin and promotes its phosphorylation and subsequent
degradation by the proteasome (For review see Brembeck, et al 2006). In the absence of
Ape, P catenin levels increase and leads to abnormal accumulation in the nucleus in
addition to its normal expression at the cell membrane. Nuclear P catenin acts as a
transcription factor, and is the main downstream mediator of Wnt signalling. The
aberrant expression of P catenin in the nucleus in the absence of Ape thus mimics Wnt
signalling, promoting the transcription of proliferation and survival associated genes
including c-myc and Cyclin Dl, which can promote malignancy. In humans, mutations
in theAPC gene can be found in 60% (Powell, et al 1992) of colorectal tumours; in
addition inherited mutations is the APC gene lead to the syndrome of familial
adenomatous polyposis coli, in which subjects develop multiple colonic adenomas early
in life which subsequently progress to carcinoma (OMIM reference +175100;
http://www.ncbi.nlm.nih. gov/entrez/dispomim.cgi?cmd=entry&id=l 75100).
The mouse Ape gene is transcribed from two known promoters (Karagianni, et al 2005).
The first promoter is immediately upstream of exon 1 and is not formally a CpG island
promoter although it contains a 50 bp segment which meets all CpG island criteria other
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than length. This promoter is the predominant promoter in the gut. A second more
recently discovered promoter is the predominant promoter in ES cells. This promoter
region is 40 kb upstream of the initiating ATG, is a CpG island promoter, and leads to
transcripts with the addition of a 55 nt untranslated sequence at the 5' end. The internal
promoter has been shown to be hypermethylated in human tumours; however there are
differences in the human promoter structure, most importantly that the human internal
promoter includes a CpG island. Loss of Ape in the intestine in an inducible transgenic
mouse model (Sansom, et al 2004) leads to rapid (within 5 days) increases in
proliferation, alterations in cell migratory behaviour and up-regulation of Wnt target
genes.
As mentioned in Section 1.6 , Apc+Imm mice are heterozygous for a mutation in the Ape
gene which leads to premature termination at amino acid 850 (Su, et al 1992). This
mutation arose as part of a chemical mutagenesis experiment. The Apcmn,mm phenotype
is embryonically lethal, however Apc+Imm mice develop multiple adenomas,
predominantly in the small intestine with smaller numbers of colonic tumours. This
leads to rectal bleeding and anaemia, normally causing death at around 7 months of age.
Tumour development proceeds from the development of microadenomas, which can be
detected from as early as 5 weeks of age, with subsequent development of adenomatous
polyps. Analogous to the human condition, these adenomas also progress to form
invasive adenocarcinomas. Loss ofApe appears both necessary and sufficient for
microadenoma formation in Apc+Imm mice (Yamada, et al 2005), although evolution of
polyps is known to be modulated by other loci (Gould, et al 1996, Silverman, et al
2002a).
5.2 Over-expression of Dnmt3b does not cause spontaneous tumours
The most simplistic hypothesis for the role of DNA methylation in carcinogenesis is that
abnormal methylation events occur essentially at random. If these random errors happen
to involve tumour suppressor genes, this could cause their silencing and lead to cancer.
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According to this hypothesis, it would be expected that expressing a de novo
methyltransferase in cells in which it is not normally expressed would enable the
development of abnormal events, and lead to an increased incidence of cancer.
There have been no macroscopically detectable tumours in any of the Tg(Dnmt3b)+
mice so far in any of the first 220 observed, based on gross post mortem dissection of
animals that had died spontaneously and were found sufficiently soon after death not to
have decomposed, and the lack of spontaneous externally visible tumours in any
animals. In addition there was no evidence of microscopic tumours in histology from
two Tg(Dnmt3b)+ F1 animals examined at 139 days, or in any other animals which
have had had tissues taken for histology for other reasons. It can be concluded that any
effect of Dnmt3b over-expression on spontaneous tumour formation is absent or
extremely small.
It could validly be argued that an increase in cancer predisposition is not detected in
these animals because of their reduced lifespan due to non-malignant disease, and that
spontaneous cancer formation may have been seen if the animals had a normal lifespan.
While this argument cannot be refuted, it can partially be addressed by the chimaeric
founder animals which had a normal lifespan. Out of 10 chimaeric animals, there was
one stomach tumour occurring at approximately 2 years of age. This level of incidence
is not significantly different to the published lifetime cancer incidence of 7% in 129
strain mice (Festing 1979). The findings support the hypothesis that the effect of
Dnmt3b on spontaneous tumour formation is small, ifpresent at all.
5.3 Aberrant methylation of known tumour suppressor genes is detectable in
Tg(Dnmt3b)+ mice
In order to address the possibility that no cancers had occurred in the Tg(Dnmt3b)+ mice
because no genes relevant to cancer had become methylated, the methylation status of a
number of known tumour suppressor genes were examined by M-QPR. A candidate
105
gene approach was employed, concentrating on genes that have been shown to be
methylated in tumours from mice, as there are almost certainly differences in the
occurrence of methylation in tumours between mice and humans, since humans have
more CpG island genes than mice.
Figures 5.1-5.4 show the distribution of abnormal methylation in tissues from wild type
and transgenic animals (F8 generation) of a number of known tumour suppressor genes
(Hid- 5' promoter, Cdknlb (p21), Cdkn2a (pl9) and Mlh-1), as measured by M-QPR.
The salient points of these data are as follows. There is clear evidence of substantially
increased methylation of hie 1 in heart and kidney in the transgenic mice. There is also a
consistent increase in Cdkn2a (pi9) and Cdknlb methylation in heart and kidney though
at a lower level, possibly indicating methylation of a sub population of cells in the tissue.
There is no convincing difference between methylation patterns for Mlh-1, with
methylation detectable in both wild type and transgenic mice. In addition, low levels of
pl9 and Hid methylation appear to be detectable in tissues from wild type mice
although there is variation between samples.
The results indicate that an increased level of a de novo methyltransferase is a sufficient
condition to cause dense methylation of known tumour suppressor genes, at least at low
level. However this has not translated in to an increased spontaneous tumour incidence.
The functional significance of such low level methylation is uncertain, since it is not
clear whether this relates to methylation of a minority subpopulation of cells or to
methylation occurring in a small proportion of cells from the predominant cell type. It is
also unclear whether the methylation observed with this technique is mono-allelic or bi-
allelic.
5.4 Sensitivity to skin carcinogenesis is not greatly increased
In order to investigate whether Dnmt3b over-expression causes increased susceptibility
to carcinogenesis, A preliminary study using the model of multistage skin
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carcinogenesis (Owens, et al 1999) was conducted. 4 transgenic and 6 non-transgenic
littermate mice (F7 generation) were exposed topically to the carcinogen
dimethylbenzanthracene (DMBA) at 0, 2, 4 weeks with promotion using the mitogen 2-
o-tetradecanoylphorbol-13-acetate (TPA) applied topically twice weekly for 10 weeks.
Treatment started at 4-6 weeks of age. No macroscopic skin tumours were seen in any
of the treated transgenic mice. Transgenic mice became unwell at the expected age, with
autopsy studies revealing cardiomegaly as expected but no gross tumour formation. The
remaining four control animals were observed to identify the background rate of tumour
formation. One control animal developed a skin tumour 14 weeks after the start of
treatment. The remaining animals were sacrificed at 240 days and remained tumour
free.
The results are not conclusive, due to the lower than expected incidence of tumours in
the control animals. This may be due to the relative resistance of the C57BL6 strain of
mice to multistage carcinogenesis (Reiners, et al 1984). In addition, the reproducibility
of this method of dosing is somewhat uncertain, since there is likely to be much
variation in the amount of carcinogen actually applied to the skin in each topical
treatment. Thus there was no attempt to repeat the experiment with larger numbers or
alternative tumour promoting agents. Nevertheless, the experiments suggest that
susceptibility to tumour formation caused by multistage chemical carcinogenesis is not
massively increased by Dnmt3b over-expression.
5.5 Tumour progression, but not Ape methylation, is increased in Apc+Imm mice
crossed with Tg(Dnmt3b)+ mice
The most direct evidence for a causative role of methylation in the development of
cancer would be to demonstrate the methylation of tumour suppressor genes in a model
in which the mechanism of tumour formation by silencing of these genes is well defined.
Tg(Dnmt3b)+ mice (from F8 to F11 generations) were therefore crossed with
Apc+,mm mice to produce mice heterozygous for both mutations (see Section 7.2.5).
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Apc+Imm, Tg(Dnmt3b)+ and Apc mm , Tg(Dnmt3b)- mice were sacrificed at 125 days and
tumour burden was estimated by taking transverse sections at approximately 30 levels
through the small intestine and calculating the mean number of tumours per section-
referred to as mean tumour index (MTI) (see Section 7.2.7). This statistic cannot be
viewed as a simple estimator of total tumour number, and changes in MTI could result
from changes in either number or tumour size distribution.
A total of 7 Apc+/ mm, Tg(Dnmt3b)+ mice and 17 Apc+ mm, Tg(Dnmt3b)- mice survived
to 125 days. The number of Tg(Dnmt3b)+ mice is smaller since some mice died before
125 days as a result of cardiac disease. As expected, multiple microadenomas,
adenomatous polyps and adenocarcinomas were seen in intestines of both groups of
animals (Figure 5.5 for examples of histology). Figure 5.6 shows the mean tumour
index for each animal studied, classified by genotype. In both Tg(Dnmt3b)+ and
Tg(Dnmt3b)- animals, there appear to be a small number of animals with a particularly
high tumour burden with the majority of animals having a smaller tumour burden. The
size of the effect of Dnmt3b over-expression on tumour number was estimated by
calculating the ratio of the median MTIs between the two groups. Based on this statistic,
the tumour burden was modestly increased in Tg(Dnmt3b)+ mice but this was not
statistically significant, with a ratio of MTI Tg(Dnmt3b)+ / Tg(Dnmt3b)~ of 1.3 (95%
confidence interval 0.84 to 2.68).
There are regional differences (p<0.0001 by Kruskal-Wallis test) within the gut as
regards tumour burden, with an increased tumour burden in the distal gut regardless of
Tg(Dnmt3b) genotype. This distal predominance is significantly more marked in
Tg(Dnmt3b)+ animals (Figure 5.8). Hence there may be a difference in the distribution
of tumours between Tg(Dnmt3b)- and Tg(Dnmt3b)+ animals, either as a result of
increased tumour initiation or growth which is confined to the distal gut. Since the
effect seems to amplify the normal distal predominance, it could be argued that it is most
likely that Dnmt3b is interacting with pre-existing condition that give rise to tumours
rather than acting as an independent contributor to tumour formation.
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In order to study the effects of Dnmt3b over-expression on tumour evolution from
benign adenoma to malignant adenocarcinoma, polyps were also classified according to
the presence or absence features ofmalignant transformation- the presence of invasion
or dysplasia (Figure 5.7). The proportion of dysplastic polyps was increased in
Tg(Dnmt3b)+ with a relative risk of dysplasia (i.e. probability of Tg(Dnmt3b)+ polyp
being dysplastic / probability of Tg(Dnmt3b)- polyp being dysplastic) of 1.52 (p<0.003
by Fisher's exact test, 95% confidence interval 1.2-2.0). The relative risk of invasion
was also increased but not significantly (p=0.54 by Fisher's exact test, relative risk 1.51,
95% confidence interval 0.60-3.8).
To investigate whether any differences in tumour numbers between
Apc+Imm, Tg(Dnmt3b)+ and Ape min, Tg(Dnmt3b)~ mice may be mediated through
methylation at the Ape locus, the promoter methylation status of the Ape gene was
investigated. To examine the methylation status of the Ape promoters in normal gut
tissue, DNA from whole gut from both Ape + +, Tg (Dnmt3b)~ and Apc+/+, Tg(Dnmt3b)+
mice was examined by bisulphite sequencing. No evidence of methylation was found in
either promoter in either Tg(Dnmt3b)+ or Tg(Dnmt3b)- gut samples (Figure 5.9). In
addition the methylation status of the external CpG island promoter was examined by
M-QPR in order to detect low levels of methylation. The level of methylation in normal
gut is very small ifpresent (of the order of 0.1%), and there was no significant
difference between the Tg(Dnmt3b)- and Tg(Dnmt3b)+ animals. It can be concluded
that the Ape gene is not susceptible to spontaneous methylation as a consequence of
Dnmt3b over-expression.
To examine the Ape methylation status in tumours, individual tumours were
microdissected from the paraffin embedded gut samples. DNA was extracted from
these, and pooled DNA from 20 Apc+/mm, Tg(Dnmt3b)+ tumours and 20 Apc+Imm,
Tg(Dnmt3b)- tumours was analysed for methylation by bisulphite sequencing.
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From the internal promoter, good quality sequence was obtained from 22 clones from
Apc+ mm, Tg(Dnmt3b)+ tumours and 20 clones from Apc+Imm, Tg(Dnmt3b)- tumours.
The results show dense methylation of several adjacent CpG residues in 4 clones from
both wild type and transgenic animals. In addition, sporadic methylation of single CpG
residues in 3 clones from the Tg(Dnmt3b)+ tumours and 1 clone from Tg(Dnmt3b)-
tumours (Figure 5.10) was present. From the external promoter, there was no evidence
of methylation in 20 clones from from Apc+Iram, Tg(Dnmt3b)- mice (Figure 5.11). There
was no evidence of dense methylation in 21 clones from Apc+nmn, Tg(Dnmt3b)+
tumours. However 7 clones showed methylation at individual CpG residues.
It can be concluded that the internal Ape promoter is densely methylated with detectable
frequency in intestinal tumours from Apc+Imm animals regardless of Tg(Dnmt3b)
expression. However there is no evidence for any increase in the frequency of dense
methylation caused by Dnmt3b over-expression. Since Ape inactivation is a necessary
condition for polyp formation, it follows that even if the small changes in tumour burden
noted above were genuine, they must be caused not by increased tumour initiation as a
result of methylation of the wild type Ape allele, but by effects on tumour growth
mediated at other loci.
To investigate this point further, two approaches were taken to examine whether there
are differences in silencing at the Ape locus. Firstly, DNA from individual tumours was
also assayed for loss of heterozygosity at the Ape locus by PCR and Hindlll digestion.
Secondly, immunohistochemical staining was performed for beta-catenin as a surrogate
marker of Ape inactivation.
Results of the loss of heterozygosity analysis for 8 tumours from each genotype are
shown in Figure 5.12. The most important finding from this experiment is that DNA of
sufficient quality to be successfully amplified by PCR has been successfully extracted
from the majority of microdissected tumours, and so the bisulphite sequencing data is
likely to be representative of several independent tumours. The analysis shows that the
110
microdissection has been successful in enriching for tumour DNA since samples from
the tumours show a much stronger min band than wild type band. It is not possible to
determine from this analysis whether the presence of a weaker wild type band indicates
that the dissection of tumours has included more normal tissue or whether there is
genuinely some loss of heterozygosity at the Ape locus in a small proportion of cells
within the tumour. An independent observer, blinded to the genotype of the mice was
unable to find any difference in nuclear beta-catenin staining between Tg(Dnmt3b)+ or
Tg(Dnmt3b)- sections (Figure 5.13), viewing 5-6 sections from distal intestine from 5
mice in each group. This is in keeping with the hypothesis that there is no increase in
silencing of the Ape locus in Tg(Dnmt3b)+ mice.
The increase in sporadic methylation in both promoter regions raises the possibility of an
effect of Dnmt3b on causing sporadic methylation events. It is not possible to discount
the possibility of individual events being artefacts as a result of incomplete bisulphite
modification. However the observation that conversion rates are not appreciably
different between the two groups would argue against this explaining the differences in
the experiment as a whole. Importantly the increase in sporadic methylation appears to
have occurred in the tumour samples and not the samples from histologically normal
Apc+ + tissue. This again supports the hypothesis that changes in the malignant cell other
than increases in methyltransferase level provide a milieu which favours the
development of aberrant methylation. Again differences in bisulphite conversion
between paraffin embedded tissues and fresh prepared tissues cannot be excluded, but if
anything the conversion rates are better in the tumour samples.
To summarise, there is no evidence that over-expression of Dnmt3b causes tumours in
Apc+/m,n mice by methylating the wild type Ape allele. However, on detailed analysis,
Dnmt3b over-expression does appear to alter aspects of tumour behaviour such as the
distribution of tumours and the rate of progression to dysplastic carcinoma in the context
of a genetically tumour prone background.
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5.6 Discussion
The results in this chapter show that Dnmt3b over-expression does not lead to a large
increase in tumour susceptibility. This is despite the fact that abnormal methylation of
known tumour suppressor genes can be detected, and the fact that the Dnmt3b levels
achieved in Tg(Dnmt3b)+ mice are sufficient to cause both changes in methylation and
phenotypic changes. Nevertheless, Dnmt3b over-expression does appear to influence
tumour biology in a well defined tumour prone model, although this does not appear to
be mediated by direct silencing of the locus which causes cancer.
One possible explanation for the lack of a strong cancer phenotype might be that in the
transgenic animals, Dnmt3b is not expressed in cells which give rise to cancer. While
this argument cannot be directly refuted, because attempts to investigate the detailed
tissue distribution of Dnmt3b expression of Dnmt3b by immunohistochemistry on
paraffin sections were unsuccessful (data not shown), data from other models where the
transgene is expressed under control of the CAG promoter have shown strong
expression in relevant cells (Wiekowski, et al 2001). Specifically, there is strong
expression in the intestinal epithelium, including the intestinal crypts in which tissue
stem cells reside and microadenoma formation is thought to occur in Apc+/mm mice.
What does this lack of a clear cancer phenotype tell us about the role of methylation and
methyltransferases in cancer? The results argue strongly against the possibility that
dysregulation of methyltransferases can act as the primary initiating events in cancer.
This is perhaps not very illuminating, since there are no known reports in cancers of
translocations or mutations causing overactivity of de novo methyltransferases.
However given the appearance of abnormal methylation events provoked by non-
malignant phenomena such as aging (see Section 1.6), de novo methyltransferase
activity must be induced under certain conditions in adult life. Nevertheless, the fact
that no definite effect on tumour induction is seen even despite expressing Dnmt3b to
supra-physiological levels would tend to suggest that aberrant DNA methylation as the
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initial event in gene silencing is likely to be very rare at physiological levels of Dnmt3b
expression.
Since silencing of tumour suppressor genes by methylation is the most plausible
mechanism for a role of DNA methylation in causing cancer, the finding of abnormal
tumour suppressor gene methylation in Tg(Dnmt3b)+ mice is instructive. It shows that,
in principle, dysregulation of a de novo methyltransferase is sufficient to cause
methylation of tumour suppressor genes. However, the proportion of cells within the
whole tissue which are susceptible to methylation is very small. The factors which
allow methylation in the context of methyltransferase over-expression remain undefined;
it is unclear whether the low level of methylation relates to methylation occurring in a
minority cell type within the tissue, or whether methylation is occurring in a
subpopulation of cells which have other factors permissive of methylation. The
functional significance of such low levels of methylation also is unclear. Clearly
methylation of tumour suppressor genes has not translated into an increased spontaneous
cancer incidence. There are many possible explanations for this. Firstly it is not known
from our PCR based assay whether methylation is mono-or bi-allelic. It would not be
surprising ifmono-allelic methylation has no functionally detectable consequences in
the absence of genomic deletion. Secondly, the effects of bi-allelic loss of a single
tumour suppressor gene are often subtle. Mice with null mutations of many of the genes
studied here suffer only small increases in tumour susceptibility (Chen, et al 2003b,
Deng, et al 1995, Sharpless, et al 2004), and so it is not surprising that of methylation of
these genes in small numbers of cells has not led to spontaneous tumours. Finally, and
more radically, it could be argued that the methylation seen in Tg(Dnmt3b)+ mice has
only occurred in cells in which it is irrelevant, for example if the gene is already
silenced. If this were the case, it would support the hypothesis that methylation events
seen in tumours and cell lines may not necessarily reflect functional changes in gene
expression.
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Nevertheless, the detection of methylation shows that under certain (undefined)
circumstances, tumour suppressor genes which have been found to be commonly
methylated in cancer are able to be methylated simply by inducing de novo
methyltransferase activity. Since the genes chosen for study here were selected using a
candidate gene approach rather than as a result of a screening assay, it raises the
possibility that such genes are methylated in cancer since they are especially prone to
methylation. This hypothesis could imply that these genes may be a common factor in
the pathogenesis of many different types of cancer. On the other hand, it could also be
taken to indicate that these genes are especially prone to methylation as a bystander
effect of the malignant process, whether this has any functional consequence or not. In
addition, the lack of spontaneous tumour development argues that there has not been
widespread silencing of tumour suppressor genes, as there are many genes (including the
Ape gene) which when deleted give rise to an aggressive tumour prone phenotype which
would be seen within the lifespan of the Tg(Dnmt3b)+ mice. Taken together, these
results suggest that although tumour suppressor genes which are methylatable are not
uncommon, the silencing of an active gene in a functionally important manner is much
rarer.
How do our findings tie in with other experiments on the role of methyltransferases in
the development and progression of tumours in Apc+mm mice? The most important
study to compare with is the inducible deletion of Dnmt3b in the intestine (Lin et al
2006). To recap, this study showed that Dnmt3b is upregulated in established
macroadenomas from Apc+ min mice. Conditional deletion ofDnmt3b in the intestine
was achieved by producing mice with loxP sites flanking exons 16 to 19 of the Dnmt3b
gene (Dnmt3b 21ox/21ox)5 and breeding these mice with transgenic mice with Cre
recombinase under the control of transcriptional regulatory elements from the fatty acid
binding protein gene (Fabp), which is intestine specific. Comparing (Ape +/mm,
Dnmt3b2Xoxl2{ox , FabpCref) and (Ape min, Dnmt3b2loxl2lox, FabpCre') mice, the authors
found a 40% reduction in the number of macroscopic colonic tumours, with no
difference seen in the small intestine, possibly as a result of low recombination rates in
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the small intestine. No differences in the number microadenomas, as defined by
abnormal (3-catenin staining were found. Dnmt3b was not essential for tumour growth,
since tumours not expressing Dnmt3b protein were found. However Dnmt3b expression
did seem to provide a selective advantage since in the colon, a higher proportion of
established macroadenomas expressed Dnmt3b, whereas approximately 50% of
microadenomas expressed Dnmt3b. The authors concluded that the effect of Dnmt3b
deletion must act to prevent the transition between microadenomas and macroscopic
adenomas, since there was no difference in tumour volume between (Apc+ min,
Dnmt3b2iox/2lox, FabpClL 1) and (Apc+/mm, D?tmt3b2lox/2lox, FabpCrL~) mice. This is
consistent with the findings of our study suggesting that Dnmt3b over-expression
appears to have no effect on tumour initiation at the Ape locus, but appears to affect
subsequent tumour behaviour.
A key difference between the induction of Dnmt3b seen in the above study and in
Tg(Dnmt3b)+ mice is that the increase in Dnmt3b in Tg(Dnmt3b)+ mice is present in
the normal tissue rather than being increased only in tumours. Therefore, one might not
expect to add anything to the effects of Dnmt3b on macroadenoma formation outlined
above, since the enzyme becomes upregulated in polyps anyway. Similarly, the fact that
dense Ape methylation levels are found in both Apcimm, Tg(Dnmt3b)+ and Apc+/mm,
Tg(Dnmt3b)~ animals, but that there is no great difference between methylation
frequencies between the two groups suggests that Ape methylation is a late event,
occurring after tumour formation and the induction of Dnmt3b. Furthermore since dense
Ape methylation is not detectable in normal mucosa from Tg(Dnmt3b)+ mice, it seems
that tumour formation is the necessary condition rather than de novo methyltransferase
expression in determining Ape methylation. Since Ape inactivation is necessary for the
formation of intestinal tumours in Apc+/mm mice, this would imply that dense
methylation ofApe promoters is occurring in a functionally inactive gene (either
methylation of the mutated allele, or an allele previously silenced by other mechanism
such as histone modifications). This suggests that any effect of Dnmt3b over-expression
on tumour number is mediated at loci other than the Ape locus. Since Ape inactivation is
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widely accepted as an early event in tumour formation, this hypothesis is consistent with
the published findings that Dnmt3b deletion affects polyp formation but not
microadenoma formation.
To develop this point further, since Dnmt3b is increased in tumours in Apc+ minmice
without the necessity for it being over-expressed by a trangene, it follows that
differences between Apc+Imm, Tg(Dnmt3b)+ and Apc'/mm, Tg(Dnmt3b)- are likely to arise
from methylation events (or other effects of Dnmt3b) occurring prior to tumour
formation. In this model, over-expression of Dnmt3b has led to methylation events in
histologically normal cells, which does not disturb the behaviour of the cell, perhaps
because it has occurred in genes which are silent in the normal state. Upon inactivation
of the Ape gene, for example by mutational loss of the wild type allele, the cell
undergoes malignant transformation. In the Tg(Dnmt3b)+ mice, genes (for example
tumour suppressor genes) which would normally become reactivated in response to
transformation may have been methylated, thus preventing their re-expression. This
may alter the natural history of the tumours, and although it would have no effect on
tumour initiation it could affect their subsequent progression. The findings of low- level
tumour suppressor gene methylation in histologically normal tissue may be relevant in
this regard, promoting tumour growth once tumours are initiated by other means such as
genomic deletion.
A problem arising from this hypothesis, which also underpins the whole field of gene
silencing in cancer, is why increased methylation should increase rather than decrease
cancer. There is no prima facie reason why silencing should not affect genes which
promote cancer such as oncogenes; in fact it might be argued, given the role of
methylation in retrovirus silencing, that this would be more likely. The finding of
methylation of Wnt3, a putative oncogene, in Tg(Dnmt3b)+ mice (see Section 3.4) also
demonstrates that oncogene methylation can indeed occur. The problem is especially
critical in the Ape model, since the immediate effect ofApe inactivation is the
promotion of transcription of (3 catenin target genes, and if these genes had been
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methylated it might have protected against cancer. The obvious answer is that it is easy
to find examples where methylation events have promoted cancer progression since
proliferation will be favoured, whereas it would be difficult to find (and much harder to
prove) cells that would have become malignant had certain genes not been silenced,
unless this phenomenon was very common. An interesting possibility is that both
effects occur and counterbalance each other, which is why the differences seen in
Tg(Dnmt3b)+ mice are fairly subtle, and also might explain the paradox that loss of
maintenance methylation increases some tumours but decreases others (Yamada, et al
2005). A more radical explanation is either that tumour suppressor genes are
intrinsically more prone to silencing than oncogenes or that the set ofpotentially
methylatable genes includes more tumour suppressor genes than oncogenes, thus tipping
the balance in favour of oncogenesis in a methylation-prone environment.
The idea that methylation events in tumours occurs both prior to, and as a consequence
of an oncogenic insult, with pre-existing methylation patterns altering subsequent
tumour behaviour, has an interesting consequence. It indicates that the set of genes
methylated in a given tumour may be divided into those methylated subsequent to
malignant transformation, which may be common to tumours of similar origin, and those
which precede malignant transfonnation, which may differ substantially between
different tumours. In theory, this might make it possible to classify tumours into those
with pre-transformation methylation and those in which methylation changes are simply
secondary to malignancy. This would have interesting and in some ways paradoxical
therapeutic implications. Demethylating agent therapy would be more likely to be an
independent contributor to a treatment regimen in tumours where methylation
abnormalities are not simply secondary to the malignant process. Secondly, it poses a
diagnostic problem since the search for genes commonly methylated in given cancers is
most likely to discover those which are secondary to the cancer, whereas what would be
more useful is to discover those which differ between apparently similar cancers and
thus may have discriminating value. This may not be feasible in clinical practice, unless
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there are genes that offer discriminating value but are sufficiently frequently methylated
to warrant measurement in routine practice.
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wt1 wt2 wt3 3b1 3b2 3b3
Brain 0 0 0 0 0.27% 0.06%
(0.19-0.38%) (0.05-0.08%)
Gut 0 0 0 0 0 0.21%
(0.20-0.22%)
Heart 0 0 0 2.5% 6.9% 12%
(2.2-2.7%) (6.0-7.8%) (11-13%)
Kidney 0 0 0 1.73% 1.14% 0.74%
(1.1-2.6%) (0.64-2.0%) (0.30-1.9%)
Lung 0 0 0 0 0 0
Figure 5.1 Cdknla methylation
Figures 5.1-5.3 Methylation of 5.1) Cdknla (p21cipl), 5.2) Cdkn2a (P19arf) and 5.3) Hid (5'
promoter) as measured by M-QPR. Tables show methylation index in various tissues (range +/-
transformed standard error).
















Wt1 wt2 wt3 3b1 3b2 3b3
Gut 0.00% 1.24% 0.00% 0.00% 0.00% 0.18%
(0.53%-2.91%) (0.12%-0.28%)
Kidney 0.00% 0.00% 0.05% 0.24% 0.22% 0.00%
(0.01 %-0.17%) (0.20%-0.29%) (0.13%-0.36%) 0.00%
Lung 0.05% 0.05% 0.00% 0.03% 0.08% 0.05%
(0.03%-0.08%) (0.03%-0.09%) (0.02%-0.05%) (0.05%-0.13%) (0.04%-0.05%)
Heart 0.00% 0.00% 0.00% 1.08% 3.03% 2.82%
(0.79%-1.47%) (2.41-3.82%) (1.84-4.33%)




















wt1 wt2 wt3 3b1 3b2 3b3
Brain 0 0.69% 0 0.47% 0.76% 0.44%
(0.51%-0.95%) (0.37%-0.59%) (0.64%-0.92%) (0.37%-0.51%)
Gut 0 0.34% 0 0 2.23% 0.49%
(0.25%-0.47%) (0.76%-6.6%) (0.38%-0.63%)
Heart 0.18% 0.24% 0.47% 8.6% 30% 21%
(0.11%-0.30%) (0.20%-0.28%) (0.43%-0.51%) (5.7%-13%) (28%-33%) (18%-23%)
Kidney 0 0 0 2.7% 2.5% 1.7%
(2.2%-3.3%) (1.9%-3.3%) (1.2%-2.7%)
Lung 0 0 0 0 0 0















Figure 5.4 Mlhl methylation. Methylation ofMlh 1 in heart and gut as measured by M-QPR. The error bars







Figure 5.5 Histology of tumours from Apc+/min mice. H+E stained transverse sections of
small intestine from intestines ofApe +/mm mice showing A) benign adenomatous polyp B)



























0 - Ape +/min Ape +/min
genotype
genotype n Mean SD SE 95% CI of Mean
Tg(Dnmt3b)- 17 0.49 0.28 0.07 0.34 0.63
Tg(Dnmt3b)+ 7 0.75 0.38 0.14 0.40 1.10
Ratio of means(pos:neg) 1.54 (95%CI 0.99 to 2.44r
genotype n Median IQR 95% CI of Median
Tg(Dnmt3b)- 17 0.40 0.24 0.29 0.53
Tg(Dnmt3b)+ 7 0.52 0.51 0.43 1.41
Ratio of medians (pos:neg) 1.30 (95% CI 0.84 to 2.68) *
Figure 5.6 Effect of Dnmt3b overexpression on tumour burden in Apc+/mi" mice. Scatterplot
and summary statistics comparing tumour burden (as measured by mean tumours/section)
between Tg(Dnmt3b)+, Apc+/mm and Tg(Dnmt3b)- ,Apc+lmmmice.
* Confidence intervals for ratio of medians and ratio ofmeans are estimated by bootstrapping
with 2000 resamples of the data using nonparametric resampling and bias-corrected and
accelerated percentile method for estimating confidence intervals.
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A)
genotype invasive not invasi\e Total
Tg(Dnmt3b)+
Ape +/min 7 87 94
Tg(Dnmt3b)-
Apc +/min 10 193 203







Ape +/min 52 44 96
Tg(Dnmt3b)-
Apc +/min 71 132 203
Total 123 176 299
P=0.003
Figure 5.7 Effect of Dnmt3b overexpression on tumour progression in Ape +/m'" mice.
Contingency tables comparing proportion of polyps from Ape +/min mice comparing features of
malignant transformation between Tg(Dnmt3b) genotypes. The number o f po lyps differ
between the two groups since polyps in which the base ofthe tumour was not clearly seen were






0-5 5-10 10-15 15-20 20-25 25-30














Figure 5.8 Regional differences in tumour burden. A) Mean tumours per section in each segment of the gut at
given distance from the stomach in Apc+/mm mice, classified according to Tg(Dnmt3b) status. Error bars represent
standard error. The significance value is for the existence of a regional difference by Kruskal-Wallis test (non
parametric analysis of variance).
Panel B) shows which segments are significantly different from each other at the 5% significance level (post-hoc
analysis of variance with Bonferonni correction for multiple testing). There is a significant difference in tumours
between 2 regions if an arrow can be followed between the boxes representing the 2 regions. The direction of the
arrow denotes that there is a greater number of tumours in the region at the start of the arrow than in the region at
the end of the arrow. For example, the 25-30 cm region from the Tg(Dnmt3b)+ animals has significantly more
tumours than each of the 0-5cm and 5-10cm regions from Tg(Dnmt3b)+mice, and also has significantly more
tumours than each of the 0-5cm , 5-10cm and 10-15cm regions from Tg(Dnmt3b)- mice.
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A) Internal promoter B) External promoter
Distance upstream from transcript start Distance upstream from transcript start
Genotype Clone 210 192 190 188 1/1 144 142 121 %Conversion Genotype Clone 397 391 371 363 358 355 convers ion%
Ape +/+ A1 n 100
Tg(Dnmt3b )- A2 n 100 Ape +/+ 03E n n n 100
B1 93 Tg(Dnmt3b)- 03F 100
62 100 03G n ? n 100
C1 100
03H ? n n 100
n
04A n n n n 100
F1 - 100
G1 100 04 B n n 100
H1 94 04C 100
A6 n - - - 100 04D n n 100
A7 - - - 100 04 E 100
B6 - - - 100 04 F 100
D6 ? n 100 08F n ? n 100
E6 |- - - 100 08G n ? n n n 100
G6 n 100 08H n n 100
09A n 100
Ape +/+ A4 - - 100 09B n 100
Tg(Dnmt3b)+ B4 - - - 100 09C n n n 100
C4 - 100 09D n n n 100
D4 - 100 09E n n n 100







C7 . 100 10B n 100
E7 . 100 10C n T^ 100
10D n 100
10E n n n 100
10F n ? n 100
10G n 100
10H n i n n 100
Apc +/+ 02C 100
Tg(Dnmt3b)+ 02D 100
02F 100
02G n ? n n n 100
03A n 100
03B 100
03C n n 100
03D n ? n 100
06B n n n n 100
06C 100
06D n 100
06 F n n 100
06G n n n 100
06 H n ? n 100
07B n n n n n 100
Figure 5.9. Methylation status ofApe promoter regions. Methylation ofA) Internal Ape promoter B) External
Ape promoter as measured by bisulphite sequencing. DNA was extracted from freshly harvested distal small
intestine from Ape , Tg(Dnmt3b)A- and Ape , Tg(Dnmt3b)- mice. n=unmethylated, n =ambiguous sequence
— =unreadable sequence. Frequency of CpH-CpT conversion in each clone is given as a measure of completeness
of bisulphite conversion
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Distance upstream of transcript start Conversion
Genotype Clone 210 192 190 188 171 144 142 121 %
Ape +/min 01D 100
Tg(Dnmt3b)+ 01G 100







03D n n 100
03E im . • 100
03F I • 100
03G | . _■ • 100
03H 100
01B 100





Ape +/min 05G 100
Tg(Dnmt3b)- 06A 100
04D • 100














05F n n 100
06B n n 100
06C 100
06E n n 100
06H 100
Figure 5.10 Ape internal promoter methylation in microdissected tumours.
Figures 5.10 and 5.11. Methylation status of 5.10) Internal Ape promoter and 5.11) External Ape promoter as
measured by bisulphite sequencing . DNA was pooled from 20 tumours microdissected from paraffin blocks of
intestines f<comApc+lmn. Tg(Dnmt3b)+ and ApcMmn, Tg(Dnmt3b)~ animals. ■= methylated.. =unmethylated.
n=ambiguous sequence — =unreadable sequence. CpH-TpH conversion frequency is given for each clone in the
right hand column as a measure ofbisulphite conversion completeness.
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Distance from transcript start Conversion
Genotype Clone 397 391 371 363 358 355 347 338 336 334 330 321 314 297 275 261 253 249 %
Ape +/min 07A 100
Tg(Dnmt3b)+ 07F n n n 94
07G n....n...... . 92
07H n 100
08B n...n.n...n. 100
08C Bi • 95
08D 100
08E n ......... n 100
08G n..... ........n.. 100
08H n n 100
09D n |B n 95
09E n........nnn-- 100
09F n |B 100
09G nnn. .n. 100







Ape +/min 10A 95
Tg(Dnmt3b)- 10C 91
10D 100
10E n ................ 100
10H n ..... n .......... 100
11B n.. n.n.. 100
11C n.nnnn. 100
11H nn. .nnn--- 100
12A 100
















Figure 5.12 Loss of heterozygosity analysis from microdissected tumours. 3% agarose gel
showing HindIII digested Ape gene PCR product. Results are shown for 16 individual
microdissected tumours from Ape +/min, Tg(Dnmt3b)+ and Ape +/mm, Tg(Dnmt3b)- intestines .
WT= wild type band (121 bp); min=mutant band (138 bp). Control samples: min= undigested
PCR product;







Figure 5.13 Beta catenin staining of distal s mall intestine from Ape +/min mice. The
photomicrographs show nuclear beta catenin staining within polyps (P), membrane staining in
villi (V), and largely absent staining in basal crypts (C). Meissner's plexus neurons (M) also
express membrane beta catenin.
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6. Concluding remarks
In this thesis, the production of what are to my knowledge are the first lines of
transgenic mice which express a de novo methyltransferase in adult somatic cells. The
production of mice which over-express Dnmt3b essentially completes the basic set of
transgenic mouse experiments manipulating the DNA methyl transferases. The results
of these different models are summarised in the table below.
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Dnmt3a Null Survive Runted, neural tube
(9) to term abnormalities ? ? ? ? ?
?= not done. N/A- impossible (e.g lethal phenotype prevents experiment). References in table: (1) Li, et al.,992. (2)
Gaudet, et al. 2003 . (3) Yamada, et al. 2005. (4) Eads, et al. 2002. (5) Cormier, et al. 2000. (6) Trinh et al. 2002.(7)
Belinsky, etal. 2003. (8) Biniszkiewicz, et al. 2002 . (9) Okano, et al. 1999 . (10) Ueda, et al. 2006. (11) This thesis.
Can we find any common features between these studies illustrating the role of DNA
methylation in vivol Reviewing the role in development first of all, it appears that at
least some embryos are able to survive until E9.5 in both methyltransferase deficient and
methyltransferase over-expressing mice. In normal mouse development rudimentary
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organs are morphologically distinguishable by this stage. This suggests that the earliest
stages of embryogenesis and organ specification are not critically regulated by DNA
methylation. However DNA methylation does appear essential for later survival. Since
DNA methylation patterns are largely established early in the normal embryo but
lethality in the various transgenic models occurs later, it seems most likely that DNA
methylation has a predominant role in maintaining, as opposed to initiating,
differentiated expression patterns established in early embryogenesis. Since the effect
of Dnmt3b deletion is severe whereas the effects of Dnmt3b over-expression are minor
in development, it can be concluded that de novo methylation is necessary but that
existing levels of Dnmt3b in the embryo are functionally saturated- in the sense that
further increases do not cause further silencing. In contrast, both deletion and over-
expression of Dnmtl cause a severe phenotype. How do we reconcile this apparent
difference? While it is of course difficult to draw general conclusions from specific
phenotypes caused by specific over-expression models, one interpretation is that
maintenance activity is the rate limiting step in establishing significant methylation
under normal circumstances. Cooperation between Dnmtl and the de novo
methyltransferases (Kim, et al 2002) could lead to non-linear relationships between
methyltransferase levels and steady state levels of methylation (Sontag, et al 2006),
possibly creating increased sensitivity to disturbances in Dnmtl levels . A second
interpretation is of course that the toxic effects of Dnmtl expression are not mediated
through methylation, although the loss of methylation at certain imprinted loci in Dnmtl
over-expression (Biniszkiewicz, et al 2002) suggests that there is an effect on
methylation.
The phenotypic changes between the different models seem to have little in common,
other than the fact that CNS abnormalities appear to be common. Although
Tg(Dnmt3b)+ mice have no apparent structural, the abnormal maternal behaviour in
these mice could suggest that DNA methylation changes have altered CNS functions. It
is an attractive hypothesis, given the prevalence of DNA methylation in vertebrates that
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a major function of DNA methylation is the maintenance of tissue specification
following organ differentiation and has special importance in the central nervous system.
Moving on to the role of DNA methyltransferases in determining methylation patterns,
the project has provided some insights. Considering firstly the question of whether CpG
islands are unmethylated because of the lack of de novo methyltransferase activity, it has
indeed been shown here that increases in de novo methyltransferase activity are
sufficient to alter methylation patterns in somatic cells. However it is clear that
upregulation of de novo methyltransferase activity is not a sufficient condition to cause
methylation since the majority of CpG islands still remain unmethylated even when the
gene is not transcribed. Moreover, loci at which aberrant methylation has been found
are transcriptionally silent, demonstrating that aberrant methylation caused by increases
in de novo methylation can occur at quiescent loci and would thus be predicted not to
affect cellular function.
However, the development of phenotypic changes suggests that alterations in
methylation are indeed able to alter cell biology. While, strictly speaking, it has not
been proven that the phenotypic changes seen in Tg(Dnmt3b)+ mice are caused by
methylation, the existence of global methylation changes which precede the onset of the
cardiac phenotype suggest that alterations in methylation are not simply secondary to the
phenotype. The fact that the mice are developmentally normal and that phenotypic
changes seem to be specific in nature and confined to defined organ systems suggests
that the ability of methylation to disturb transcription in a manner that is important for
the biology of the cell is quite restricted. In other words, although the number of loci
prone to methylation as a result of de novo methyltransferase upregulation may not be
insignificant, the number loci that can be actively silenced by methylation is very small.
Moreover, phenotypic changes occur without exception in mice which show strong
transgene expression. If abnormalities were caused by random inactivation of genes by
methylation, one would expect sporadic occurrence of different abnormalities. The
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results thus suggest that the susceptibility to silencing by methylation is tightly regulated
and must be specified by coexisting factors.
The lack of spontaneous cancer formation is perhaps a special case of this hypothesis
that active silencing by methylation is a rare event in the context of de novo
methyltransferase over-expression, whereas methylation changes may be less so. It may
also be a special case of the idea that silencing by de novo methylation is saturated, since
many tumours are thought to arise from tissue stem cells which express Dnmt3b, and
thus a further increase in Dnmt3b expression may not add much to gene silencing.
Although there is detectable methylation of tumour suppressor genes, there has clearly
not been widespread silencing. It could be argued that an increased tumour incidence
could have been seen had the mice lived longer. However, there are genes which cause
an aggressive cancer phenotype when inactivated (including the Ape gene). If
inactivation by stochastic errors of methylation were a common cause of cancer it would
be likely that at least some cancers would have been seen within the lifespan of the
Tg(Dnmt3b)+ mice. Given that methyltransferases are often increased in cancer, it
follows from the preceding arguments that out of the many methylation events which
undoubtedly occur in cancer, only a minority may have a causative role. It thus would
seem likely that if methylation events do have a causative role in cancer, this may be
restricted to a smaller number of loci than has often been proposed in the literature.
Nevertheless, the differences in tumour progression seen in Apc+/mm mice suggest that
abnormal methylation does have a role in cancer pathogenesis, but operates in this
model mainly as a secondary phenomenon. In this hypothesis, changes in the
transformed cell lead to an increased sensitivity to silencing by methylation. However
the loci at which methylation silencing is important for tumour behaviour is still likely to
be a subset of the loci which are abnormally methylated, and is likely to differ between
different types of cancer. The hypothesis also emphasises the need for caution in
interpreting the results of methylation studies performed in transformed cell lines since
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the sensitivity to silencing by methylation in cell lines may not reflect the situation in
vivo.
What implications do the findings have for the use of DNA methylation in clinical
practice? To conclude this thesis, the clinical implications of this study are discussed in
the form of a Socratic dialogue between the author, Dr. A (a clinician), and Prof. B (an
advocate for the importance of DNA methylation in cancer). Any resemblance of these
characters to individuals living or dead is purely coincidental.
Dr. A: Your mouse model has certainly shown some unexpected results. But it seems a
long way from anything going on in the clinic.
TL: Indeed. But methylation inhibiting drugs such as 5'-azacytidine are currently being
heavily promoted for clinical use, and so there is a current need for understanding of the
biology of methylation. This project does raise questions about whether demethylating
drugs will find a widespread role in cancer.
Prof B. But the importance of methylation in cancer is well established!
TL: I agree that there are specific examples such as microsatellite instability in
colorectal cancer in which methylation changes appear to mimic the effects of genetic
loss found in inherited forms of the cancer, and in these cases a role for methylation
either in the initiation or maintenance of these changes seems very likely. Indeed the
demonstration of the cardiac phenotype is very suggestive that in given circumstances,
DNA methylation abnormalities can have important effects. However this study does
offer proof that tissues can exist with increased methylation levels without apparent
consequences. It also offers proof that abnormalities of methylation can occur at genes
that are already silent and thus do not affect transcription. These findings raise doubts
about the interest of the ever increasing number of papers published describing
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methylation of more and more genes in different forms of cancer, since the silencing of
many of these genes may not have functional importance...
Dr.A: And so reversing their methylation with 5'-azacytidine would not have any
clinical effect. This is in keeping with the disappointing results of 5'-azacytidine
therapy in almost all tumours. You have convinced me that many of the methylation
changes in cancer may be secondary; this was previously suspected anyway. Is there
any way in which we can sort out for which tumours which it might be useful?
TL: This is a difficult problem. The examples where DNA methylation is most strongly
implicated rely on the existence of a known genetic abnormality which has a well
defined molecular mechanism. The number of such well-defined abnormalities will no
doubt increase rapidly with the results of ongoing genomic studies aimed at finding
inherited polymorphisms which lead to differences in cancer incidence. However in the
meanwhile we must rely on other criteria. Certainly the demonstration of downstream
consequences of silencing and demonstration that the gene would normally be expressed
in the normal counterpart cell are necessary, but this doesn't prove that the gene was not
previously silenced by other means.
Dr A: It sounds rather labour intensive for routine clinical use. I think that what is likely
to happen is that demethylating agents will be used empirically in clinical trials in
conditions in which there are statistically high frequencies of important methylation
abnormalities.
TL: I agree, and clinical efficacy is at the end of the day the most important evidence. It
will be important nevertheless to try and distinguish whether any responses are due to
cytotoxic or demethylating actions, emphasising the importance of having downstream
effects to follow.
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Prof B: Even if methylation abnormalities are mostly secondary, this does not rule out
an important function. Your own data with the Ape mice shows this.
TL: Granted. But the distinction has implications for the aims of administering
demethylating agents. It suggests that they may be more likely to have a role in
preventing or delaying disease progression as removal of secondary methylation
abnormalities would be unlikely to cure. Especially in the light of the suggestion from
our decitabine treatment experiment suggesting that remethylation can occur rapidly in
the context of active methyltransferase activity.
Prof B: Quite apart from the potential therapeutic implications, the patterns of
methylation abnormalities surely can tell us about the nature of the disease. This would
be useful for diagnosis and prognosis.
TL: Our demonstration that methylation patterns produced by Dnmt3b over expression
seem to differ, independently of the strength of transgene expression or of the
transcriptional state at a given locus. I think that this does indicate that other factors
must regulate methylation patterns, and so I agree that methylation patterns may tell us
about the nature of the disease. It is an attractive idea that methylation patterns may be
established (in at least some cases) in tissue stem cells which express de novo
methyltransferases, and one could speculate that perhaps methylation patterns may be a
footprint of, for example, differences in chromatin structure or histone modifications in
the cell of origin of the tumour.
Prof B: This is indeed just speculation. You need a more global technique to verify this.
But I agree it might be interesting to use genomic array techniques to see whether
methylation patterns show tissue-dependent clustering in the transgenic mice, and also
whether tumour methylation patterns form distinct clusters.
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Dr. A: This might also resolve the question of the hypermethylator phenotype and its
relationship to prognosis.
TL: As you know, I have problems with the definition of the hypermethylator
phenotype- it does not seem clear to me whether there is a distinct phenotype or whether
the numbers of CpG islands methylated is simply correlated with the aggressiveness of
the tumour. I agree that array type techniques may help determine whether methylation
patterns are closely determined, as I suggest, or simply occur at random. Paradoxically,
taking a more abstract approach to determination of methylation patterns in this way
may help to determine whether there are specific genes which have a particular role to
play, although the statistical methodology would be critical. This could give new insight
into the pathogenesis of tumours as well as giving a more manageable set of genes to
examine for clinical predictive work. It is perhaps most likely that methylation
abnormalities may fall in to two categories for clinical work- abnormalities which occur
commonly in all cancers or all cancers of a given type, which could be used as a
common marker for diagnosis or monitoring, and abnormalities at specific loci which
may define specific subgroups of disease which may benefit from specific interventions.
Prof B: (aside to Dr.A) He does go on and on doesn't he. (To everyone) We can discuss
these points for a long time until we have further data. I think we are in danger of
missing closing time. Can I suggest we continue another day?
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7. Methods
7.1 Production of Dnmt3b over-expressing mice
7.1.1 Preparation of Dnmt3b expression constructs
Plasmids with full length Dnmt3bl cDNA cloned in to PGEMT vector were obtained
from Rudolph Jaenisch. The PCAGASIZ expression vector was obtained from Austin
Smith (University of Edinburgh). Dnmt3b expression constructs were prepared by
cutting the Dnmt3b plasmid with Not/ and Xhol and ligating this insert between the NotI
and BamHI sites in to the PCAGASIZ vector. The Xhol and BamHI sites had been
partially filled in with Klenow polymerase to create compatible ends.
The preparation of the original Dnmt3b expression construct and verification of activity
was performed by Bernard Ramsahoye, University of Edinburgh.
Fig 7.1 shows details of the expression vector and restriction sites.
Figure 7.2 gives a schematic overview of the strategy for producing Dnmt3b over-
expressing mice.
7.1.2 Production of modified Dnmt3b expression construct.
A modified Dnmt3b expression construct with frt sequences flanking the resistance gene
was produced as in Figure 7.5. Gel purified oligonucleotides containing thefrt sequence
or frt antisense sequence with added lisrII or Clal restriction sequences at the 5' end
















Complementary oligos were annealed to form double stranded linkers with overhanging
ends by mixing equal volumes of sense and antisense nucleotides, heating to 95 °C for 1
hour, cooling to 72°C for 1 hour then allowing to cool to room temperature. Successful
annealing was verified by running the product on a 3% agarose gel. The insert was then
phosphorylated by incubating 5 pi of product with 1 pi T4 PN kinase and 50 nmolATP
in a total volume of 50pl for 1 hour. The product was heat inactivated at 65°C for 20
mins, ethanol precipitated and resuspended in 10 pi.
Plasmid containing the original Dnmt3b construct was cut with Clal by digesting 5 pi of
plasmid miniprep for 4 hours at 37°C then dephosphorylated by incubating with lunit
shrimp alkaline phosphatase (Boehringer) for 1 hour at 37°C before heat inactivating by
heating to 65°C for 20 minutes. The linearised plasmid was run on a 1% agarose gel, the
band was excised and DNA purified using the Qiagen minelute kit. Clal linker was
ligated into the vector by incubating 1 pi of dephosphorylated plasmid and 3 pi of the
141
Clal linker ligated with T4 ligase (Promega) and the manufacturer's buffer for 2 hours
before cloning into DH5alpha bacteria. Clones were expanded and plasmids extracted
using the Qiagen Qiaprep kit according to the manufacturers instructions. Screening for
integration and correct orientation was carried out by PCR ( 95°C melting 1 min, 60°C
annealing 1 min, 72° extension 2.5 min x 35 cycles) using a forward primer within the
Dnmt3b sequence AATTTGAGCCACCCAAGTTG and using either the sense and
antisensefrt oligonucleotides as reverse primer (Figure 7.5). Clones with the correct
orientation were cut with RsrII and phosphorylated as above, and the RsrII linker ligated
as above and cloned. Clones were screened for integration by Xbal restriction digestion
(presence of integration giving a 1.1 kb fragment) and the correct orientation was
confirmed by sequencing, using a sequencing primer within the zeocin resistance gene
(GACGTGACCCTGTTCATCAGCGCG).
The resulting plasmid (clone FC2A) was expanded using the Qiagen maxiprep kit
according to the manufacturer's instructions, linearised by digestion with Fspl, ethanol
precipitated and resuspended to a give a final concentration of 1 pg/pl under tissue
culture conditions for incorporation into El4 embryonic stem cells by electroporation.
El4 embryonic stem cells were originally obtained from the Centre for Genome
Research (University of Edinburgh). Passage 13 ES cells were used for the original line;
passage 22 cells were used for the second line of mice.
Results of cloning steps and a schematic view of the modified construct are shown in
Figure 7.5.
7.1.3 Embryonic stem cell culture
Embryonic stem cells were maintained by growing in gelatinised 25 ml tissue culture
flasks (Corning) in antibiotic free GMEM medium (Gibco) containing 0.25% sodium
bicarbonate, 1% non-essential amino acids, 4 mM L-Glutamine, 2 mM sodium pyruvate
1,0.1 mM 6-mercaptoethanol 10% fetal calf serum and 100 U/ml leukaemia inhibitory
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factor (LIF). LIF was obtained as a culture supernatant from COS-7 cells transiently
transfected with a murine LIF expression plasmid (pCAGGSLIF-418). LIF transfection
and cell culture was performed by Helen Taylor and Julie Buchanan in the John Hughes
Bennett Laboratory, University of Edinburgh. Cells were grown at 37°C in a humidified
5% C02 atmosphere and medium was changed on alternate days. Cells were passaged
when almost confluent (approx twice weekly).
Cells were passaged by removing medium, washing once with 10 ml PBS, then
incubating for 5 mins at 37°C with 2 ml trypsin solution (0.025% trypsin, 0.1 % chicken
serum, 1.3 mM EDTA in PBS). Cells were resuspended by gentle agitation of the flask
and then trypsin activity was quenched by adding 8 ml of complete medium. The cell
suspension was transferred to a 60 ml conical centrifuge tube and centrifuged at 100
RPM for 5 minutes. The supernatant was removed and the cells were resuspended in 10
ml of medium. 9 ml of medium and 1 ml cell suspension were then added to 25 ml
flasks which had been gelatinised by adding 10 ml 1% gelatin in PBS for 20 mins and
then removing the gelatine solution.
7.1.4 Cell culture
ES cell culture was performed in a dedicated ES cell tissue culture suite using sterile
techniques in a laminar flow hood.
7.1.5 Cryopreservation of ES cells
ES cells were stored by resuspending cells from a sub-confluent flask as above in
medium and adding DMSO to a final concentration of 10%. 1 ml aliquots were frozen
overnight at -70°C and then stored at -140°C. Cells were thawed in a water bath at 37°C
for the minimum amount of time, and the cell suspension was then added to centrifuge
tubes containing 9 ml medium. The cell suspension was centrifuged at 1000 RPM for 5
minutes then the pellet resuspended in 10 ml fresh medium+LIF. The cell suspension
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was transferred to a 25 ml gelatinised tissue culture flask and cultured as above. Medium
was changed after approximately 8 hours to reduce any residual DMSO contamination.
7.1.6 Electroporation.
Cells for electroporation were cultured in a 75 ml flask until almost confluent. Cells
were trypsinised as above, transferred to a centrifuge tube with four volumes of medium
and centrifuged at 1000 RPM for 5 mins. The pellet was resuspended in 1 ml cold PBS
and cells counted using a haemocytometer. Cell concentration was adjusted to 7 xlO6
cells/ml by adding further PBS. 40 pg linearised vector was added to 0.8 ml of cell
suspension (5xl06 cells) in an electroporation cuvette, and electroporation was carried
out using a Biorad gene pulser at 240 V/ 500 pF. After incubating on ice for 20 minutes,
the cell suspension was added to 10 ml medium+LIF.
10cm gelatinised cell culture dishes (Corning) were seeded with 1 ml of cell
suspension(0.5xl06 cells) and 9 ml medium+LIF and cells were cultured as above. Two
plates were seeded with non-electroporated cells as a control for adequacy of selection.
Medium was replaced after 24 hours with 10 ml medium+LIF and 25 mg/1 zeocin. Cells
were cultured in selective medium, changing medium every 2 days until cell colonies
were visible (approx 10 days).
Colonies were picked by removing the medium from the plates and replacing it with
10ml PBS. Colonies were aspirated using a 10 pi pipette and placed in to wells of a
round bottomed 96 well plate containing trypsin. After picking colonies, plates were
incubated for 5 minutes at 37°C. 150 pi medium+zeocin+LIF was then added to each
well and cells were disaggregated by pipetting several times before transferring to a
gelatinised 96 well flat bottomed plate. Cells were expanded, adding fresh zeocin
containing medium every two days, until wells were subconfluent. Cells were
trypsinised and transferred to gelatinised 12 well plates and expanded in selective
medium until semi confluent. Finally, cells were trypsinised from the 12 well plates and
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transferred to gelatinised 25 ml flasks and expanded in selective medium until
subconfluent. Cells were washed and resuspended in fresh medium before
cryopreserving cell suspensions until needed for electroporation. Transgene integration
was verified by PCR (Figure 7.5d)
7.1.7 Blastocyst injection
Cryopreserved ES cells were thawed as above and passaged in culture with zeocin-free
medium for 1 week before blastocyst injection. The protocol adopted for the generation
of transgenic mice by injection of ES cells into blastocysts is described in detail in
(Hogan 1986).
ES cell clones were cultured under normal conditions to ensure that they were
approximately 30% confluent prior to the day of injection. Blastocysts from naturally
matedC57BL/6 females were harvested at 3.5 days post-coitum. Injections were
performed in M2 medium (Sigma) with 10 to 15 ES cells being injected into each
blastocyst before transfer to pseudopregnant recipient females (12 blastocysts per
recipient). All surgical procedures were performed in accordance with home office
guidelines with appropriate analgesia and anaesthesia.
Blastocyst injections were performed by Dr. Jim Selffidge, Molecular Medicine Centre,
University of Edinburgh.
7.1.8 Breeding of chimaeras
Male chimaeras were mated with C57BL6 females in trios, moving each chimaera to a
new pair of females every week. Offspring derived from the ES cell contribution to the
germline were selected by agouti coat colour. Agouti mice were genotyped by PCR and




Animals were maintained at the Biomedical Research Facility at University of
Edinburgh. Animal work was carried out according to the provisions of the Animals
(Scientific Procedures) Act (UK) 1986.
7.2.2 Genotyping Tg(Dnmt3b)+ mice
Routine Tg(Dnmt3b) genotyping was performed by western blot on ear clip samples
taken at weaning. Ear clips were pulverized using liquid nitrogen and suspended in 50 pi
SB solution (see materials Section 7.7). Suspensions were heated to 95°C for 15 min to
remove protease activity and then centrifuged at 13000 RPM for 1 minute. 10 pi of
supernatant was analysed by western blot for Dnmt3b (see below).
PGR genotyping, if required, was performed using primers:
L primer TGGCTCTGATATTCTAATGCCAAA
R primer TCATCCTGATACTCTGTGCTGTCTCC
PCR amplification was performed using Hot Star Taq mastermix (Qiagen) with
conditions: Initial denaturation : 95°C 15 minutes; PCR cycle: Denaturation 95°C 30
sec, Annealing 60°C 30 sec, Extension 72°C 1 minute (45 cycles); Final extension:
72°C 15 minutes.
7.2.3 Mbd2 mice
A colony of Mbd2 '' mice was bred from founder animals obtained from Prof. Adrian
Bird, University of Edinburgh. Tg(Dnmt3b)+, Mbd2~ ~ mice were produced by crossing
male Tg(Dnmt3b)+ mice with female Mbd2~'' mice. The offspring were genotyped for
Mbd2 and Dnmt3b. Male F1 compound heterozygote offspring (Tg(Dnmt3b)+Mbd2 +/~)
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were backcrossed on to Mbd2'l~ females to produce offspring with the expected
Mendelian proportions 25% Tg(Dnmt3b)+ Mbd2~'~: 25% Tg(Dnmt3b)+Mbd2+/~: 25%
Tg(Dnmt3b)- Mbd2~'~: 25% Tg(Dnmt3b)-Mbd2+/~. Progeny were genotyped for Dnmt3b
by western blot as above, and by PCR for Mbd2 as below. Survival analysis was carried
out using Kaplan-Meier estimation using XLStat.
7.2.4 Genotyping Mbd2 mice
Mbd2 mice were genotyped by PCR. DNA was extracted from tail tips taken at
weaning, using Qiagen DNAeasy kit according to the manufacturer's instructions. 2 pi
DNA was amplified using Hotstar Taq Mastermix (Qiagen) with primer sets: Wild type-
AAGAACAAGCAGAGATCCG and ACGCTGGCCTAGTGCCGTGC; Knockout
TCCGCAAACTCCTATTTCTG and TTGTGGTTGTGCTCAGTT- with cycling
conditions 95°C melting temperature 30sec, 55°C annealing for 30 sec, 72°C extension
for 1 min for 35 cycles. PCR products were analysed on a 1% agarose gel. Typical
results are shown in Figure 7.3a.
7.2.5 Apc+Imm mice
Apc+/mm mice were bred from founder animals obtained from Charles Patek, University
of Edinburgh. The Apeh min strain was maintained by crossing male mice positive for the
mutation with wild type female littermates. Tg(Dnmt3b)+, Apc+/min compound mice
were produced by crossing male Tg(Dnmt3b)~, Apc+ min mice with female Tg(Dnmt3b)+
mice. Offspring were fostered at birth to CD1 females which had been mated at the
same time as the transgenic mice in order to provide foster mothers. Fostering was
necessary to prevent infanticide which occurred invariably within 24 hours ofbirth with
Tg(Dnmt3b)+ mothers.
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7.2.6 Genotyping Ape+/m,n mice
The Apc+/mm mice were genotyped by PCR and restriction digestion. DNA was
extracted from tail tips taken at weaning, using Qiagen DNAeasy kit according to the
manufacturer's instructions. 2 pi of the extracted DNA was amplified using Hotstar Taq
Mastermix (Qiagen), left primer TCTCGTTCTGAGAAAGACAGAAGCT and right
primer TGATACTTCTTCCAAAGCTTTGGCTAT, with cycling conditions: 95°C
melting temperature 30 sec, 60°C annealing for 30 sec, 72°C extension for 1 min for 35
cycles. 5 pi of PCR product were digested overnight with 10 u Hindlll. Digests were
run on a 3% agarose gel, with wild type DNA giving a band at 121 bp and DNA
containing the min mutation giving a band of 138 bp. Typical results are shown in
Figure 7.3b.
7.2.7 Analysis of tumours from Apc+Imin mice
Mice for analysis of intestinal tumours were sacrificed between 120 and 130 days of age
by cervical dislocation. Intestines were dissected out and perfusion fixed by injecting
with formalin using a 23 gauge needle, until the intestine was just inflated, then stored in
formalin for at least 24 hours before processing. The entire intestine was unravelled and
transverse sections were taken at 5 cm intervals along the length of the small intestine
for paraffin embedding. Multiple transverse sections were cut at different levels in the
block and stained with H+E.
Scoring of tumours was performed by Dr David Brownstein, Dept of Veterinary
Pathology. Scoring was performed blinded to the genotype of the animal. Criteria used
for scoring were as follows: Polyp: elevation >1 mm above the surrounding gut lumen.
Invasiveness: Presence or absence of invasion into the muscularis mucosa. Dysplasia:
presence or absence of abnormal nuclear morphology.
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For molecular biology analysis, individual tumours were microdissected from the
paraffin blocks. 3 pm sections were cut from blocks and stained with H+E. The H+E
image was projected on to the paraffin block to use as a guide to identify the location of
polyps, which were then cut from the block. 20 tumours were isolated from Apc+Imm,
Tg(Dnmt3b)+ animals and 20 tumours from Apc~mm, Tg(Dnmt3b)- animals.
Microdissection was performed by Dr David Brownstein, Dept of Veterinary Pathology.
Individual tumours were de-waxed by heating in 1 ml xylene for 5 minutes at 50°C,
centrifuging for 1 minute at 13000RPM, then washing in 1 ml
100% ethanol twice. DNA was extracted using the Qiagen DNAAmp micro kit
according to the manufacturer's instructions but with an extended proteinase K digestion
time of 24 hours. DNA from each tumour was eluted in a final volume of 20 pi of 10
mM Tris.
Loss of heterozygosity analysis was performed by PCR amplification and Hindlll
digestion (see Section 7.2.6) using 2 pi of eluted DNA from each tumour as a template.
Bisulphite modification was perfonned on pooled DNA in order to have sufficient DNA
for analysis following bisulphite treatment. 5 pi of DNA eluted from each of the 20
tumour samples from ApcT m'n, Tg(Dnmt3b)- and Ape min, Tg(Dnmt3b)+ tumours was
pooled, ethanol precipitated and resuspended in 20 pi. The pooled DNA was bisulphite
treated using the Qiagen Epitect bisulphite kit using the manufacturer's protocol for
bisulphite modification of formalin-fixed-paraffin-embedded samples.
The promoter regions of both promoters of the Ape gene were amplified using 2 rounds
of fully nested PCR, then cloned and sequenced (see Bisulphite sequencing Section
7.3.3).
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7.2.8 Multistage skin carcinogenesis
Skin carcinogenesis was performed using a modification of the protocol in Owens et al.
5-6 week old mice were shaved on the right flank and 200 nmol DMBA (Sigma) in 200
pi acetone was applied topically using a pipette. DMBA treatment was repeated on
weeks 2 and 4. Tumour promotion was performed with the mitogen TPA (Sigma). 5
nmol TPA in 200 pi acetone was applied topically to shaved skin. TPA was
administered twice weekly for 10 weeks. Experiments were performed with mice
housed in IVC filtered cages separate from non-experimental mice.
7.2.9 5'aza 2-deoxycytidine treatment of mice
5' Aza 2-deoxycytidine (AdC) treatment was performed using two separate protocols.
For the first experiment AdC was administered at a dose of 1 mg/kg in a 100 pg/ml
solution in PBS by subcutaneous injection. The protocol is based on that in (Laird, et al
1995) which was sufficient to cause demethylation in the gut in Apc+,mm mice. Animals
were injected weekly for 11 weeks starting from 5-6 weeks of age. Animals were
weighed weekly during administration to monitor for toxicity.
In the second protocol, AdC was administered twice weekly at a dose of 2.5 mg/kg by
intraperitoneal injection. This protocol was based on that used in (Hu, et al 1998) to
cause demethylation of the Igf2r imprinted gene. Animals were treated either with a
course of 5 injections or continued treatment. Animals treated for 5 injections were
sacrificed for analysis, either 24 hours after the final injection or 14 days after the final
injection.
Hearts were dissected out from sacrificed animals. Half was stored in formalin for
histology and half was stored at -70°C in RNAlater (Qiagen) for later measurement of
methylation. Demethylation was measured by extracting DNA using the Qiagen
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DNAeasy kit according to the manufacturer's instructions then measuring methylation
of the Igf2r differentially methylated region by M-QPR.
The AdC was stored at -70°C in a 2.5 mg/ml solution in PBS and diluted in PBS to
working concentration prior to administration.
7.2.10 Analysis of cardiac histology
Animals were sacrificed by cervical dislocation and weighed. Hearts were dissected out
and weighed. Half of the heart was frozen in RNAlater for molecular biology analysis
and half was fixed in formalin for at least 24 hours before paraffin embedding according
to standard protocols. 3 pm sections were cut and stained with H+E and Sirius Red
(collagen) stains according to standard techniques. Histological preparation was
performed by the technical staff of the Dept of Veterinary Pathology, University of
Edinburgh. Microscopy was performed by Dr David Brownstein, Dept of Veterinary
Pathology, University of Edinburgh.
7.2.11 Immunohistochemistry
3 pm sections were cut from paraffin embedded tissue blocks, mounted on slides, de-
waxed and rehydrated according to standard procedures. Antigen retrieval was
performed by immersing slides in 100 mM citrate pH 6.0 and heating in a microwave for
20 minutes in a plastic slide holder, before being allowed to cool to room temperature.
Tissue sections were incubated in 3% hydrogen peroxide for 15 minutes to block
endogenous peroxide activity then washed in TBS-T for 5 minutes. Primary antibodies
were applied to the tissue section as follows: Beta catenin: Mouse monoclonal anti-beta
catenin (BD Biosciences catalogue 610153) diluted 1:50 in 100 mM Tris pH 7.4; PCNA:
Rabbit polyclonal anti-PCNA (Abeam catalogue AB2426-1) diluted 1:50 in 100 mM
Tris pH7.4. Primary antibodies were incubated at room temperature for 1 hour before
washing in TBS-T for 15 mins. HRP-conjugated secondary antibodies (Dako Envision
system) were applied undiluted and incubated for 1 hour at room temperature before
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washing in TBS-T for 15 minutes. Visualisation was by incubating in diaminobenzidine
(Dako) according to the manufacturers instructions for 3-5 minutes or until brown
staining was visible. Slides were counterstained in Mayer's haematoxylin for 5 seconds
and rinsed in tap water before mounting with aqueous mounting medium (Crystal
Mount, Sigma). The majority of the immunohistochemical staining has been performed
by Shin Teoh, University of Edinburgh undergraduate student, under my supervision.
Independent review of the p-catenin stained sections was performed by Prof. David
Harrison, University of Edinburgh.
For in vivo BrdU labelling, mice of 6 weeks and 4 months of age were injected
intraperitoneally with 0.1 pmol/kg BrdU (Roche). Mice were sacrificed 6 hours after
injection and tissues immediately dissected out and fixed in formalin. After paraffin
embedding according to standard procedures, 3 pm sections were cut and stained for
BrdU using the BD Pharmingen BrdU In Situ Detection Kit (BD Biosciences) according
to the manufacturer's instructions.
7.3 DNA methvlation techniques
7.3.1 Methylation sensitive restriction fingerprinting
MSRF was performed according to the methods in (Davies 2002). A schematic
summary is shown in Figure 7.4. Briefly, genomic DNA was extracted from the heart,
lung and gut of normal and transgenic mice by phenol/chloroform extraction. Positive
control methylated DNA was produced by incubating 1 pg genomic DNA with 10 u/pg
DNA of Nss/methylase and S-adenosyl methionine for 4 hours. 1 pg DNA was digested
with 1 Ou of the methylation inhibited enzyme BstUI for 4 hours or underwent control
digestion with buffer overnight, then both BstUI treated and control digests were
digested overnight with 10 u Msel.
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The digested DNA was PCR amplified at low specificity using short primers Al =
AGCGGCCCGCG and either A2: ACCCCCAGCCG or A3: TGGGGTCGGCGC using
HotStarTaq mastermix (Qiagen) with Q-solution (Qiagen) incorporating 0.2 pCi 32P
dCTP (Amersham Redivue) per reaction. Cycling conditions were (melting temperature
94°C 2 mins, annealing temperature 40°C 1 min , extension temperature 72°C 2min) x35
cycles with final extension time 10 min at 72°C. PCR products were separated by
loading 5 pi on a 6% TBE/acrylamide gel and running at 1000V/60W until the
bromophenol blue front from the loading dye reached the end of the plate. The gel was
then taken up on to filter paper and dried for 1 hour at 70°C in a gel dryer before
developing for 12-48 hrs by autoradiography.
Fragments showing abnormal methylation were excised from the gel. DNA was eluted
by incubating excised gel fragments in 100 pi water for 1 hour, heating to 95°C for 10
minutes and centrifuging at 800 g for 5 mins. DNA was precipitated from the DNA by
ethanol precipitation and resuspended in 10 pi water. 4 pi was re- amplified using the
same PCR protocol and primers as the initial reaction (without 32P dCTP incorporation).
PCR products were separated on a 1 % agarose gel and bands were excised, DNA
extracted from the gel using Qiagen Minelute kit, and then cloned and sequenced as in
Section 7.5.2. Products were identified by BLAST search on the NCBI website
(http://www.ncbi.nlm.nih.gov/BLAST/) against the mouse genome. The methylation
status of regions identified was confirmed by bisulphite sequencing.
7.3.2 Bisulphite modification of DNA
Bisulphite modification for confirmation of the MSRF experiments was performed
according to the methods in (Hajkova, et al 2002). 600 pg genomic DNA was digested
for 4 hours with Sacl. Digested DNA was melted at 100°C for 5 mins then incubated at
50°C in a final concentration of NaOFI of 0.3 M for 15 mins. NaOH treated DNA was
embedded in 2 volumes of low melting point agarose at 50°C. 2.5M sodium bisulphite
solution was prepared as described. 1 ml samples ofbisulphite solution were overlaid
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with mineral oil and chilled at -20°C before adding the DNA. The DNA/agarose solution
was added to the cold bisulphite solution in 1 Opl aliquots by forming beads in the
mineral oil layer. DNA was placed on ice for 20 mins then incubated at 50°C for 4
hours. The bisulphite solution was then removed and the agarose pellet washed 4x in TE
buffer pH 8, 2x in NaOH 0.2M then TE buffer x3. Agarose pellets containing the
bisulphite modified DNA were stored under lOOpl TE buffer at 4°C.
Bisulphite modification for analysis of the Ape gene was performed using the EZ-DNA
methylation kit (Cambridge Biosciences) according to the manufacturer's instructions.
7.3.3 Bisulphite sequencing
Bisulphite treated DNA was amplified using PCR primers surrounding the region of
interest designed against the predicted bisulphite modified genomic sequence. Primers
were designed so as not to include C residues immediately 5' to G anywhere in the
primer sequence, in order to amplify methylated and unmethylated sequences with equal
efficiency. Primer design was assisted by the web based design programs Methprimer:
(http://www.urogene.org/methprimer/indexl .html)
and Primer3 :
(http://ffodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgi). Primer sequences are given
in Table 7.1. Amplification was performed using HotStarTaq (Qiagen), for 45 cycles
with cycling conditions: Denaturation lmin x 95°C, annealing 1 min (temperature in
Table 1), extension 1 min x 72°C. A second round of hemi-nested PCR was necessary
to obtain specific products in the case ofLrfn5 and the CpG island Ape promoter. A
fully nested second round of PCR was used for the Ape internal promoter when used for
DNA extracted from paraffin embedded tissue. PCR products were separated on a 1%
agarose gel, and bands of the correct size were cut from the gel and DNA extracted
using Minelute columns (Qiagen). Purified DNA was ligated in to PGEMT-Easy vector,
and cloned as in Section 7.5.2. Colonies were expanded in 96 well plates and
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automated plasmid extraction and sequencing reaction with T7 primer was carried out
using a Biomek 2000 Automated Workspace robot.
7.3.4 Quantitative PCR for methylation (M-QPR)
Approximately 1 pg of genomic DNA of each was digested overnight with methylation
sensitive enzymes (10 u Hpall and 10 u Hhal) followed by heat inactivation at 65°C for
15 minutes.
Quantitative PCR for genomic DNA was performed in 384 well plates on an Applied
Biosciences 7900 analyser using sybr green detection. Template DNA was amplified
using Quantitect sybr green mastermix (Qiagen) with gene specific primers at a
concentration of 1 uM with addition of Q solution (Qiagen) if this was found to improve
efficiency in the validation experiments.
Primers were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3 www.cgi) with optimal conditions specified - product length 100-
200 bp, primer Tm 59-61 °C, maximum primer Tm difference 0.5°C). Amplicons were
chosen so as to include the maximum number of restriction sites for Hpall and Hhal, in
order that the assay should be specific for regions that are densely methylated since a
PCR product would only be produced if all sites included in the region are methylated.
Assays were validated by amplifying a standard curve of 4-fold dilutions of undigested
genomic DNA from mouse tail-tips, using cycling conditions- initial activation 95°C for
15 mins, denaturation 95°C 15 sec, annealing 55°C 30 sec, extension 72°C 30 sec.
Following 50 cycles of amplification, a DNA melting curve was performed to check that
the product Tm was as expected and that there was little non-specific amplification (as
defined by presence of products with multiple Tm values). Assays were chosen for
experimental analysis if there was near 100% amplification efficiency in the standard
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curve with a minimum of non-specific amplification. Primer sets used are detailed in
Table 7.2. Examples of standard curves and dissociation curves are shown in Figure 7.6
DNA concentrations were standardised for the experimental reaction by performing an
initial quantification of the digested DNA using the NOR control primer set (which has
no Hpall restriction sites) and a check for complete digestion using primers in the
unmethylated CpG island extending from the clathrin light chain (Ctla) promoter region.
Samples were diluted on the basis of this initial assay in Hpall buffer to the same
concentration. Samples giving a product in at least 2/3 replicates in the clathrin assay
were excluded from the methylation analysis.
For the experimental determination ofmethylation, digested and standardized DNA as
above was amplified using gene specific primers using the same conditions as in the
validation step with quantification by measurement of sybr green fluorescence at 1 °C
below the product Tm at the end of each amplification cycle. Absolute quantities of
DNA surviving digestion was measured by reference to a standard curve of undigested
DNA run in the same plate using linear regression. All reactions were performed in
triplicate, and reactions where a product was seen in at least 2/3 replicates were
considered as positive. The quantity of DNA was recorded as the arithmetic mean of all
successful replicates.
A "methylation index" was calculated as a measure of methylation by dividing the
absolute quantity of DNA surviving digestion by the starting quantity of DNA as
determined by amplification with the NOR control primer set. Theoretically this should
give the fraction of DNA which is methylated at all restriction sites between the two
primer sites. A measure of the confidence of the calculated methylation index can be
given by a transformed Standard error I qIW* -or of methylated copies)+Log(s,d error of initial copies)];
which estimates the variation in the sample mean methylation index based on the
standard error of the difference in PCR detection thresholds.
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In order to validate the assay, the methylation status of the Wnt3 and Lrfn5 promoter
CpG islands in the heart were measured, since the methylation status of these regions
had been shown by bisulphite sequencing (Section 3.3).
The Wnt3 assay appears to be particularly robust at a qualitative level, with clear
differences between the normal and transgenic animals which is consistent with the
bisulphite data (Figure 7.7a). The methylation index does appear to be of a similar order
of magnitude to the percentage of densely methylated clones in the bisulphite
sequencing data, but there is insufficient data at this stage to confirm the accuracy of
quantification of methylation levels
The Lrfn5 assay is less robust since there is amplification of non specific products which
will alter the efficiency of amplification of the intended product. Nevertheless, there is a
clearly significant difference in methylation index between the wild type and transgenic
animals (Figure 7.7 b). In addition, there is a qualitative difference in the dissociation
curves, presumably as the increased quantity of methylated template in the transgenic
gives a selective advantage to amplification of the correct product (Figure 7.7c). The
assay is therefore adequate as a comparative assay to look at differences in methylation
levels between paired sample groups, and the lack of a detectable PGR product probably
does indicate that the sample studied is unmethylated, but positive results may need
confirmation by bisulphite sequencing if accurate quantification is needed.
As an overview of the comparison with the bisulphite sequencing data, therefore, the
methylation index appears to underestimate the proportion of methylated chromosomes
in an a sample in which the region studied is genuinely methylated in a proportion of
tissues. This is unsurprising as the test is fairly stringent, requiring all restriction sites to
be methylated to achieve a PCR product, thus quantifying only the most densely
methylated alleles. Conversely, there is likely to be a false positive rate of detection,
either as a result of non-specific PCR products or as a result of inadequate digestion
which is below the sensitivity of the clathrin screening test. In addition, since the
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numbers of restriction sites differ between PCR amplicons, it is not possible to use the
technique to compare methylation levels between different loci in a quantitative way,
and the technique is most valid for comparison of differences in methylation at a
particular locus between an experimental and control sample.
7.3.5 Nearest neighbour analysis
Quantification of global CpG methylation levels by nearest neighbour analysis was
performed by Dr Bernard Ramsahoye, John Hughes Bennett Laboratory, Edinburgh
according to the methods in (Ramsahoye, et al 2000): Briefly, genomic DNA digested
with Msel ( TTAA) and separated on a 1% agarose gel. The 2-4 kb fraction was cut
from the gel in order to select for CpG island- rich DNA regions. DNA was extracted
from the gel using Qiagen Minelute kit according to the manufacturer's instructions.
The extracted DNA was then digested with the restriction enzyme Mbol (N||GATC).
Following heat inactivation, ethanol precipitation and resuspension, the digested DNA
•39
was filled in with Klenow polymerase and a- P dGTP. The reaction was terminated by
addition of EDTA and unincorporated nucleotides removed using a Sephadex spin
column. DNA was digested to single nucleotides using micrococcal nuclease and
phosphodiesterase. The digested nucleotides were separated by thin layer
chromatography. Quantification of nucleotides was performed by autoradiography and
densitometry analysis of the autoradiographs.
7.4 Microarray Analysis
Total RNA was prepared from the heart of 1 wild type and 1 transgenic mouse, both
aged 130 days, by phenol extraction.
Microarray hybridisation was performed by Dr Kevin Robertson University of
Edinburgh. RNA quality was initially assessed using formaldehyde gels and by
measurement of absorbance at 260/280 nm following standard procedures. A further
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assessment of RNA quality was then undertaken using an Agilent Bioanalyser (Agilent
Technologies, GmBH).
Total RNA was prepared for microarray analysis as follows. In brief, 10 |ig of total RNA
from each sample was used to generate double stranded cDNA using an oligodT primer
containing a T7 promoter. This template was used to generate amplified, biotinylated
cRNA using a Bioarray High Yield RNA Transcription Labeling Kit (Enzo Diagnostics,
Farmingdale, NY, USA). After confirming that all cRNA samples were of good quality
using the Agilent Bioanalyser, 10 |lg of labelled cRNA was hybridized to Affymetrix
MG-U74Av2 GeneChip arrays for 16 hours at 45°C. Arrays were then washed in an
Affymetrix Fluidics Station 400 (Affymetrix, USA) stained with streptavidin-R
phycoerythrin (Molecular Probes, USA) and biotinylated goat anti-streptavidin antibody
(Sigma Chemical, St. Louis, MO, USA) and scanned according to standard protocols.
All analyses were undertaken in Affymetrix Microarray Suite 5.1 software as follows:
arrays were scaled (normalised) to an overall target intensity of 100 prior to comparison
and notable differences in gene expression were identified by a 'comparative analysis'
of the two samples (detailed in
http://www.affymetrix.com/support/technical/whitepapers/sadd_whitepaper.pdf).
Filtering was undertaken on the basis of the detection call. The detection call algorithm
is used to provide an indication of whether the expression level of a transcript is below
the threshold of detection for the system. As an output of this analysis step, a value for
the probability that a transcript expression level is provably different from zero is
generated. If a transcript has a p value of less than 0.04 then it is 'called' present,
between 0.04 and 0.06 it is called marginal and greater than 0.06 it is called absent.
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7.5 Basic molecular biology techniques
7.5.1 Western blot for Dnmt3b
Protein extracts were loaded in 10% acrylamide precast gels (Biorad) and were
separated at 75 V by electrophoresis in SDS buffer. Proteins were transferred on to
nitrocellulose membrane at 14 V using semi-dry transfer cell with semi-wet buffer.
Membranes were probed by blocking in 5% low fat milk (Marvel) in TBS-T for 1 hour
then incubating with polyclonal sheep anti-Dnmt3b serum (raised against the N-terminal
200 amino acids) diluted 1:1500 in 5% milk/TBS-T at room temperature on a rotary
shaker. Membranes were washed in TBS-T for 2x15 minutes then incubated at room
temperature for 1 hour with HRP-conjugated donkey anti-sheep secondary antibody
(Sigma) at 1:5000 concentration. Following 2x15 min washes in TBS-T, membranes
were developed by covering the membranes with approx 1ml ECL solution and
exposing X-ray film (Kodak).
If a loading control was required, membranes were re-probed using rabbit polyclonal
antiserum raised against the C-terminus of histone H3 as primary antibody (produced by
Alain Verrault, University of Montreal) at 1:30000 dilution, and HRP-conjugated sheep
anti-rabbit (Sigma) in 1:5000 concentration as secondary antibody. Some of the western
blots in Figure 2.3 were performed by my lab technician Jayne Culley.
7.5.2 Cloning PCR products
PCR products for cloning were ligated into PGEMT-easy vector using the PGEMT-easy
vector system I kit (Promega) according to the manufacturers instructions. Ligated
vector was added to 20 pi JM109 competent cells (Promega) and incubated for 15
minutes on ice before subjecting to heat shock for 45 seconds at 42°C. Mixtures were
incubated on ice for 2 minutes before adding 80pl LB broth and incubating at 37°C for
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lhour with shaking. Following incubation the mixture was spread on to LB-agar plates
containing 100 mg/ml ampicillin with 35 pi of 20 mg/ml X-gal and 12ul of 0.2 g/ml
IPTG per plate. Plates were incubated at 37°C overnight. White coloured colonies were
picked with a sterile toothpick and incubated in 3ml LB broth with lOOmg/ml ampicillin
overnight. Bacteria were pelleted by centrifugation and plasmid extracted using the
Qiagen Qiaprep Spin kit according to the manufacturer's instructions.
7.5.3 Sequencing
Sequencing of plasmids was performed by adding 5 pi of plasmid to 0.8 pi of BigDye
3.1 terminator mix (ABI), 4 pi Better Buffer (Web Scientific), 1.2 pi distilled water and
1 pi 4 nM T7 sequencing primer (GTAATACGACTCACTATAGGGC ) for PCR
products or sequence specific primers as detailed in the relevant sections. Sequencing
reactions were performed using the following conditions: Initial denaturation- 96°C 1
minute, (melting 96°C 20 sec, annealing 50°C 10 sec extension 60°C 4 min)x 25 cycles,
final extension time 60°C 4 mins. Products were ethanol precipitated, washed once in
70% ethanol and air dried for 1 minute at 90°C before storing at -20°C while awaiting
reading. Sequence was read using an Applied Biosystems 3100 genetic analyzer.
7.5.4 Quantitative RT-PCR
RNA was extracted from tissues of Tg(Dnmt3b)+ mice and age matched wild-type
C57B16 mice by phenol/chloroform extraction. Approximately 1 pg RNA was used for
cDNA production using the Promega RT-PCR kit according to the manufacturer's
instructions using oligo-dT as template.
Gene expression of Wnt3 and Lrfn5 was measured by quantitative real time RT-PCR
using Taqman sequence detection. 10 ng of cDNA was amplified using Taqman
mastermix (Applied Biosciences) and standard off-the-shelf probe/primer sets from
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Applied Biosciences (reference numbers: Wnt3= Mm00437336_ml;
L^5=Mm00724566_ml). Amplification was performed for 50 cycles at a melting
temperature of 95°C for 15 seconds and a combined annealing/extension temperature of
60°C for 1 minute. Expression levels were calculated relative to beta-actin expression
measured by quantitative RT-PCR using a standardised control probe/primer set
(Applied Biosciences ref: 4352933E). All reactions were performed in triplicate, and
results are expressed as the mean of all successful replicates. Gene expression was
considered as detectable if a PCR product was detected with at least 2/3 replicates.
7.5.5 DNA extraction
Tissue samples were disrupted by freezing in liquid nitrogen then pulverising with a
hammer. Samples were digested in DNA extraction buffer containing lmg/ml
proteinase K at 50°C until all solid material had dissolved. DNA was extracted by
adding an equal volume of pH 8.0 Tris saturated phenol. The aqueous phase was taken
off and phenol extraction was repeated once. The excess phenol was removed from the
aqueous phase of the second extraction by adding an equal volume of 49:1
chloroform/IAA. The aqueous phase was taken off and DNA was recovered from this
by ethanol precipitation. The pellet was resuspended in 10 mM Tris pH 8.0.
DNA extraction from mouse tail tips was performed using the Qiagen DNA Easy kit
according to the manufacturer's instructions.
7.5.6 RNA extraction
Tissue samples were disrupted by freezing in liquid nitrogen then pulverising with a
hammer. 2 ml of Solution D (see materials) was added to the tissue sample and then the
mixture was homogenised using a rotor homogeniser or by multiple passage through a
19 gauge needle and syringe. 500 pi aliquots were either stored at -70°C or RNA was
extracted immediately by phenol extraction. 50 pi of 2 M sodium acetate pH 4.0, 500 pi
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water saturated phenol and 100 pi 49:1 chloroform:IAA was added to the homogenate
and mixed by vortexing. The mixture was centrifuged at 13000 RPM for 20 mins at
4°C. The aqueous layer was removed by pipetting and extracted a second time with
phenol/chloroform as above. The aqueous phase from the second extraction was added
to 500 pi chloroform/IAA, mixed by vortexing, and separated by centrifugation for 1
minute. The aqueous phase was ethanol precipitated before resuspending in water.
7.5.7 Ethanol precipitation of nucleic acids
2.5 volumes of 100% ethanol and 0.1 volumes of 3M sodium acetate (pH 5.4 for DNA,
pH 4 for RNA) were added. The mixture was allowed to precipitate for 1 hour at -70°C
before centrifuging at 13000 RPM for 20 mins. The pellet was washed in 100 pi 70%
ethanol and centrifuged for 5 minutes, before resuspending in water or Tris buffer as
required.
7.6 Bioinformatics and Statistics
Sequence analysis was performed using the program Bioedit (available as freeware from
http://www.mbio.ncsu.edu/BioEdit/bioedit.html). Multiple sequence alignments were
performed using the ClustalW algorithm (http://www.ebi.ac.uk/clustalw/). Bisulphite
sequencing data was analysed using a PERL script (source in Appendix). Statistical
analysis was performed using the Analyse-It plug-in for Microsoft Excel
(http://www.analyse-it.com/) or XLStat (Addinsoft). Numerical simulations for
bootstrap analysis were performed using Mathematica (Wolfram Research). Source code
for the bootstrap analysis is available from




All reagents, unless otherwise specified were obtained from Sigma. Oligonucleotides
were ordered from MWG and restriction enzymes were obtained from New England
Biolabs. Radionucleotides were obtained from Amersham.
DNA extraction buffer: 10 mM Tris pH 7.4, 100 mM EDTA, 0.5% w/v SDS.
ECL solution was prepared as 2 stock solutions: Solution 1: 100 mM Tris pH 8.5 to
which was added 1ml 250 mM Luminol in DMSO and 440 pi coumaric acid per 100
ml. Solution 2: 100 mM Tris pH 8.5 to which was added 64 pi 30% Hydrogen peroxide
per 100 ml. The working solution was prepared by mixing equal volumes of solutions 1
and 2 immediately before use.
SB solution was made up as a 4x stock solution (40 ml glycerol, 12 g SDS, 25 ml 1M
Tris-HCl pH 6.8, 20 ml 2-mercaptoethanol made up to 100 ml with distilled water).
Stock solution was diluted with distilled water and bromophenol blue added as required.
SDS buffer: 12 g/1 Tris, 57.6 g/1 Glycine, 4g/l SDS.
Semi wet transfer buffer: 5.8 g/1 Tris, 2.9 g/1 Glycine, 0.38 g/1 SDS, 20% v/v Methanol.
Solution D: 4 M Guanidium thiocyanate, 25 mM sodium thiocyanate, 0.5% Sarkosyl,
0.1 M 2-mercaptoethanol. Stock solutions without mercaptoethanol were prepared and
stored at -20°C. Mercaptoethanol was added to stock solution before use.
TBS-T: 8 g/1 NaCl, 0.2g/l KC1, 6g/l Tris, 0.1% v/v Tween20. pH adjusted to 7.4.with
HC1.
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421 T-216 to+205 50
Hop(CpG island 2) aaagagtaaatatttattggtagtattgtt
ctaactacaaaatttaaaaaaaaccctcct
370 See text 50
Ces3 gtaggtatttggttgttgttgttgtttg ttt
ctctataaaatctctaaactatctactac
351 T-322 to +29 48
Viaat tagaaagttttggtttattat
aaaaaaaacttctccaacacttc
512 Exon2 328 to 841 48
Wnt3 gaagggggtgttttaggttagtag
caaataaaactccattaaaaacaa
407 T-357 to+50 48
Lrfn5 (1st round gtgattaaagggttatgtgagaa
ctaccctttaccataactcaacac
578 T-442 to+136 48
Lrfn5 (heminested) gtgattaaagggttatgtgagaa
aaataactcctacccctacctttc










160 T-369 to-198 46




295 T-421 to-126 50




196 (T-421 to -225) 46
Tabic 7.1 Bisulphite amplification primers. Details ofprimers used for PCR amplification ofbisulphite modified














* 114 0 0 76
Clathrin gttgagttgggctgtcatgg
cccgcaatctcactctcttg
T+97 149 4 4 85*
Wnt3 cttcccagagccggagtt
gactttcgggcttgtcagag
T-244 193 4 4 84*
Lrfn5 ggatcttgagaaggaccagaact
gctcacacacactcacacattct
T-426 110 3 4 80*
Hic1 cctcttggcccaggtgtg
cccggtcggtctgtcttg




















T-302 210 2 5 89*
Mlh1 cctattggctggagatttcg
ctgattgggcagcatgaat
T-258 187 0 3 84
Igf2r ttgtcaggcctcgagtaggta
g tcctcg ttcagg tgctctc





T-574 156 3 3 86*
Table 7.2 M-QPR primers Details ofprimers used for real time PCR amplification for M-
QPR, regions amplified, number ofrestriction sites in ampliconand melting temperature (Tm)
ofPCR product. Amplification data for each cycle was recorded at 2°C below the melting
temperature. * indicates PCR was performed with addition ofQ solution, Tm quoted is Tm
including Q solution.
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Figure 7.1 Preparation of Dnmt3b expression constructs
Xhol2281
Figure 7.1 Preparation of Dnmt3b expression constructs. Strategy for production of Dnmt3b
overexpression construct. CMV IE- CMV enhancer. IRES intcrribosotrial entry site. pA-
polyA. ColEl- E.Coli replication origin.
AmpR-Ampicillin resistance gene. Zeocin- Zeocin resistance gene.
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Figure 7.2 Production of Tg(Dnmt3b)+ mice
Dnmt3b1 expression construct















- - * -f *
*»
■ Anti-Dnmt3b
Fig 7.2 Production of Tg(Dnmt3b)+ mice. CAG-CAG promoter IRES interribosomal entry
site
Zeo- zeocin resistance gene. Dnmt3b- full length Dnmt3bl cDNA
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A) Mbd2 mice




Genotype L +/mjn +/min +/+ +/+ +/+ +/min +/min
Min138 bp
WT 121 bp
Figure 7.3 Ape and Mbd2 genotyping. Ethidium bromide stained agarose gel electrophoresis




















Figure 7.4 Schematic summary of methylation sensitive restriction fingerprinting (MSRF)
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b) Clone 3' frt oligo in to Rsrll site












| RES Zeo j
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d) Electroporate into E14 ES cells
Select in zeocin
Verify integration by PCR
ES cell clones







B) Positive control (no Hpall/Hhal sites)
Standard Curve Plot
Quantity
Figure 7.6 Quantitative PCR standard curves/ dissociation curves. Examples ofvalidation experiments for
sybr green real time PCRoqteriments. Left hand figures show standard curves for 4-fold dilutions of undigested
genomic DNA. Ct=PCR cyle where detection threshold is reached. Quantity-arbitrary units (initial dilution=256
arbitary units). Right hand figures show dissociation curves for PCR product following amplification- 1st
differential of sybr green fluorescence against temperature as temperature is raised. Melting temperature is





















wt1 | wt2 I wt3
Wild type
3b1 [ 3b2 | 3b3
Transgenic
Lrfn5 dissociation curves
Figure 7.7 Validation of M-QPR. Measurement of methylation in heart of known methylated genes by M-QPR.
A) Wnt3 B)Lrjh5. Error bars represent transformed standard errors. C) shows dissociation curve for Lrfti5 PCR
products, (differential of sybr green fluorescence with respect to temperature), showing qualitative difference
between transgenic (methylated template) and wild type samples.
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9. Appendix
9.1 Perl source code for bisulphite sequencing analysis
#! C;\perl\bin\perl
#bisulphite reporter
#Input format- copy and paste pre-aligned sequences into txt file with path specified in Sinfile
#-the first sequence is the reference genomic sequence and the 5'end must extend
# beyond the 5' end of the other sequences or be filled up with
#The 5'end is filled up with as in ClustalW output
#file structure for each sequence is ">title" <cr> "sequence"
#report is written to file contained in $outfile. Output is space delimited text
#so it can be imported in to excel.
#GETTING SEQUENCE FILE (put path in to Sinfile)
#open sequence file- contained in array @sequence
Sinfile = "C:/Documents and Settings/Tom Latham/My Documents/Sequences/BS8(Apc
tumours)/external/external(2nd fit)infile.txt";













#loop to find positions of cpgs and cp(not g);
for ($i=0; $i<$len;$i++)
{
if (@seq[$i] eq "c" && $seq[$i+l] eq "g") {Scpg .= $i." "};
if (@seq[$i] eq "c" && $seq[$i+l] ne "g") {Scpn .= Si." "};
}
open (TXT, "»$outfile");






#@cpg is position of CpGs. Sncpg is number of cpg in ref sequence.










print TXT " @alignment[2*$i]";
}
# Report on CpH frequency as measure of conversion.














if ($match eq "C") {$conv++};
if ($match eq "U") {$uconv++};
if($matcheq {$noseq++};
if ($match eq "n") {$poorseq++};
if ($match eq "?") {$unmatch++};
}
Sefficiency = (($uconv+$conv) ne 0) ? int((100*$conv)/($uconv+$conv)) : "n/a" ;
$name=@alignment[(2 *$i)];
chomp($name);




print "0/0 $ runtime";
# subroutines
sub cpgmatch




if (@_[0] eq "c" && @J1] eq "g") {$ret= "M"};
if (@_[0] eq "t" && @_[1] eq "g") {$ret= "U"};
if (@_[0] eq "-" && @_[1] eq "-") {$ret=




#cpnmatch(n) returns conversion status of dinucleotide at position n




if (@clone[@_[0]] eq "t" && @clone[@_[0]+l] eq @seq[@_[0]+l] && @clone[@_[0]+2] eq
@seq[@_[0]+2]) {$ret="C"};
if (@clone[@_[0]j eq "c" && @clone[@_[0]+l] eq @seq[@_[0]+l] && @clone[@_[0]+2]
@seq[@_[0]+2]) {$ret= "U"};
if (@clone[@_[0]] eq | @clone[@_[0]+l] eq {$ret=
if (@clone[@_[0]] eq "n" | @clone[@_[0]+l] eq "n") {$ret= "n"};
return $ret;
}
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